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Hydrogels have been increasingly used in the treatment of skin and soft tissue wounds in recent 
years due to their superb water holding and cell-growth promoting properties. When 
impregnated with antibiotics, they can also treat or prevent bacterial infections. Due to the 
global increase in antibiotic resistance, antibiotics are now becoming less effective and 
bacteriophage (viruses able to kill bacteria) offer a new alternative. Triggered release 
mechanisms also slow resistance development, as bacteria are not continually exposed to sub-
lethal levels of therapeutic. Here, Staphylococcus aureus (S. aureus) was focussed on as it is the 
most common pathogen present in skin and soft tissue infections. The main aim of this work was 
to form biocompatible hydrogel systems which were able to give passive or triggered release of 
bacteriophage particles by S. aureus virulence factors. Micropatterned hydrogels were also 
investigated to assess the response in eukaryotic systems.  
This study found that Bacteriophage K was highly infective against S. aureus, with 94% strains 
(out of 86 strains) showing complete or intermediate sensitivity. Bacteriophage were 
immobilised into PVA and agarose hydrogel systems without a significant loss in concentration 
or efficacy. A photocrosslinkable polymer, HAMA (hyaluronic acid methacrylate) was also 
investigated which could be crosslinked in situ into a robust hydrogel; this hydrogel was sensitive 
to hyaluronidase (HAase), an enzyme secreted by the majority of S. aureus strains. On incubation 
with purified HAase and S. aureus supernatant, hydrogel degradation was recorded (Carbazole 
assay and SEM imaging) compared to buffer and HAase – negative S. aureus strains.  
When combined into a bilayered hydrogel system, 2% agarose/HAMA hydrogels gave triggered 
release of bacteriophage by pure HAase and HAase positive bacterial supernatant. However, in 
live culture triggered killing was not possible. HAMA could also be successfully printed, and NIH-
3T3 fibroblasts showed directed aggregation but no adhesion to HAMA hydrogels.  
In general, hydrogel systems which gave triggered release of Bacteriophage K only in the 
presence of S. aureus HAase were successfully formed. However, the passive leakage of 
bacteriophage into the wider environment was seen in live culture. This could be remedied by 
direct coupling of the bacteriophage to the polymer network, and is a possible avenue for future 
work. This system was significant as it proved that S. aureus HAase can be used as a trigger for 
bacteriophage release from hydrogel systems. In eukaryotic cells, HAMA hydrogels did not 



























Chapter 1 : Introduction and Literature Review 
 
Hydrogel dressings are now widely used in skin and soft tissue wound treatment due to their 
optimal properties. They provide a highly hydrated environment which promotes wound repair, 
allowing cell migration and proliferation, as well as drainage of the wound site. Hydrogels can 
also be incorporated with a variety of additional therapeutics (e.g. antibiotics, antimicrobial 
peptides or antimicrobial polymers) which can prevent infection. Topical wounds, such as burns, 
surgical sites or diabetic ulcers are frequently susceptible to infection due to the natural 
presence of bacteria on the skin and the surrounding environment; by far in the majority of 
cases, infections are due to Staphylococcus aureus or later Pseudomonas aeruginosa1. The use of 
antibiotics to treat these infections is being hindered by the recent upsurge in antibiotic 
resistance, where bacteria previously susceptible to an antibiotic become resistant.    
Over the past few decades, research into tackling antibiotic resistance has focussed on the 
development of novel active synthetic antibiotics with different chemical structures. Until 
recently this has generally been sufficient, however increased globalisation has put pressure on 
this approach. Bacteriophage (naturally occurring viruses able to infect and kill bacteria) are a 
little used antimicrobial therapeutic which offer a promising alternative to antibiotics.  Another 
way that the development of antibiotic resistance can be slowed is by preventing the 
prophylactic or passive application of antibiotics, and only using them when an infection is 
present. In a hospital setting, this can only be done if the infecting bacterial strain is known; 
determining what is present is notoriously slow and can result in patient mortality. A system 
which can detect and treat an infection in situ would aid infection treatment and patient care. 
With this in mind, this research aimed to create hydrogel systems which were able to selectively 
release bacteriophage only when a bacterial infection was present. The approach offers a 
number of advantages. Firstly any infection would be quickly treated in situ, without the need of 
dressing removal or medical intervention. Also, the unnecessary or passive release of 
bacteriophage would be prevented, which in turn would slow any development of resistance. 
The burst release of a high concentration of bacteriophage, versus a sustained low concentration 
release is more likely to completely treat an infection. Here, S. aureus sensitive systems were 
investigated as the virulence of the organism is well understood and it is the most common 
Gram-positive bacterium present in wound infections.  
 
 





1.1. Bacterial Infections 
 
Bacteria are a large group of single celled, prokaryotic organisms which are found in all corners 
of the planet including soil and radioactive waste. There are thought to be approximately 5 x 
1030 bacteria on earth2. Due to their innate simplicity, bacteria are extremely proficient at 
adapting to extreme conditions, and are able to undergo aerobic and anaerobic respiration (as 








Bacteria range in size from 10-7 to 10-4 m and are found in a variety of shapes including spheres 
(cocci), rods (bacilli) and coiled (spirochetes). They are far simpler than eukaryotic cells (Figure 
1.1) as they lack complex membrane-bound organelles such as the nucleus, mitochondria, 
endoplasmic reticulum and Golgi apparatus. Bacteria however can also have flagella, which aid 
cell movement, and pili, which are involved in bacterial conjugation and gene exchange, which 
are not present in eukaryotic cells. In eukaryotes mimic these through use of cilia. 
The bacterial cell wall structure can be different depending on bacterial species, and is seen in 
Figure 1.2. Bacteria are either Gram-positive or negative, depending on the presence of an outer 
membrane layer, which gives additional protection and stability to the cell. Certain molecules on 
the bacterial surface such as lipopolysaccharides act as antigens to the body, which stimulate an 
immune response3.  
 
Figure 1.1: Schematic diagram of prokaryotic (left) and eukaryotic (right) cells © Pearson Education, Inc 




Figure 1.3: Diagram of bacterial growth phases: the lag phase, exponential phase, 
stationary phase and death phase 










Membrane protein  
 
Bacteria replicate through a process known as binary fission – where each bacterium divides into 
two separate daughter cells. Bacterial growth can be modelled in four phases, shown in Figure 
1.3: the lag phase, log phase, stationary phase and death phase. The lag phase (A) involves the 
initial adaption of bacteria to the new growth conditions; bacteria do not divide, but synthesise 
the new RNA, enzymes, etc. required for growth in the new environment. Once bacteria are able 
to efficiently replicate, growth moves into the exponential phase (B). With an excess of 
nutrients, bacteria divide every few minutes at a constant exponential rate (e.g. the doubling 


















During the stationary stage (C) the rate of growth slows due to nutrient loss and the 
accumulation of toxic by-products. Eventually the rate of death is higher than the rate of growth 
and growth enters the death phase (D); all nutrients have been used up and the bacteria die. 
Bacteria are notorious opportunistic pathogens. They take advantage of a compromised host 
and go on to infect causing tissue damage, disease and significant morbidity and mortality. 
Infection frequently occurs more in immunocompromised or immunosuppressed patients where 
the body’s natural defences have been lowered. These include those with skin wounds (e.g. 
burns, diabetic ulcers and surgical site wounds), cancer or HIV/AIDS, as well as the very young, 
elderly, or pregnant women.  
1.1.1. Clinical problem 
One of the most significant scientific breakthroughs of the 20th century has been the discovery 
and development of antibiotics against bacterial infections. Before antibiotics, bacterial 
infections were the leading cause of human morbidity and mortality for the majority of human 
existence. Perhaps the most devastating example of these occurred in the 14th century, where 
the Black Death (a bubonic plague caused by the bacterium Yersinia pestis) killed between 30 – 
60% of the entire population of Europe4. Later, diseases such as tuberculosis, Scarlet Fever, 
meningitis and pneumonia, as well as sexually transmitted diseases, were frequently common 
and fatal5. Surgery and childbirth were all both highly dangerous due to subsequent bacterial 
infection.  
The discovery of the penicillins and sulphonamides in the 1940s revolutionised medicine. The 
work of Fleming, Florey and Chain on penicillin, and Ernst on the sulphonamides began a period 
of unprecedented research into new effective antibiotics which treated large swathes of 
previously deadly diseases. As a result, mortality rate significantly decreased. The organ 
transplants and chemotherapy that is so essential for medicine today would not be possible 
without antibiotics.   
In recent years however, the chronic use of antibiotics has led to the emergence of bacteria 
resistant to a range of antibiotic drugs, as well as providing optimal environments for the 
selection and spread of resistance6. For example, the treatment of acute respiratory infections 
with antibiotics is a common procedure, even though the cause is in most cases viral7, 8. In 
healthcare, the over or unnecessary prescription of antibiotics by physicians, as well as incorrect 
self-dosing by patients (either through lack of information or negligence) drives this 




development. In developing countries, antibiotic resistance is exacerbated by the unregulated 
sale of antibiotics over the counter.  
Antibiotics are additionally used in huge quantities in agriculture as a prophylactic and as a 
growth promoter, creating a ‘reservoir’ where resistance can evolve. Although in 2006, the EU 
banned the use of all antibiotics as growth promoters, the practise is still widespread in the US 
and other countries9. Antibiotics in agriculture are also able to seep into the surrounding soil and 
watercourses, facilitating the transfer of resistance to the wider microbial population.  
 
The situation is worsened by the lack of new antibiotics coming onto the market. The 
comparative ‘boom’ of the second half of the 20th century has been surpassed with fewer and 
fewer antibiotics now being approved; only two between 2008 and 2011 (Figure 1.4)10. This 
drastically limits the choice of drugs clinicians have available for infection treatment. In 2015, 
Teicoplanin was documented as possibly the first new class of antibiotics in a decade; the drug 
has efficacy against S. aureus and Mycobacterium tuberculosis in mice, but is yet to go into 
human trials11. In that case, the way in which the drug was discovered is more significant than 
the drug itself. 
Antibiotics are not commercially viable for large pharmaceutical companies to research 
compared to chronic and lifestyle-associated diseases where drugs are taken long-term. It is 
estimated that to bring a novel antibiotic to market takes 10 years and between $800 million 
Figure 1.4: Number of approved antibiotics between 1980 and 2011. Reproduced with permission from 
Bassetti et al 





and $1.7 billion, all without the guarantee of approval at the end12. There have been efforts to 
tackle this “market failure”; agencies such as the EU are funding incentives such as the 
‘Innovative Medicines Initiative’ which works to promote and speed up the development of new 
medicines.   
The critical rise in antibiotic resistance and fall in antibiotic discovery is a severe public health 
concern. In 2009, the World Health Organisation (WHO) announced that antibiotic resistance 
was one of the three greatest threats to health13. In 2011 the UK Government’s chief scientific 
officer, Professor Dame Sally Davies, described that antibiotic resistance posed a “catastrophic 
threat”. The post-antibiotic era described by the WHO in 2014 is a stark reminder of the very 
real possibility of a world where antibiotics are ineffectual14. Without antibiotics common 
infections and minor injuries could kill; routine operations, cancer therapy or transplants would 
not occur.  
1.1.2. Wounds and wound infections 
In recent years, the bacteria named by the Infectious Diseases Society of America as ‘ESKAPE’ 
pathogens have been targeted as the main cause of hospital-acquired infections. Linked by their 
ability to ‘escape’ treatment by antibiotics, ESKAPE pathogens comprise Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species; there is also a case for including the gut bacterium 
Clostridium difficile in the group15-17. All of these pathogens, as well as causing the majority of 
infections in healthcare settings, represent paradigms of pathogenesis, transmission, and 
resistance that if understood can be applied to all other infections.  
Skin and soft tissue wounds are particularly vulnerable to opportunistic infections, which cause 
considerable damage as they metabolise and proliferate. The most common bacteria associated 
with skin and soft tissue infections are the normal host flora: S. aureus and Streptococcus 
pyogenes1. In 2009, skin and soft tissue infections (SSTIs) were responsible for 51% of all 
hospitalisations attributed to S. aureus in the US, with each case costing $11,622 to treat18. 
Gram-negative organisms such as P. aeruginosa, Escherichia coli and Acinetobacter are not 
normally found on the skin, but can be acquired from the environment and go on to cause 
infection at later stages19.  
Bacterial infections of skin and soft tissue (cellulitis), wounds, surgical sites and burns cause 
damage to the surrounding tissue including redness, pain, pus and tissue destruction and 
necrosis as bacteria grow and proliferate20. The severity of further infection is determined by the 




extent and depth of the wound, as well as the number of colonising bacteria. The release of a 
range of virulence factors by bacteria facilitates adhesion, immune system evasion, leukocyte 
killing and tissue destruction21.  
1.1.3. Biofilms 
The majority of microorganisms in the environment do not exist as planktonic, floating, single 
cells; most form complex communities which irreversibly adhere to surfaces called biofilms. 
Biofilms can contain either single or multiple strains or species of bacteria. Bacteria in biofilms 
are surrounded by a self-produced extracellular polymeric substance (EPS) which comprises 
genetic material, proteins and polysaccharides.  
 
Figure 1.5: Stages of biofilm development. Reproduced with permission from Sauer et al  
The structure and development of biofilms on surfaces has been well characterised, and can be 
described in five distinct stages as described in Figure 1.522-24: (1) Reversible attachment - 
bacterial cells reversibly attach to a surface using a variety of sensing mechanisms, e.g. flagella, 
pili and outer membrane proteins. (2) Irreversible attachment - bacteria irreversibly bind to the 
surface and secrete EPS to adhere. (3) Growth and replication – adsorbed cells grow and 
multiply forming microcolonies which become encapsulated by EPS. (4) Maturation – a three-
dimensional structure develops with an established microbial community ‘glued’ in EPS. (5) 
Detachment – some cells detach and disperse into the bulk fluid, going on to form new biofilms.  
Biofilms frequently form on surfaces within the body where they cause persistent and chronic 
infections on catheters, shunts, implants and prostheses, as well as burn wounds25, 26. For 
example, indwelling catheters are the most common cause of healthcare associated 
bloodstream infections, with 200,000 infection cases a year associated with their use27-29. A 





number of Gram-positive and Gram-negative organisms have been isolated from these 
environments including ESKAPE pathogens and Proteus mirabilis.  
Biofilms are inherently more tolerant to the immune response, antibiotics, biocides and 
hydrodynamic shear forces compared to planktonic bacteria due to the impermeable EPS30. This 
makes these established infections particularly hard to treat. Bacteria growing in a biofilm also 
exhibit a phenotypic ‘switch’ when in a biofilm where the growth rate and regulation of many 
genes is altered, including phenotypes for antimicrobial resistance, which similarly hinders 
treatment31, 32.  
1.1.4. Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a Gram-positive, coagulase positive, facultative anaerobic 
coccus which appears as yellow, grape-like clusters; the name is derived from the Greek 
‘staphylē kόkkos’ meaning ‘bunch of grapes’, and the Latin ‘aureus’ meaning ‘gold’ (Figure 1.6). 
S. aureus is found naturally on the mucous membranes of the upper respiratory tract and skin 
microbiota. It is thought that approximately 20% of the population are persistent and 60% are 
intermittent carriers33. S. aureus can cause both community and hospital acquired infections, 









S. aureus is a leading cause of morbidity and mortality worldwide, and is responsible for a range 
of varying severity diseases35. It usually causes minor infections of the skin and soft tissues, 
resulting in pimples, furuncles, boils and impetigo36. However, if able to systemically invade, it 
can cause serious deep-seated infections such as pneumonia, osteomyelitis, meningitis, 
endocarditis and bacteremia which can be fatal. Gram-positive species are frequently associated 
Figure 1.6: False-coloured SEM image of S. aureus ©J. 
H. Carr, Public Health Image Library 




with burn and soft tissue infections. S. aureus is also notorious for its toxicity; secreted exotoxins 
are capable of initiating systemic shock and organ failure such as that seen in Toxic Shock 
Syndrome (TSS) and Staphylococcal Scalded-skin Syndrome (SSSS) 37, 38.  
1.1.4.1. Virulence Factors 
S. aureus secretes a wide range of toxins (exotoxins) into its surrounding environment which are 
thought to be used by the bacterium to invade and break down tissue into usable nutrients. 
These include cytotoxins, superantigens (Enterotoxins A, B, C and D, exfoliatin and TSS toxin) and 
enzymes (coagulase, proteases, lipases, nucleases, hyaluronidase and collagenase) 39, 40. These 
molecules are highly potent and stimulate a strong immune response when detected.  
Cytotoxins are small protein molecules - α, β, γ, and δ-haemolysin, Panton-Valentine leukocidin 
(PVL), and Phenol-soluble modulins - which cause the lysis of eukaryotic cells to aid bacterial 
invasion. Protein units exist as soluble monomers which assemble to form β-folded ‘barrels’. The 
protein barrels associate with the cell membrane and form a pore – this facilitates the free 
movement of water and ions through the cell membrane, eventually causing cell lysis. PVL is a 
cytotoxin known to lyse human leukocytes (white blood cells); it is associated with increased 
virulence in S. aureus and is common in the majority of community-acquired MRSA isolates41, 42.  
Collagenase and hyaluronidase, HAase, are both secreted to break down the main polymers 
(collagen and hyaluronic acid) which make up connective tissues and skin. For the purposes of 
this report, the function and mechanism of hyaluronidase excretion in S. aureus will be discussed 
in detail in Section 1.4.4.4. Coagulase is an interesting enzyme in that it converts the 
glycoprotein fibrinogen to fibrin – with S. aureus the fibrin covers the bacterium, and on contact 
with blood forms a clot which is thought to protect the microbe from phagocytosis.  
1.1.4.2. Regulation of S. aureus virulence factors  
The accessory gene regulator (agr) and the staphylococcal accessory regulator (sar) are the main 
regulatory mechanisms that control the production of S. aureus virulence factors (Figure 1.7)43. 
S. aureus relies on a mechanism called quorum sensing to detect changes in the outside 
environment, which is dependent on population density. 











As bacteria grow, they secrete small molecules called auto-inducing peptides (AIPs); as the 
population gets larger, so then does the concentration of AIPs. Over a threshold concentration, 
AIPs bind to a membrane associated histidine kinase, AgrC, on the bacterial surface. This then 
initiates the phosphorylation of an internal protein, AgrA inside the bacterium. Phosphorylated 
AgrA then activates is own promoter P2 on the gene, but also the promoter P3, which drives the 
transcription of RNAIII. RNAIII modulates the expression of virulence factors; an upregulation of 
RNAIII results in increased exotoxin production and virulence, and a decrease in surface 
proteins43.  
In S. aureus, sar has also been found to play an important part in virulence factor regulation. The 
sar locus encodes for the SarA protein, which binds to bacterial DNA and modulates gene 
expression44.   
In S. aureus, hyaluronidase is expressed by the gene hysA. Until very recently, little has been 
known about the regulation of this enzyme; the full sequencing of hysA in 1995 has now led to a 
more comprehensive outlook. Hyaluronidase expression is thought to be activated by the 
regulator agr and repressed by sar in a similar way to other S. aureus virulence factors45, 46. 
When the agr system is activated, HAase levels increase until agr is deactivated. This is the same 
system as described earlier, making HAase expression to a certain extent RNAIII dependent.  
Figure 1.7: Diagram explaining the self-regulating function of the agr system. Reproduced with permission 
from Novick et al 
AIP = Autoinducing peptide 
Example nomenclature: 
AgrA = AgrA protein 
agrA = agrA gene 
P = promotor 




Recent work by Ibbensen et al has found that by creating mutations in the global regulator CodY, 
they were able to show that not only does CodY directly influence both the agr system and the 
hysA gene, but also could play a part in the link between virulence and nutrient availability47.  
1.1.5. Antibiotic resistance 
Antibiotic resistance occurs when bacterial DNA either mutates or acquires other genetic 
material through horizontal gene transfer, which enables bacteria to become resistant to one or 
a class of antibiotics. Bacteria acquire these genes from integrons (transferable genetic 
elements), plasmids or bacteriophage. The emergence of a number of clinically acute antibiotic 
resistant strains, including methicillin-resistant S. aureus (MRSA), vancomycin-resistant 
Enterococcus (VRE) and multidrug-resistant tuberculosis (MDR-TB), is now widespread. The WHO 
estimates that antibiotic resistant infections cost the EU approximately €1.5 billion and the US 
$30 billion a year48.  
The acquisition and interchanging of genetic material is a natural phenomenon commonly seen 
in bacteria. This is due to the speed at which bacteria replicate and the ease at which they can 
exchange genetic material. The overuse of antibiotics gives an added selection pressure which 
drives for resistant strains49. The most common mechanisms that bacteria become resistant to 
antibiotics include: alteration of the target site, alteration to target site access (e.g. efflux pumps 
or decreasing cell wall permeability) and production of enzymes which modify or destroy the 
antibiotic50.   
One way of slowing the emergence of antibiotic resistant strains is to only use antibiotics when 
an infection is present. When antibiotics are present in low concentrations in the environment, a 
reservoir is formed where there is a selection pressure on any bacteria present to become 
resistant. In this way, a triggered high dose of antibiotics will be more successful in killing all 
bacteria and preventing resistance from evolving than a low constant dose51.  
1.1.5.1. Methicillin resistant S. aureus, MRSA 
The emergence of MRSA was reported in 1961, a year after the introduction of the β-lactam 
antibiotic methicillin. MRSA now encompasses any strain of S. aureus which is resistant to β-
lactam antibiotics such as penicillins, cephalosporins and carbapenems. Over recent years the 
prevalence of MRSA in S. aureus infections has escalated dramatically – MRSA is currently the 
most common antibiotic resistant pathogen in US hospitals52. In 2008 MRSA was responsible for 
more deaths in the US than HIV/AIDS and tuberculosis combined53.  





Although the number of cases has been decreasing since its peak in 2008, the US Centres for 
Disease and Control (CDC) reported over 80,000 cases of MRSA infection in 201154. Originally, 
MRSA was confined to the hospital environment, termed hospital-associated MRSA (HA-MRSA), 
where the high usage of antibiotics in the environment drove resistance. Now however, certain 
MRSA strains have appeared in the wider community only, going on to infect young healthy 
patients (community-associated MRSA, CA-MRSA). The higher morbidity and mortality 
associated with CA-MRSA, as well as its increased genetic diversity, virulence and ability to resist 
broader classes of antibiotics make CA-MRSA a serious concern55.   
S. aureus resistance to methicillin occurs due to the production of an altered penicillin binding 
protein known as PBP2a, which has a decreased affinity to β-lactam antibiotics.  PBP2a is 
encoded by the mecA gene, which is found on a mobile genetic island known as the 
Staphylococcal cassette chromosome mec, SCCmec. The SCCmec element also contains 
additional regulatory genes, and sequences to aid integration and excision into host DNA. At 
least five different SCCmec types have been described. Types I - III are associated with HA-MRSA; 
type IV and V are most common in CA-MRSA with the SCCmec generally smaller in size to aid 
horizontal gene transfer56-58.  
1.1.5.2. Alternatives to antibiotics 
A number of alternatives to antibiotics are being investigated, and are becoming more promising 
in the light of the emergence of antibiotic resistance. Firstly, various methods can be 
implemented to prevent antibiotic infection in the first place, with vaccination being the primary 
choice. Vaccines of attenuated bacteria have been used for decades to impart immunity against 
disease causing bacteria. The Bacillus Calmette–Guérin (BCG) vaccine for example, uses 
attenuated Mycobacterium bovis to protect against tuberculosis. Investigations into vaccines 
against more clinically relevant species such as C. difficile, S. pneumoniae, E. coli, Salmonella and 
Listeria monocytogenes have all been reported59.     
In the event of an infection becoming established, there are also many alternatives that have 
been overshadowed by antibiotics since their discovery.  Bacteriophage and bacteriophage lysins 
are in many ways the most promising alternative. These are natural predators of bacteria, and 
are discussed in detail in Section 1.2. Although it is unlikely that antibiotics will ever be 
completely replaced, these alternatives offer a new method of treating resistant infections 
either in conjunction or singly.  
 






Bacteriophage, or phage, viruses are the most common biological entity on the planet with an 
estimated population of 1031, outnumbering bacteria by a factor of ten60. They are the natural 
viral predators of bacteria, and are responsible for the removal of half the world’s bacterial 
population every 48 hours61. Bacteriophage are ubiquitous, with phage most commonly found in 
areas containing high bacterial populations such as soil, river water and sewage. In humans, they 
are found naturally in the mucosal membranes and GI tract living symbiotically with commensal 
bacteria62. They are able to infect bacteria (but crucially no other cells) through their cell wall 
and cause the bacterium to lyse and die (Figure 1.8). Phages can have a very narrow host range 
due to their very specific bacterial binding sites. They are also a common element in horizontal 
gene transfer between bacteria, facilitating bacterial genetic diversity63.  
1.2.1. Discovery and historical use 
Bacteriophage were discovered independently a century ago by Twort and d’Hérelle in 1915 and 
1917 respectively64. D’Hérelle was the first to propose the name ‘bacteriophage’ for the viruses 
after bacteria and phagein (from the Greek: φαγεῖν, to devour). Although not investigated 
further by Twort due to the outbreak of WW1, research into bacteriophage and their 
possibilities was continued by d’Hérelle64. In 1923, d’Hérelle, along with microbiologist George 
Eliava, founded the Eliava institute in Tbilisi, Georgia, which to this day is a centre for 
bacteriophage therapy and research.  
At the time companies initially seized on bacteriophage as a new therapy against infectious 
diseases. The ‘Société Française de Teintures Inoffensives pour Cheveux’, a forerunner to 
Figure 1.8: TEM images of (left) Initial bacteriophage adsorption onto the host bacterium, ©Graham Colm, 
(right) bacterial lysis due to bacteriophage infection, ©Biozentrum, University of Basel/Science Photo 
Library. 





L’Oréal, released a range of phage preparations for infectious diseases (e.g. Bacté-coli-phage, 
Bacté-pyo-phage and Bacté-staphy-phage)65. In the US, large pharmaceutical companies such as 
Eli Lily also developed phage products66.  
The age of antibiotics, beginning with the development of sulfa drugs in the 1930s and penicillin 
in the 1940s bought about a sharp decline in the research and use of bacteriophage for infection 
treatment. In the West, bacteriophage were superseded by the apparent glut of easily 
manufactured, broad spectrum antibiotics which were reliable and could be mass produced. 
However, phage therapy remained prevalent in Eastern European counties, notably the ex-
Soviet countries of Russia, Poland and Georgia. Now, in an era where bacterial resistance to 
antibiotics is sadly all too common, bacteriophage therapy has undergone a renaissance as a 
possible alternative.  
1.2.2. Classification and morphology 
Due to the sheer number and diversity of bacteriophage in our ecosystem, phage can be 
classified in a number of different ways through their morphology, type of genetic material (DNA 
or RNA), their host organism or their life cycle. The current standard method of phage 
classification was set out in 1971 by the International Committee on the Taxonomy of Viruses 
after a seminal report by Bradley67, 68. A brief description of the 10 main bacteriophage classes 
can be seen in Table 1.1, adapted from Ackerman et al68.  
The vast majority of bacteriophage (approximately 96%) fall into the order Caudovirales, which 
comprise the familes Myoviridae, Sipoviridae and Podoviridae. These bacteriophage all contain 
double stranded DNA encapsulated in an icosahedral capsid head, and either a contractile, long 
non-contractile or short tail respectively. Bacteriophage tails frequently contain tail fibres which 
are essential for adsorption onto host bacteria; it is these fibres that impart the narrow host-










 Family  Nucleic acid, properties and size Example 
 Myoviridae dsDNA, contractile tail T2, P2, T4 
 Siphoviridae dsDNA, long non-contractile tail λ 
 Podoviridae dsDNA, short tail T7, P22 
 Microviridae ssDNA 27 nm,  12 knoblike capsomers ΦX174 
 Corticoviridae dsDNA 63 nm complex lipidic capsid PM2 
 
Tectiviridae dsDNA inner lipid vesicle PRD1 
 Leviviridae ssRNA 23 nm polio virus-like MS2 
 Cystoviridae dsRNA, segmented, lipidic envelope 70-
80 nm 
Φ6 
 Inoviridae ssDNA, filaments or rods M13, fd 
 Plasmaviridae dsDNA, lipidic envelope, no capsid MVL2 
Table 1.1: Morphology and genetic properties of bacteriophage families, adapted from Ackerman et al 
1.2.3. Bacteriophage life cycle 
The life cycle of bacteriophage and how they infect host bacteria has been well characterised. As 
mentioned above, bacteriophage tail fibres are involved in the initial viral adsorption onto the 
bacterial surface. In general, in Gram-positive bacteria phage tail fibres are able to bind to 
specific receptors made from the peptidoglycan and teichoic acids in the cell wall. In Gram-
negative bacteria, other receptors are involved which are part of the outer membrane; protein 
(such as OmpA, C and F, and Lam) and lipopolysaccharide receptors are the most common in 
these bacteria. 
After initial adsorption to surface receptors, the bacteriophage tail binds irreversibly to the 
bacterial cell wall. Generally, the tail then contracts; this drives its central tail tube through the 
bacterial outer membrane in a similar fashion to a hypodermic needle. Phage DNA is then 
injected into the cytoplasm of the host bacterium and further replication can commence69. 
Once inside the bacterial cytoplasm, phage can undergo two different replication cycles 
depending on the phage type and external factors. These are known as the lytic cycle (seen in 





virulent bacteriophage) and the lysogenic cycle (seen in temperate bacteriophage). These are 














1.2.3.1 The Lytic Cycle 
The lytic cycle is undergone by the majority of bacteriophage as their standard replicative 
mechanism.  Once the bacteriophage DNA has reached the cytoplasm, it integrates into host 
DNA and immediately expresses proteins which inhibit bacterial defence mechanisms (e.g. DNA 
restriction enzymes and proteases).  The genes then take over bacterial metabolism and initiate 
the production of new phage virions. The head, tail and tail fibres are constructed separately and 
then assembled at the last moments. Proteins are then expressed which break down the 
bacterial cell wall to enable phage release. These are known as holins and lysins, and are 
discussed in further detail in Section 1.2.8. The released bacteriophage then go on to infect new 
host bacteria, leaving the destroyed original cell; the cycle is repeated until no host bacteria are 
left.  
Figure 1.9: Lytic and lysogenic life cycles of bacteriophage. Reproduced with permission from Campbell et 
al 




1.2.3.2 The Lysogenic Cycle  
The lysogenic cycle is the second, less common replicative pathway undergone by 
bacteriophage. Lysogeny is characterised by two main factors which differ from the lytic cycle72. 
Firstly, after the incorporation of phage DNA (now called the “prophage”) into the host genome, 
this DNA is replicated as normal through bacterial binary fission and passed down to every 
daughter cell. Secondly, lysogenic phage infection is not infective; it does not produce phage 
virions.  
In bacteria infected with lysogenic phage, the prophage can exist either in the host genome or as 
a plasmid. The prophage remains integrated and passed down in the bacterial chromosome until 
a process known as induction. During induction, an environmental or genetic trigger initiates the 
excision of prophage from the bacterial DNA; this then induces the phage to go into the lytic 
cycle and new whole bacteriophage are made. All bacteriophage undergo the lytic cycle at some 
stage, however some go through lysogeny beforehand. 
1.2.4. Advantages of bacteriophage therapy 
The specific advantages of bacteriophage as antimicrobials have been collated in a recent review 
by Loc-Carillo et al73. Firstly, compared to antibiotics the side effects sustained through phage 
therapy are minimal. Whereas multiple side effects have been reported with antibiotics 
(intestinal disorders, allergies and secondary infections), because bacteriophage are comprised 
of only nucleic acids and proteins, they are inherently non-toxic. Although phage could interact 
with the body and cause an immune response, with the use of highly pure phage preparations in 
medical studies this is not a significant concern.    
Secondly, on infection with lytic bacteriophage, bacteria are lysed completely, eliminating the 
chance of bacterial regrowth. In the case of bacteriostatic antibiotics such as macrolides and 
tetracyclines, this is not the case. Also, bacteriophage are able to infect regardless of antibiotic 
susceptibility as they use completely different mechanisms action; this gives them a high activity 
against MDR strains such as MRSA 74, 75.  
On application, bacteriophage congregate at the site of infection. The phage will continue to 
replicate and infect the host organism until that organism is removed. This is known as “auto-
dosing”; a small amount of phage solution increases in concentration in response to the host 
concentration. This not only means that a low initial dose is needed, but the phage are 
concentrated at the site of infection. With antibiotics, concentration does not change in 





response to the number of bacteria; antibiotic is distributed throughout the body and eventually 
metabolised and excreted regardless of the state of infection. 
The narrow host range of bacteriophage reduces the chances of resistance occurring across a 
whole bacterial species. Any mutations that a bacterium develops to resist a specific phage are 
only suitable for that phage/bacterium interaction. This also allows the preservation of normal 
gut flora, giving none of the gastrointestinal problems associated with antibiotics. Some broad 
spectrum antibiotics are able to cause secondary infections such as Clostridium difficile colitis 
due to this disruption76.  
In the event of resistance developing against bacteriophage, finding new infective phages is 
quick, straight-forward and relatively cheap, taking days to weeks. Bacteriophage also exhibit 
versatility in terms of application, being active in liquids, emulsions, creams and on solids77-80. In 
general, although never a complete replacement to antibiotics, bacteriophage offer an 
additional treatment with certain favourable characteristics. 
1.2.5. Disadvantages of bacteriophage therapy 
There remain certain limitations in the use of whole bacteriophage as a therapeutic.  Firstly, any 
bacteriophage which will eventually be used as a therapeutic must be lytic. As temperate phage 
are able to insert their DNA into the host genome, this alters host DNA and carries the risk of 
horizontal transfer of virulent or cell cytochemistry changing genetic elements. For example, the 
gene responsible for methicillin resistance in strains of MRSA, mecA, is thought to have originally 
come from a lysogenic phage81, 82. This problem can be remedied by gene sequencing of the 
whole phage genome to rule out lysogenic components.  
It is also possible for bacteria to develop resistance to bacteriophage themselves through 
alteration or removal of the surface receptors necessary for phage binding83, abortive infection 
or production of  intracellular enzymes (whereby on phage infection the enzymes cleave the 
structures needed for phage assembly, e.g. DNA or capsid proteins) 84, 85. In 2007, Barrangou et 
al also reported that CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) in the 
bacterial genome were able to transfer resistance against bacteriophage to other organisms86. 
Despite this, it is important to note that bacteriophage can then evolve in retaliation against 
these changes to continue infecting.  
The specificity of a bacteriophage can be a disadvantage in a clinical setting. The narrow host 
range of phage means that the exact strain of bacterium must be known in order to choose the 




appropriate phage. Phage cannot be used in the same manner as broad-spectrum antibiotics, 
where treatment can be given before the exact infective organism is known. To counteract this, 
bacteriophage are most effectively administered in phage ‘cocktails’87, 88. These are mixtures of 
different phages which combined give treatment over a broad spectrum compared to single 
bacteriophage. 
As bacteriophage can be recognised as foreign bodies, a certain response is expected by the 
immune system when exogenous phage are administered to the body. At low concentrations, 
phage are usually completely cleared from the blood and internal organs through elimination by 
the liver and spleen89. Immune response of phage is largely based on the type and concentration 
of phage, and route of administration; topically administered phage rarely elicit a response, 
however high concentrations of systemic phage can initiate antibody release90, 91. Another 
concern is that the lysis of high concentrations of bacteria by phage can release exotoxins and 
superantigens into the system, stimulating an inflammatory response. This can be controlled to a 
certain extent through the use of lysis-deficient phage92.  
Large pharmaceutical companies remain hesitant to invest in bacteriophage therapy. 
Bacteriophage are considered by the FDA as a biological product, meaning clinical trials must be 
stopped in the event of phage mutation, regardless of if this mutation is dangerous. Standard 
protocols for the isolation and production of phage cocktails suitable for clinical trials were 
published by Merabishvili in 200993. Also, it is very hard to secure patent protection for phage 
products. Even if phage were regulated, compared to antibiotics, bacteriophage are generally 
harder to manufacture, store and purify on a large scale.  
1.2.6. Bacteriophage as a therapeutic   
The majority of phage products seen today are licenced for agricultural or food use; for example 
preparations against E. coli, Campylobacter, Salmonella and Listeria have all been licenced to 
prevent food poisoning94. Some preparations are also available for medical use in Eastern 
Europe, e.g. from the former Soviet Union (Georgia and Russia) (Figure 1.10). Despite the 
general promise of bacteriophage as a medical therapeutic, there are currently no phage 
preparations that have been approved or are in Phase III clinical trials in the EU or USA95. 
Although used for decades, there are few clinical trials to support bacteriophage as a safe, 
reliable and potent therapeutic; in the West phage were forgotten, and when therapy was 
continued in Eastern Europe trials were frequently not carried out to international standards. 





The major hurdle that prevents more bacteriophage products going into clinical trials is the 
regulatory ‘grey-area’ in which phage are placed96, 97. At the moment they are regulated in a 
similar way to antibiotics, however as viruses that are able to evolve, it is hoped that phage will 
be treated in a similar way to the seasonal influenza vaccine.    
Although no phage preparations have been licenced as a medical treatment, many hundreds of 
studies have been carried out in small-scale research settings which seem promising. These have 
been extensively reported and have been collated in a number of comprehensive reviews 65, 98, 99. 
For example in 2009 a small scale, randomised, double-blind, placebo controlled trial of phage 
was successful in treating the majority of patients with chronic otitis caused by antibiotic-
resistant P. aeruginosa infection100. There has also been research reported on different forms of 
bacteriophage delivery; a recent study by Lehman et al has described the beneficial use of 
bacteriophage-hydrogel coated catheters in P. aeruginosa and P. mirabilis infections103. 
Perhaps an indication of the drive of the international community to make phage therapy a 
viable alternative in infection control can be seen with the PhagoBurn project97. PhagoBurn is a 
new phage research program funded by a €3.8 million FP-7 grant from the European 
Commission that involves researchers from France, Belgium and Switzerland. Their aim is to 
coordinate a two year Phase I/II clinical trial to assess the use of phage therapy against E. coli 
and P. aeruginosa burn wound infections. The results from these trials and lessons learnt from 
large scale manufacturing are hoped to form the basis of future regulatory guidelines for phage 
therapy.  
1.2.7. Bacteriophage and biofilms 
As described earlier, biofilms are sessile communities of bacteria which offer a safe haven 
against pH, osmotic shock and even UV light. Biofilms also are notoriously resistant to antibiotics 
Figure 1.10: Pyobacteriophage preparations for use in broad-range infections ©Eliava Institute 




due to poor diffusion inside the matrix; the systemic administration of antibiotics against 
biofilms on indwelling catheters for example, is usually ineffective with a failure rate of at least 
30%101. With this in mind, bacteriophage are a new therapy thought to be particularly beneficial 
in the removal of bacterial biofilms 102, 103.  
Firstly, bacteriophage secrete enzymes known as polysaccharide depolymerases (originally to 
degrade the bacterial cell wall after phage assembly) which degrade the biofilm EPS matrix. As 
the EPS breaks down, the biofilm becomes more fragile and bacteria are now more susceptible 
to the environment, antibiotics and indeed bacteriophage themselves. In 2007, Lu et al were 
able to engineer a T7 phage with a biofilm-degrading enzyme which reduced E. coli biofilm cell 
counts by 4.5 orders of magnitude104.   
Secondly, once bacteriophage have degraded the EPS matrix they can go on to infect and lyse 
bacteria present. The phage infect and multiply as they go through the matrix, eroding at the 
biofilm. Doolittle et al were able to follow this diffusion with fluorescently labelled phage105 A 
drawback of using phage in this way is that some biofilms can contain many different bacterial 
strains and species; phage infection is so strain specific that full killing could possibly not occur. A 
compromise can be used by firstly administering phage, and then treating with antibiotics; this is 
known as dual therapy. The phage breaks down the EPS matrix (the main barrier to antibiotic 
diffusion) and then allows better diffusion and subsequent efficacy of antibiotics. This was seen 
by Kirby et al in 2012 for example, with gentamicin and S. aureus phage SA5 showing higher 
bacterial killing when used in combination than as separate treatments106.  
1.2.8. Bacteriophage Lysins 
Bacteriophage lysins are phage-encoded murein hydrolase enzymes. They are secreted by 
bacteriophage during the final stage of the lytic cycle and facilitate the release of whole phage 
from the bacterium into the surrounding environment after assembly. Firstly, bacteriophage-
encoded proteins, holins, are excreted into the cytoplasm and form pores in the bacterial cell 
membrane. Bacteriophage lysins are then able to move through these pores, which then gives 
access to the peptidoglycan. These degrade specific bonds of the peptidoglycan depending on 
which bond is the specific target; they are classified into six groups (Figure 1.11)107. After 
enzymatic degradation, the bacterial cell loses structural integrity; water is able to move through 
the now porous peptidoglycan into the cytoplasm, causing the cell to eventually burst108.  





When applied exogenously, recombinantly expressed purified bacteriophage lysins can elicit the 
same response without the addition of holins (as there is now no barrier to bacterial 
peptidoglycan) or bacteriophage. Because of this action, lysins are thought to be a promising 
alternative to current antibiotics and phage therapy109-111. Currently many extensive reviews and 
investigations have been carried out into lysins as antimicrobials, especially in Gram-positive 
species with active lysins found against all clinically relevant Gram-positive bacteria112, 113. 
Lysins have a number of advantageous properties over antibiotics and whole bacteriophage114, 
115. They have a broader host range than some bacteriophage with lysins able to lyse many 
strains of a species, regardless of antibiotic resistance. For example, the anti-Staphylococcal lysin 
LysK exhibits killing over a number of clinically relevant S. aureus species including 
MRSA116.Optimal properties of bacteriophage lysins can be fine-tuned with the chemical 
tailoring of enzymes. The truncated lysin CHAPk is derived from LysK – the catalytic amidase-2 
domain and cell-binding SH3b domain were both removed and lytic activity was retained.  
Compared to whole bacteriophage, lysins are far quicker in initiating bacterial cell lysis. The 
enzymes are active immediately, as opposed to whole phage which rely on bacteria being in the 
exponential growth phase. Also, because lysins do not carry genetic material, they eliminate the 
risk of transduction of virulence factors into bacterial DNA. The acquisition of resistance to lysins 
is additionally very low (if seen at all) as it is thought the target structure for lysin attack 
(peptidoglycan) is not easily changed by the bacterium117.  
Although a promising lead against Gram-positive infections, lysins retain a lack of efficacy against 
Gram-negative bacteria. This is due to the presence of the thick outer membrane, which 
Peptidoglycan 
Holin Phospholipid membrane 
Figure 1.11: Murein hydrolase enzyme sites of attack: 1. N-acetylmuramoyl-L-alanine amidase, 2. L-
alanoyl-D-glutamate endopeptidase, 3. Interpeptide bridge endopeptidase, 4. N-acetyl-β-D-muramidase, 
5. Transglycosylase, 6. N-acetyl-β-D-glucosaminidase 




surrounds and protects the Gram-negatives. Bacteriophage lysins are unable to permeate this 
membrane and so cannot go on to degrade cell peptidoglycan. Despite this, some active lysins 
have been characterised. For example, in 2012 Lukacik et al succeeded in lysing strains of Gram-
negative Y. pestis and E. coli by fusing a T4 phage lysin to a membrane transporter binding 
domain118.  
1.3. Vesicles 
Phospholipid molecules are the major constituent of cell membranes, consisting of a hydrophilic 
phosphate ‘head’ and a hydrophobic lipid ‘tail’ (Figure 1.12). Because of these dual properties in 
the same molecule, phospholipids are described as being amphiphilic. The hydrophilic 
headgroup is most commonly a choline, ethanolamine, serine or glycerol linked to a negatively 
charged phosphate group. Phospholipid tails consist of two hydrocarbon chains, either saturated 
or unsaturated.  
In aqueous solution the amphiphilic nature of phospholipids causes molecules to self-assemble 
over a certain concentration into supramolecular aggregates. This concentration is known as the 
Critical Micelle Concentration (CMC). Phospholipids initially align at the interface, with 
headgroups in the aqueous and tails in the air layers. Above the CMC the whole interface is 
covered and the only way for more phospholipids to go into solution is to form aggregates. 







What kind of aggregate forms is determined by the phospholipid head size and tail length 
(Figure 1.13). If the projection area of the tail is smaller than the headgroup, micelles are formed 
as this is most favourable. Phospholipids in micelles are aligned so the headgroup is in contact 
with the aqueous media and tails are inside, forming a lipophilic core. Micelles are useful for the 
in encapsulation of lipophilic molecules in aqueous media because of this. If tails are very similar 
Fatty acid chains 
Phosphate 
Choline 
Figure 1.12: Structure of the phospholipid DPPC 





in size to the headgroup, thin membranes known as phospholipid bilayers are formed. Vesicles 
are formed by lipids with a large tail in comparison to the headgroup (>16 carbons). They are 
ideally formed to encapsulate aqueous materials such as dye molecules, drugs and other 
chemicals. Recently there has been renewed interest in vesicles due to their similarity in size and 









Vesicles can form in varying sizes, ranging from small unilamellar vesicles (20 – 50 nm) to giant 
unilamellar vesicles (> 1 µm). They have many uses in biomedicine as delivery systems, as they 
are able to increase the stability of previously unstable drugs. Inside the body they are 
advantageous as they do not initiate an immune response and are able to pass through the 
Blood Brain Barrier (BBB). Liposomal formulations of many drugs such as Doxorubicin and 
Paclitaxel are being researched or are already on the market. For example, Doxil, a liposomal 
formulation of doxorubicin is a drug recently approved by the FDA for Kaposi’s sarcoma and 
ovarian cancer. Vaccines for influenza and hepatitis A have been developed in vesicular forms 
which were found to increase in vivo stability119-121.  
1.4. Hydrogels 
1.4.1. Hydrogel wound dressings 
Following a wound occurring, the healing process as well as the healing time will depend on the 
depth and severity of the wound. It is imperative for this process to be as quick as possible to 




Figure 1.13: Vesicle, micelle and bilayer structures formed from 
phospholipid bilayers 
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Figure 1.14: a) Hartmann Hydrosorb™ hydrogel wound dressing sheet, b) Medicare Burnshield hydrogel 
spray for burns and scalds, c) Sorbact® antimicrobial hydrogel 
or opportunistic pathogens. The standard treatment method for burns and other skin and soft 
tissue wounds is initial debridement of the wound, and then application of bandages or gauze to 
protect the wound as it heals. This however has a number of drawbacks: wound fluid cannot 
drain, bandages can adhere to the wound, the progress of healing cannot be seen without 
bandage removal and a perfect environment for bacterial infection is established. Increasingly, 
research is turning to polymeric hydrogels as better dressing alternatives.  
Hydrogels exhibit the optimal characteristics of solids and liquids, as they can be both strong and 
flexible, as well as having high water content with good diffusive properties. They are crosslinked 
polymer networks that can hold vast quantities of water for their weight (> 90%). Hydrogels are 
also able to reversibly absorb and release water in response to external stimuli, e.g. 
temperature, pH and ionic strength, allowing the development of ‘smart’ and ‘triggered release’ 
hydrogels. Currently there are many hydrogel formulations on the market for wound treatment, 
especially for burns (Figure 1.13), as well as in cell culture and tissue engineering122.  
  
Hydrogel dressings are ideal for the promotion and facilitation of wound healing. Firstly 
hydrogels are able to absorb wound exudate, which promotes the free movement of the 
keratinocytes and fibroblasts needed for re-epithelialisation. Hydrogels are also more flexible, 
comfortable and soothing than conventional dressings. The highly hydrophilic environment can 
prevent cell attachment and so hydrogels can generally be non-adhesive; this reduces the pain 
and discomfort associated with dressing changes.   





Currently a vast range of formulations have been investigated which aim to improve and 
advance current wound dressings. As well as hydrogel dressings, other novel approaches include 
hydrocolloid, alginate, adhesive film, foam and biological dressings. Dressings can additionally be 
incorporated with other factors which promote healing or prevent infection such as growth 
factors, supplements and antimicrobials; these are easily able to diffuse through the porous 
structure to the wound site. The optimal characteristics for a wound dressing are summarised in 
Figure 1.15123. Although many dressings will comprise the majority of these characteristics, no 













Currently there has been a general trend to form hydrogels which are formed from multiple 
polymeric materials (natural and synthetic). This not only aids in creating hydrogels with the best 
physical properties, but also can help with different aspects of wound healing and management 
(e.g. re-epithelialisation, collagen synthesis or infection control)124, 125. Hydrogels derived from 
polysaccharides have additional benefits of excellent biocompatibility, biodegradability and 
natural abundance126.  
 
Figure 1.15: Characteristics for optimal wound dressings and 
devices. Reproduced with permission from Mayet et al 




1.4.2. Natural polymers 
Natural polymers are defined as polymers which are obtained from natural sources, such as 
animals, microbes or vegetables. Natural polymers are inherently biocompatible, biodegradable 
and similar to the extracellular matrix (ECM), and so are ideal for use in wound dressings.  
The most common natural polymers used are polysaccharides (chitin, chitosan, hyaluronic acid, 
alginate, cellulose) and proteins (collagen, gelatin, fibrin and keratin). Chitosan is one of the 
most abundant natural polymers used in wound dressings, and as well as having all the 
beneficial properties of a natural polymer, also exhibits anti-bacterial and wound healing 
affects127. Hyaluronic acid has received increased attention in recent years due to its role in 
wound healing, and will be discussed in detail in Section 1.4.4. Collagen is the major and most 
abundant structural component in connective tissues, and so is commonly used in wound 
dressings; it is known to stimulate wound healing, tissue development and wound debridement. 
Although collagen has favourable qualities in vivo, in vitro the protein loses structure and 
elasticity. This can be overcome to a certain extent with crosslinking of fibres to retain structure; 
in 2013, Tronci et al functionalised collagen lysine residues with photo-active methacrylate 
groups, enabling subsequent photo-crosslinking128. Collagen can also be used in coatings for 
implants and medical devices, as well as in artificial skin. 
Although natural polymers possess a number of advantageous properties, frequently their high 
biodegradability combined with low tensile strength and high cost means that they become 
unsuitable for biomedical applications. To overcome this, natural polymers can be mixed with 
either multiple natural polymers or, more commonly, mixed with synthetic polymers.   
1.4.3. Synthetic polymers 
The control of synthesis and chemical modification of polymers is a major advantage of synthetic 
polymers over natural polymers. Synthetic polymers can be made to specific requirements of 
functionality, m, purity, homogeneity and reactivity, making them far easier to understand and 
use123, 129. These polymers can be biologically inert (e.g. PEG); they do not aid wound healing 
however they equally to not illicit an immune response.  
Poly(vinyl alcohol), PVA, is one of the most commonly used synthetic polymers. It can be 
moulded into multiple forms (e.g. sheets, fibres and foams) and shows good biocompatibility, 
water absorption and oxygen permiability130, 131. A number of natural polymers have been 
combined with PVA to form wound dressings with improved properties, most commonly 
chitosan132, 133. Drug and biologically important molecules have been coupled to the inert 





poly(ethylene glycol), PEG, to improve solubility,  reduce immunogenicity and provide ‘stealth’ 
delivery; for example the Crohn’s disease drug Cimzia is delivered as the PEGylated form134, 135. 
Again, in a wound dressing PEG is frequently used as a scaffold for more biologically active 
molecules. Other non-toxic and non-immunogenic polymers such as poly(hydroxyethyl 
methacrylate), pHEMA, and poly(vinylpyrrolidone), PVP, as well as the biodegradable polymers 
poly(lactic acid) and poly(caprolactone), have all been widely used as hydrogel scaffolds to 






1.4.4. Hyaluronic acid  
Hyaluronic acid, sometimes known as hyaluronan (HA), is a high molecular weight, linear 
polysaccharide biopolymer made up of glucuronic acid and N-acetyl glucosamine sugars linked 
by alternating β-1,3 and β-1,4 glycosidic bonds (Figure 1.17). Although classed as a 
glycosaminoglycan (along with heparin and chondroitin sulphate), the polymer differs in that it is 
non-sulphated, non-protein bound and can have a molecular weight of up to 106 g/mol. HA is 
found in almost all tissues of all vertebrates, but in humans is a major constituent of the 
connective tissues, umbilical cord, synovial fluid, eye vitreous humour and especially the skin. It 
plays an active role in the body; with approximately 5 g HA (1/3 of the whole body amount) 











Figure 1.16: Chemical structures of a) poly(vinyl alcohol), PVA b) poly(ethylene glycol), PEG c) 
poly(caprolactone) d) poly(lactic acid) e) polyvinylpyrrolidone, PVA and f) poly(hydroxyethyl methacrylate) 
Figure 1.17: Repeating unit structure of hyaluronic acid 




In the body, HA is synthesised by three different hyaluronan synthase enzymes (HAS1, HAS2 and 
HAS3) which are situated in the cell membrane; the polymer is directly extruded onto the cell 
surface or into the extracellular matrix. HA is able to interact with eukaryotic cells through cell 
membrane receptors; these include CD44 (Cluster of Differentiation 44) and RHAMM (Receptor 
for HA-mediated motility) 138. The structure of HA is highly conserved throughout vertebrates, 
implying it has an important biological role.  
HA has both a structural and active function in the body. Firstly, it has incredible water holding 
properties compared to other biopolymers. It is able to occupy a large volume in tissues with a 
high concentration of associated water molecules, making it able to easily maintain tissue 
structure and hydration. The molecule also acts as a lubricant for joints due to its viscoelastic 
nature. The major role of HA in the body is in wound healing, and is discussed in Section 1.4.4.1., 
however in other areas of the body, HA has an active role in embryo development, 
carcinogenesis, inflammation, cell signalling and ageing139.  
The unique viscoelastic and water holding properties of HA, as well as its biocompatibility and 
non-immunogenicity make the molecule highly suitable for medical applications in wound 
healing, drug delivery and tissue engineering140, 141.   Chemically, the molecule contains a number 
of easily modifiable functional groups which allow crosslinking and conjugation with biologically 
active molecules and proteins142.  
1.4.4.1. Role of hyaluronic acid in wound healing 
Hyaluronic acid is known to play an active and beneficial role in all stages of wound healing. On 
initial wounding, HA synthesis is upregulated and long chain HA (> 1000 – 5000 saccharides) is 
secreted from cells, binding to fibrinogen in the blood to start clot formation143, 144. The long 
chain HA is then degraded into smaller and smaller lengths over the course of wound healing. 
The influx of HA to the wound also causes swelling and opens up the tissue facilitating 
movement of neutrophils into the wound site; here long chain HA is acting as an 
immunosuppressant.  
In the inflammatory stage, the stimulation of inflammatory cytokines such as TNF-α and 
interleukin occurs due to smaller HA fragments (< 1000 saccharides)145. In the next proliferative 
phase, even smaller HA fragments (6 – 20 saccharides) stimulate fibroblast and keratinocyte 
migration to the wound site and subsequent proliferation, as well as synthesis of collagen144, 146. 
By the maturation phase excess short chain HA is broken down further which then goes on to 
stimulate angiogenesis (sprouting of blood vessels in the ECM)147, 148.  





A number of studies have found that the application of exogenous HA to a wound site has a 
positive effect on wound healing, especially in burns, surgical wounds and chronic wounds (e.g. 
diabetic ulcers). In 2012 Voigt et al carried out a systemic review and meta-analysis of the use of 
HA in wound healing compared to conventional therapies or placebos149. In eight out of nine 
randomised controlled trials investigated, HA significantly improved wound healing. HA based 
therapeutics are currently in use in both medical and cosmetic areas; these are discussed in 
more detail in Section 1.4.4.3. 
1.4.4.2. Hyaluronic acid crosslinking 
In aqueous solution HA forms highly swollen gels which lack mechanical strength and shape, and 
so are unsuitable for use in wound dressings. Also, as mentioned earlier, in the body native HA is 
degraded extremely quickly. In order to form a usable hydrogel for medical applications HA can 
be crosslinked. This is predominantly through 3 routes: reaction of HA with itself (through 
coupling of the carboxylic acid, alcohol and acetamide groups), addition of a crosslinking 
molecule which reacts with HA, or by a two-step process where HA is first modified and then 
crosslinked. Crosslinking of HA has been summarised in a number of reviews by Schanté (2011) 
and Burdick (2011)150, 151.  
1.4.4.2.1. Modification of hyaluronic acid carboxylic acid 
One of the most common and facile approaches to crosslink polysaccharides including HA is the 
reaction with carbodiimides, which are molecules with the formula RN=C=NR. Carbodiimides 
form ‘zero-length’ crosslinks and do not directly combine into the structure; they are preferable 
as they are biocompatible and only produce urea based by-products152. One of the first 
carbodiimides investigated for HA crosslinking was DCC (N, N’-dicyclohexylcarbodiimide), 
although this reaction was toxic and required unfavourable non-aqueous conditions. Because of 
this, the water-soluble analogue EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide) is more 
commonly used153, 154.  
HA carboxylic acid groups become activated to the reactive O-acyl-isourea intermediate on 
addition of carbodiimides such as EDC (Figure 1.18). The activated HA is then able to either react 
with other HA hydroxyl groups forming a ‘zero-length’ ester bond, or amine groups that can be 
added as crosslinking molecules (typically in the form of  diamines and dihydrazides).   
 
 





Another approach which utilises HA carboxylic acids is the Ugi condensation, which involves the 
reaction of HA in acidic conditions with a diamine crosslinker (e.g. 1,5 pentanediamine), 
formaldehyde and cyclohexyl isocyanide155. This results in the formation of a diamine crosslinked 
HA (through the HA carboxylic acid groups) that has additional secondary amide and pendant 
cyclohexyl functionality.  
1.4.4.2.2. Crosslinking of hyaluronic acid alcohols 
Primary and secondary hydroxyl groups can also be involved in crosslinking reactions. Firstly, 
hydroxyl groups can react with bi-functional ethers to form ether crosslinked HA; the most 
common crosslinker used in HA hydrogels on the market is 1,4 butanediol diglycidyl ether 
(BDDE). It is cheap and easy to synthesise, and so far degradation products have not shown 
significant toxicity156. It is also possible for BDDE to form crosslinks with HA carboxylic acid 
groups in acidic conditions, however in alkaline solution (pH 10) the alcohol esterification 
predominates with more stable products148.   
In alkaline media (pH > 13), divinylsulphone (DVS) forms a sulphonyl ether crosslink between the 
hydroxyl groups of HA. DVS itself is highly reactive and toxic; in 2010, Ibrahim et al showed the 
high concentrations of DVS needed to form solid gels compromised biocompatibility and gels 
formed were of poor quality157.  
The aldehyde functionality has been used for HA crosslinking in two main ways. Firstly, alcohol 
groups found on the HA sugars can be selectively oxidised to form aldehyde groups, which can 
Figure 1.18: HA crosslinking through a) amide bond formation, b) ester bond formation and c) hydrazide 
bond formation 





then react with diamines or dihydrazides to form crosslinks through imine bonds158, 159. Which 
hydroxyl groups will be oxidised is determined by the choice of oxidising agent160. The use of 
sodium periodate (NAIO4) results in the ring opening of the glucuronic acid sugar, and the 
formation of two aldehyde groups from the C2 and C3 carbons. Dess-Martin periodinane 
selectively oxidises the N-acetyl glucosamine primary alcohol to the corresponding aldehyde 
with no destruction of the HA structure161. Secondly, HA hydroxyl groups can be crosslinked by 
the dialdehyde glutaraldehyde, forming a hemiacetal; however this reaction is known to be toxic 
and crosslinks are easily hydrolysed150.   
1.4.4.2.3. Crosslinking of hyaluronic acid derivatives 
The Huisgen cycloaddition, or ‘Click’ crosslinking, is a relatively new method of crosslinking 
which has been successfully applied to HA. The process involves the initial functionalisation of 
separate HA carboxylates with azide or alkyne groups162; in the presence of Cu+ catalyst a 1, 3 
cycloaddition then occurs forming a 5-membered ring and a crosslink. In 2007, Crescenzi et al 
successfully crosslinked HA that had been functionalised with propargylamine and 11-Azido-
3,6,9-trioxaundecan-1-amine in an aqueous, room temperature reaction with 1% CuCl163.  
Another method described by several authors is the crosslinking of HA by photo-polymerisation. 
Initially, HA is functionalised with acrylate or methacrylate groups (frequently through coupling 
to glycidyl methacrylate or methacrylic anhydride), as these groups react rapidly with free 
radicals. When mixed with a photo-active initiator and exposed to UV light, HA methacrylate 
(HAMA) is able to form crosslinks between methacrylate groups via a free-radical polymerisation 
mechanism (Figure 1.19).  
 
Figure 1.19: HA crosslinking through free radical polymerisation of methacrylated HA 




Common radical initiators used include benzophenone and benzoin derivatives such as 2-
hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure 2959). Other acrylated 
molecules can also be incorporated into the mixture prior to polymerisation to enhance the 
hydrogel structure and properties; these include acrylated PEG derivatives, proteins or collagen.  
Photopolymerisation offers a better control of hydrogel properties through alteration of the 
concentration of macromer, methacrylate groups or initiator164, 165. Interpenetrating networks 
(IPNs) of crosslinked HAMA can also be easily formed around existing polymer scaffolds which 
greatly increase the hydrogel strength and properties166.  
1.4.4.3. Hyaluronic acid hydrogel dressings 
HA can be found in many products available to the public, both medical and cosmetic (Table 
1.2). These products mainly use HA in two ways. Firstly, they can contain free unmodified HA of 
varying molecular weights which has been mixed in with other ingredients to form a liquid or 
cream, for example in cosmetics or products such as Hyalgan®. Secondly, they can be crosslinked 
HA hydrogels. Juvederm® is a temporary dermal filler used for the treatment of wrinkles, which 
is lightly crosslinked with the diether BDDE167. Many HA hydrogels available for use in wounds 




Applications Commercial Products References 
Osteoarthritis Lubrication and mechanical 







Aids cell proliferation, 





146, 170, 171 
Embryo 
Implantation 
Promotes implantation after 
embryo transfer in in vitro 
fertilisation 
EmbryoGlue® 172, 173 
Antiaging Rehydration and 




Cosmetics Moisturisation RevitaLift® (L’Oréal), 
Eucerin® Hyaluronan Filler, 
Rimmel® Moisture Renew 
Lipstick 
 
Burns Aids cell proliferation, 
migration and wound 
healing 
Hyalosafe®, Hyalomatrix® 149, 175 
Table 1.2: Commercial products used for a range of therapies which contain HA as a major component 
 





1.4.4.4. Hyaluronidase in prokaryotes 
Hyaluronidase (HAase) is an extracellular enzyme which facilitates the cleavage of HA. Enzymatic 
degradation of this molecule results in a drop in tissue viscosity, a breakdown of tissue structure 
and a higher chance of bacterial invasion.  
HAase enzymes can be sub-divided into three different classes176, 177: hyaluronate-4-
glycanohydrolases (testicular HAase), hyaluronate-3-glycanohydrolases (leech HAase) and 
hyaluronate lyase (bacterial HAase).  The first two types are both found in eukaryotes and cleave 
the HA molecule by hydrolysis of the glycosidic bonds. The hyaluronate lyases are only found in 
bacteria and cleave the HA molecule through β-elimination of the β-1, 4 glycosidic bond (Figure 




The structure of bacterial HAase has been studied in S. pneumoniae178, 179 and Streptococcus 
agalactiae180, with S. aureus HAase thought to have  a similar structure. The size of HAase 
enzymes differs between species, with a weight of 84 kDa in S. aureus and 40 kDa for S. 
pyogenes for example136.    
In bacteria, HAase is used as a “spreading factor” to aid the invasion of host tissues, and to break 
down HA into a usable carbon source. Although seen in both Gram-positive and Gram-negative 
bacteria, the enzyme is predominantly secreted as an exotoxin in Gram-positives (in Gram-
negative organisms the enzyme remains periplasmic). The most common bacteria known to 
secrete HAase are S. aureus, S. pyogenes and Clostridium 176 - species which are all common in 
soft tissue infections181. In 1980, Essers and Radebold reported that in a screen of 210 S. aureus 
strains, only one isolate was found to be HAase negative. In the same study, all but one of 150 
coagulase-negative Staphylococci (i.e. not S. aureus) showed no HAase activity at all182. 
Unfortunately more recent studies into the extent of HAase production in clinically relevant S. 
aureus have not been prevalent.    
1 2
3
Figure 1.20: Positions of cleavage of HAase molecules - 1. hyaluronate-3-glycanohydrolases, 2. 
hyaluronate-4-glycanohydrolases and 3. hyaluronate lyases. 




1.4.4.5. Hyaluronidase in eukaryotic cells 
Eukaryotic cells are also able to produce HAase, which plays a key role in the natural metabolism 
of HA in the body. The concentration of hyaluronidase in human serum is approximately 2.6 
U/mL183. There are six known genes that code for hyaluronidase in humans: Hyal-1, Hyal-2, Hyal-
3, Hyal-4, PH-20/Spam1 and Phyal-1 (a pseudogene transcribed in humans but not translated)184. 
Of these, Hyal-1 and Hyal-2 are the major HAases found in tissue.  
As mentioned in Section 1.4.4.2., native unmodified HA has an extremely short residence time in 
the body of approximately 24 hours in skin and a few weeks in tissues. It is rapidly degraded by 
human HAase and used, and subsequently replaced, by the body. The crosslinking of HA to a 
certain extent prevents HA breakdown by human HAases, increasing hydrogel residence time as 
well as mechanical properties185.  
1.4.5. ‘Smart’ hydrogel systems 
Synthetic hydrogels can be tailored to exhibit triggered swelling that is dependent on an external 
stimulus; these are sometimes known as ‘smart’ hydrogels as they automatically respond to 
their external environment. Hydrogels have been developed which are responsive to stimuli 
including pH, temperature, ionic strength, an enzymatic or chemical reaction, as well as 
magnetism or an electric current186. Stimuli are able to chemically modify the structure of the 
hydrogel and cause changes in the polymer network, most commonly by causing a change in 
swelling. 
1.4.5.1. pH sensitive hydrogels 
pH sensitive hydrogels are ionic polymer networks all containing either acidic (carboxylic acid or 
sulphonic acids) or basic (ammonium salts) pendant groups187.  These groups are able to accept 
or donate protons depending on the external pH, and swelling is initiated due to electrostatic 
repulsions between charges on the polymer chain (releasing encapsulated agents). The most 
frequently used cationic polymers include poly (acrylic acid), poly(methacrylic acid), PMAA, 
whilst anionic polymers include poly(N,N’ -diethylamino ethyl methacrylate) (PDEAMA).  
A number of drug molecules have been successfully administered through triggered pH release 
from hydrogels by taking advantage of pH changes in the body188, 189. In 2014, Car et al reported 
on the use of poly(dimethylsiloxane)-b-poly(2-dimethylamino ethyl methacrylate) (PDMS-b-
PDEAMA) for triggered release of the anti-cancer drug doxorubicin; cancer cells are known to be 
more acidic compared to healthy cells and so drug will only be released to cancer cells190. pH 





sensitive hydrogels can also be formed with polysaccharides such as hyaluronic acid, chitosan 
and dextran as the carboxylic acid and amine groups present can become ionised191. For 
example in 2014 Kwon et al investigated cellulose/HA complexes for pH-triggered release of 
Isoliquiritigenin192. 
1.4.5.2. Temperature sensitive hydrogels 
Temperature sensitive hydrogels are one of the most well-studied ‘smart’ hydrogel systems, 
with the majority of hydrogels based on poly(N-isopropylacrylamide), PNIPAAm. These hydrogels 
undergo a reversible phase transition at a critical temperature (the lower critical solution 
temperature, LCST) over which results in hydrogel collapse and a decrease in polymer 
solubility187, 193. PNIPAAm is particularly advantageous in a biomedical setting as its LCST is 
approximately 32 °C, being in the region of normal body temperature; this LCST can be altered 
by addition of hydrophilic or hydrophobic copolymers.   
Temperature responsive polymers can be used to entrap a wide range of drug molecules194, 
enzymes and cells, which go on to give a triggered release over the LCST195. They are also best 
used for topical delivery to skin and soft tissue wounds such as burns, as these injuries 
frequently show an increased temperature compared to the external environment. PNIPAAm 
has also been used for non-enzymatic removal of cultured cell sheets from culture vessels196. 
Increasingly, the thermoresponsive properties of PNIPAAm are being combined with pH 
responsive polymers for added sensitivity197, 198.  
1.4.5.3. Enzyme sensitive hydrogels 
A far smaller research area compared to pH and temperature responsive hydrogels are enzyme 
sensitive hydrogels; these are hydrogels which use enzymatic processes as a trigger mechanism 
for therapeutic release.  Targeting enzymes has a number of advantages over more common 
triggers such as temperature and pH. Enzymes can be very specific to a target substrate and 
normally are most active at normal body temperature and pH. They are also highly prevalent in 
both healthy and diseased tissue; for example, certain enzymes are only secreted in the event of 
a certain disease or trauma199.  
A number of approaches have been taken by researchers targeting specific enzymes to initiate 
triggered release of therapeutics. Various PEG based polymer hydrogels have been developed 
which can be degraded by matrix metalloproteases (MMPs); in 2012 Yang et al formed peptide 
crosslinked PEG hydrogels which released dexamethasone in the presence of MMPs112, 200. Other 
enzymes can also be targeted which are known to be secreted in certain situations. For example, 




the upregulation of elastase production by neutrophils in wound sites has been used as a trigger 
in a number of studies201-203. There have also been reports of polymers formed which have 
sensitivity to bacterial enzymes. In 2004, Lee et al reported on the development of an enzyme-
responsive peptide drug conjugate. This conjugate was susceptible to the enzyme Penicillin G 
amidase (PGA); on the incubation of E. coli (which contained the PGA gene) with this conjugate, 
breakdown and triggered release of drug was seen204.  
In 2014, Komnatnyy et al reported on the selective killing of bacteria by lipase sensitive 
polymers205. On incubation with lipase secreting bacteria (in this case P. aeruginosa), the lipase 
was able to break an enzyme-sensitive linkage between surface attached PEG and the antibiotic 
ciprofloxacin. Triggered antibiotic killing was observed where wild-type lipase secreting P. 
aeruginosa was selectively killed compared to lipase mutants.  
Triggered release of certain molecules by hyaluronidase has been recently reported by some 
groups. In 2013, sulphorhodamine and polyhexanide were selectively released from HA-starch 
nanocapsules by HAase, and in 2015 a triggered release of 7-amino-4-methylcoumarin was 
reported from HA-b-poly(caprolactone) block copolymer vesicles206, 207. In a recent 2015 paper 
by Wu et al, release of amoxicillin was described from HA coated nanoparticles, with the 
intention of using HAase secreted by S. aureus as a trigger. Although these particles did show 
high bacterial killing, subsequent investigation into HAase triggered release was not 
investigated208. In all of these cases, no trigger mechanism was reported which used enzymes to 
initiate triggered release of bacteriophage, especially using HAase secreted by live S. aureus.  
1.5. Aims and Objectives 
The aim of this project was to develop bacteria-triggered release systems for the delivery of 
bacteriophage for use in topical wound dressings. In this way, bacteriophage would be released 
only when pathogenic bacterial infection is present. This not only prevents the unnecessary use 
of therapeutic, but also decreases the probability of bacterial resistance emerging. As a viable 
alternative to antibiotics, bacteriophage offer a range of advantages over antibiotics which lend 
them to use in wound dressings. The systems investigated used bacterial virulence factors 
naturally secreted during growth to initiate triggered release, predominantly by the Gram-
positive organism S. aureus.  
This project focussed on two main trigger mechanisms. Firstly, previous work on phospholipid 
vesicles in the group had used the secretion of the holin molecule δ-haemolysin by S. aureus to 





selectively release dye and antimicrobial molecules. The use of larger giant unilamellar vesicles 
was investigated to encapsulate bacteriophage and to give triggered release in a similar manner.  
The second trigger mechanism developed was the use of crosslinked HA as an enzyme sensitive 
barrier for bacteriophage release. Hydrogel wound dressings are already widespread and can 
actively promote wound healing through combination with natural polymers such as collagen 
and hyaluronic acid. S. aureus secretes hyaluronidase, and so on S. aureus infection the hydrogel 
matrix is degraded and bacteriophage release is seen. In the presence of no S. aureus, the matrix 
acts as a typical hydrogel dressing that benefits from the wound healing properties of HA.    
As well as providing an antibacterial therapy in the event of bacterial infection, it was also 
important to investigate how eukaryotic cells responded to the hydrogel environment. Following 
on from this, the printing of crosslinked hyaluronic acid was carried out using nano-imprint 
lithography to investigate its effect on NIH-3T3 fibroblasts. By imparting a surface roughness, it 
could also be possible to grow cells in a directed fashion (a more ordered cell growth would be 
more reflective of the highly ordered skin layers).  
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All bacterial strains used were part of a strain collection kindly available to the lab from Dr Ruth 
Massey, University of Bath, UK and Prof Mark Enright, University of Manchester, UK. Tryptic Soy 
Broth, Tryptic Soy Agar, Luria-Bertani Broth, Luria Bertani Agar, glycerol and microbiological agar 
were obtained from Sigma-Aldrich (Poole, Dorset, UK). 
Magnesium sulphate, gelatin, Tris-HCl, PEG-8000 and carboxyfluorescein N-succinimidyl ester 
(CF-NSE) were all obtained from Sigma-Aldrich (Poole, Dorset, UK). 
Ethylenediaminetetraacetic acid, (EDTA), TritonX-100, 4-(2-Hydroxyethyl) piperazine-1-
ethanesulfonic acid, (HEPES), sodium chloride, cholesterol, 5(6)-carboxyfluorescein and 10,12-
Tricosadiynoic acid, (TCDA) were all purchased from Sigma-Aldrich (Poole, Dorset, UK). Sodium 
hydroxide (NaOH) was obtained from Fisher Scientific (Loughborough, Leics., UK). All lipids 
(DPPC and DPPE) were obtained from Avanti Polar Lipids (Alabaster, AL, USA).  
NIH-3T3 embryonic mouse fibroblasts were gained from the University of Munster.  Dulbecco’s 
Modified Eagle Medium (DMEM), fetal calf serum (FCS), L-glutamine, penicillin and streptomycin 
were purchased from Life Technologies, Germany.  
2.2. General Methods 
2.2.1. Preparation of bacteria 
All bacterial isolates were acquired from the University of Bath Biology and Biochemistry 
Department as 15% glycerol stock solutions stored at -80 °C. Stabs of frozen stock were streaked 
onto tryptic soy (TS) or Luria Bertani (LB) agar plates (TS for Staphylococci and LB for all other 
species) and spread to form isolated colonies. Plates were grown overnight at 37 °C and 
afterwards stored at 4 °C until needed.  
In all cases where S. aureus NE334 (hys-) was used, bacteria were cultured on plates and in TSB 
supplemented with 5 µg/mL erythromycin.  
All Staphylococcus isolates were incubated in autoclaved TS broth (30 g in 1 L deionised water), 
whilst all other species were incubated in autoclaved LB broth (25 g in 1 L deionised water).  




2.2.1.1. Bacterial live culture preparation 
Bacterial overnight cultures were grown by inoculating 50 mL centrifuge tubes containing 10 mL 
sterile TS or LB broth with one isolated colony. Tubes were then incubated overnight at 37 °C 
with 200 rpm shaking; this resulted in cultures of approximately 109 cfu/mL. For live culture 
experiments, bacteria were subcultured to return growth to the lag phase. 10 µL overnight 
culture was added to 10 mL TS or LB broth and thoroughly mixed before use.  
2.2.1.2. Bacterial supernatant preparation 
Bacterial overnight cultures were centrifuged at 4000 rpm for 20 minutes to pellet whole cells. 
The supernatant was then removed and filter sterilised through 0.22 µm filters. Supernatant was 
stored at -20°C in aliquots until needed.  
2.2.1.3. Bacterial concentration calculation 
Concentration of bacteria in cultures was calculated through serial dilution. In brief, 100 µL of 
test bacterial solution was added to 900 µL sterile phosphate buffered saline (PBS) and then 
vortexed. This was then serially diluted by a factor of 10 until a final dilution of 10-8. 10 µL of 
each sample dilution was then streaked onto an agar plate, and the plates incubated at 37 °C 
overnight. All dilutions were plated in triplicate. 
Isolated bacterial colonies were then counted, with a dilution giving between 3 and 30 colonies 
per 10 µL most valid. Bacterial concentration in colony forming units per mL (cfu/mL) was 
calculated using the formula: 












2.2.1.4. Bacterial strains used 
S. aureus strains used in all studies, their origin and their SCCmec type can be seen in Table 2.1. 
‘-‘= not methicillin resistant strains.  
Strain Origin SCCmec Strain Origin SCCmec 
15981 Spain - FFP221 Portugal I 
57/92 Germany III Fin62305 Finland IV 
8325-4 USA - Fin76167 Finland IV 
963Small USA II Fra97392 France IV 
99ST10345 Ireland II Germany131/98 Germany I 
BC00691 unknown unknown H399 UK - 
BK1563 USA II H40 UK - 
Btn2164 UK - H402 UK - 
Btn2299 UK - H417 UK - 
C125 UK - H42 UK - 
C13 UK - H560 UK - 
C154 UK - HT2001-634 Australia IV 
C160 UK - HT2002-0609 unknown unknown 
C233 UK - HT2002-0635 Australia IV 
C253 UK - HT2002-664 UK IV 
C3 UK - HT2004-0991 Algeria IV 
C390 UK - HT2005-0306 France IV 
C427 UK - JE2 USA IV 
C49 UK - KD12943 UK I 
C56 UK - LAC (USA 300) USA IV 
CAN6428-011 Canada - MRSA 252 UK II 
CAN6820-0616 Canada - 82MRSA  Belgium I 
CDC12 USA II MRSA378 UK unknown 
CDC16 USA II MRSA4JJ UK unknown 
CDC201078-USA700 USA unknown MRSA707 UK unknown 
CDC201114-USA300 USA IV MRSA71 UK unknown 
CDC960758-USA100 USA II MSSA 476 UK - 
CDC980193-USA300 USA IV MU3 Japan II 
COL England I MW2 (USA400) USA IV 
Cuba4005 Cuba  - N315 Japan II 
Cuba4030 Cuba - NE334 (hys-) USA IV 
D22 UK - Newman  UK - 
 




D279 UK - Not116 UK - 
D302 UK - Not161 UK - 
D316 UK - Not266 UK - 
D318 UK - Not271 UK - 
D470 UK - Not290 UK - 
D473 UK - Not380 UK - 
D49 UK - Not98-53 UK IV 
D508 UK - RN4282 (TSST-1) USA - 
D551 UK - RN6390B (agr+) UK - 
D97 UK - RN6911 (agr-) UK - 
D98 UK - ST239 µ1 Turkey III 
E2260 Denmark - ST239 µ2 Turkey III 
EMRSA 13 UK unknown ST239 µ20 Turkey III 
EMRSA 15 UK IV SwedenAO17934/97 Sweden IV 
EMRSA 16 UK II SwedenON408/99 Sweden  III 
EMRSA 9 UK III SwedN8890/99 Sweden IV 
EMRSA 6 UK IV TW20 England III 
H050960412 UK - WBG8343 Australia IV 
H118 UK - WW2707/97 Germany IV 
H129 unknown unknown  
Table 2.1: S. aureus strains, origin and SCCmec type used in this investigation 
Other non S. aureus species investigated can be seen in Table 2.2. 
Species Strain 
E. coli DH5α 
P. aeruginosa PAO1 
S. epidermidis 12228 
S. epidermidis RP62A 
S. kloosi DSM 20676 
S. xylosus  ATCC29971 
S. lentus ATCC 29070 
S. vitulinus ATCC51145 
S. gallinarum CCM3572 
S. chromogenes CCM3387 
S. arlettae N910-254 
S. simulans    N920-197 
S. sciuri subsp. Sciuri ATCC29062 
Table 2.2: Non S. aureus strains used in this investigation 
2.2.1.5. PCR of bacterial DNA 




Bacterial DNA was extracted by standard methods using a High Pure PCR Template Preparation 
Kit (Roche, UK). In brief, 200 µL bacterial overnight culture (108 cfu/mL) was centrifuged at 3,000 
x g for 5 minutes, the supernatant removed and replaced with 200 µL PBS. 10 µL 5mg/mL 
lysostaphin was then added and the vials incubated at 37 °C for 30 minutes. 200 µL Binding 
Buffer and 40 µL proteinase K were then added, and the vial incubated at 70 °C for 10 minutes. 
100 µL isopropanol was added and the solution filtered at 8,000 x g for 1 minute. To isolate 
bacterial DNA, the solution was washed sequentially with 500 µL Inhibitor Removal Solution, 
twice with 500 µL Wash Buffer and then finally with 200 µL Elution Buffer.  
PCR of bacterial DNA was carried out by incubating the mix below on a standard PCR replication 
cycle, with an annealing temperature of 65 °C. Analysis of amplified hysA gene was then carried 
out using agarose gel electrophoresis in 2% agarose. 
 1 µL forward hysA primer 
 1 µL reverse hysA primer 
 10 µL PCR Master mix (Taq DNA polymerase, dNTPs, MgCl2 and reaction buffers) 
 1 µL DNA 
 7 µL water 
The specifications of forward and reverse primers are detailed in Table 2.3.  
 Sequence (5’ -> 3’) Mw (g/mol) Tm (°C) 
Forward primer (FW) CCCGATGCTACAGAGAAAGAGGC 7091 64.2 
Reverse primer (RV) cccCTCTCCGTTGATACTTTCATAG 7518 63.0 
Table 2.3: Specifications of forward and reverse primers used from hysA amplification 
 
2.2.2. Preparation of bacteriophage 
2.2.2.1. Bacteriophage extraction 
Firstly, crude sewage samples were taken from Thames Water PLC (Luton, United Kingdom). In 
brief, 250 mL sewage/river water was added to 200 mL water containing 15 g TSB, 1 mM MgSO4 
and 1 mM CaCl2.  The solution was then inoculated with 5 mL per strain of turbid, actively 
growing culture of the intended host bacterium. This was then gently mixed and incubated at 37 
°C overnight. A 10 mL aliquot of the solution was subsequently removed and NaCl dissolved to a 
concentration of 1 M to remove attached bacteriophage from bacteria. To kill any bacteria in the 
sample, 500 µL chloroform was added and the vial vortexed and centrifuged at 4,000 rpm for 30 




minutes. The aqueous enrichment was removed, filter sterilised (0.22 µm filter) and stored at 4 
°C until required.  
2.2.2.2. Bacteriophage isolation 
Specific bacteriophage strains were isolated from the purified lysate by plaque picking. 100 µL 
enrichment was added to 3 mL molten Tryptic Soy top agar (TS broth supplemented with 0.65 % 
w/v bacteriological agar) containing 100 µL host strain overnight culture. This was poured onto 
TS agar plates and incubated at 37 °C overnight to get isolated plaques. If isolated plaques were 
not seen, enrichment samples were diluted in SM buffer (100 mM NaCl, 8.5 mM MgSO4, 50 mM 
Tris-HCl, 0.01 % gelatin) and the test repeated. Isolated plaques of one morphology were picked 
using pipette tips and resuspended in 300 µL SM buffer.  
2.2.2.3. Bacteriophage propagation (double overlay method) 
To make stock solutions of pure bacteriophage, 40 µL picked plaque solution was added to 3 mL 
TS top agar containing 100 µL host strain overnight culture; this was gently mixed and poured 
onto a TS agar plate. The plate was incubated overnight at 37 °C to form a confluent / semi-
confluent lysis plate. 3 mL SM buffer was added to the plate to resuspend the grown 
bacteriophage, and the plate was incubated with gentle shaking at room temperature for 4 
hours (30 rpm, Stuart gyratory rocker SSM4, Bibby Scientific Limited, UK). The resulting liquid 
was removed and 50 µL chloroform added per 1 mL to kill any live host bacteria. The vial was 
gently vortexed, centrifuged at 4,000 x g for 20 minutes and the supernatant filter sterilised to 
form pure stock solutions of one type of bacteriophage. Aliquots were stored at 4 °C until 
required. 
2.2.2.4. Bacteriophage titration 
The bacteriophage concentration of samples was calculated by serial dilution. 100 µL phage 
solution was added to 900 µL sterile SM buffer and vortexed. 100 µL of this solution was then 
serially diluted by factors of 10 until a dilution of 10-8. Each sample was carried out in triplicate. 
100 µL bacterial overnight culture was added to 3 mL molten TS top agar and the solution 
poured onto a TS agar plate. This was then allowed to set. 10 µL bacteriophage dilution was 
pipetted onto the set bacterial agar (Figure 2.1). After overnight incubation at 37 °C, plaques 
were counted and the original phage concentration per mL calculated. Plates containing 3 – 30 
plaques were the most accurate for calculating titer. 











The bacteriophage concentration in plaque forming units per mL (pfu/mL) was calculated using 
the formula: 
pfu/mL original sample = (1/dilution) x (number of plaques) x 100  ( 2.2 ) 
2.2.2.5. Bacteriophage sensitivity assay 
The sensitivity of bacterial strains to bacteriophage was assessed using the streak test assay 
described by Cooper et al1. 10 µL bacterial overnight solution was streaked in a line over the 
surface of a petri dish and air dried at room temperature for 15 minutes. 10 µL bacteriophage 
solution (109 pfu/mL) was then spotted onto the line and allowed to dry at room temperature 
for 1 hour. Plates were incubated overnight at 37 °C and analysed for bacteriophage activity.  
2.2.2.6. PEG purification of bacteriophage  
In some cases, very pure bacteriophage samples were required containing no other media by-
product contamination, e.g. globules of agar. To gain bacteriophage particles only in buffer, 
bacteriophage stock was precipitated with 100 mg PEG 8000 + 53.4 mg NaCl per mL. This was 
incubated at 4 °C for 1 hour and then centrifuged at 11,000 rpm for 10 minutes. The precipitate 
was resuspended in an equal volume of SM buffer. To remove bound bacteriophage from PEG 
8000, an equal volume of chloroform was added to the suspension, gently vortexed and then 
centrifuged at 4,300 rpm for 15 minutes. The aqueous phase was recovered and stored at 4 °C 
until needed.  
 
 
Figure 2.1: Bacteriophage dilution plating on bacterial lawn for concentration determination 




2.2.2.7. Fluorescent tagging of bacteriophage 
PEG 8000 precipitated bacteriophage were resuspended in PBS solution and adjusted to pH 8.3 
(with tris-acetate buffer). PEG 8000 was then removed with 1:1 addition of chloroform and the 
aqueous phase recovered. 7 mL phage suspension was incubated with 7 µL (5)-
carboxyfluorescein N-succinimidyl ester (10 mg/mL in DMF) at room temperature in the dark for 
24 hours. Tagged bacteriophage were then recovered again with PEG precipitation.  
2.2.2.8. Incubation of bacteriophage with live bacterial culture 
The assessment of bacteriophage infectivity with live bacterial culture was carried out using 
absorbance at 600 nm (OD600) measurements in a SPECTROstar Omega plate reader. In all 
experiments, 10 µL bacterial overnight culture was added to 10 mL fresh growth medium (TSB or 
LB) and 200 µL added per well to a 96-well plate. The plate was then incubated with shaking at 
37 °C in the plate reader for 2 hours until bacterial growth entered the exponential phase. After 
2 hours, 50 µL per well of bacteriophage solution was added to the bacteria, and the plate was 
again incubated with shaking at 37 °C overnight. OD600 measurements were taken throughout 
incubation. 
2.2.3. NIH-3T3 fibroblast cell culture 
NIH-3T3 (mouse embryonic fibroblast cell line) cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL penicillin 
and 100 µg/mL streptomycin at 37 °C at 5% CO2. Cells were incubated for 2 days and adjusted to 
104 cells/mL for all experiments. Frozen low-passage number -150 °C stocks were created by 
standard protocols. 1 mL 2 day cell culture (106 cells/mL) in growth medium was mixed 1:1 with 
80% FCS + 20% DMSO. 1 mL solution was added per vial; vials were cooled in isopropanol at -80 
°C for 2 weeks, and then stored at -150 °C until needed.  
To revive cells, 1 mL frozen stock solution was added to a 25 mL cell culture flask containing 15 
mL DMEM (10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin). This was then incubated for 24 hours at 37 °C at 5% CO2. After this time, growth 
medium was carefully removed, discarded and replaced with another 15 mL to remove dissolved 
DMSO. The flask was then incubated for a further 24 hours at 37 °C at 5% CO2. 
To passage cells, spent media was removed and cells were washed with 5 mL PBS. This was then 
removed, and 2.5 mL 0.05% trypsin/EDTA solution was added and the flask incubated at 37 °C at 
5% CO2 for 3 minutes. 10 mL growth medium was added and the flask tapped sharply to dislodge 




cells. After all cells were dislodged, the solution was centrifuged at 4,000 rpm for 3 minutes. The 
supernatant was removed and the cells were then resuspended in 1 mL growth medium. 
For all cell tests, 100 µL resuspended cells was added to 15 mL growth medium (104 cells/mL) 
and used directly. Cell counting was carried out using a hemocytometer.  
2.2.4. Preparation of vesicles 
2.2.4.1. Vesicle buffer solutions 
Aqueous HEPES buffers were made up using Table 2.4 and Table 2.5. Compounds were dissolved 
in deionised water (18.2 MΩcm-1) and left at 4 °C to solvate overnight. HEPES buffer was then 
autoclaved to sterilise. 
Compound Mass (mg) Concentration (mM) 
HEPES 1191 10 
NaCl 3120 100 
NaOH 112 5.6 
EDTA 146.1 1 
Table 2.4: Constituents of HEPES buffer 
Compound Mass (mg) Concentration (mM) 
HEPES 239 10 
NaCl 59 10 
NaOH 541 135 
EDTA 29 97.5 
5(6)-Carboxyfluorescein 1879 50 
Table 2.5: Constituents of CF50 HEPES buffer 
2.2.4.2. Giant Unilamellar Vesicle (GUV) preparation 
GUVs were formed following the procedure outlined by Moscho et al 2. In brief, the desired ratio 
of lipids was made up using 100 mM chloroform lipid stock solutions. 20 µL or this mixture was 
then added to a 50 mL round-bottomed flask containing 980 µL chloroform and 150 µL 
methanol. 6.5 mL of the aqueous phase (containing the desired molecules to encapsulated; 
namely 5(6)-carboxyfluorescein buffer or bacteriophage suspension) was then carefully added 
down the side of the round-bottomed flask. Organic solvent was then removed by rotary 
evaporation above the Tm of the main lipid for two minutes. The formation of an opalescent 
liquid indicated GUVs had been created in high concentration. 
Purification of GUVs was not possible using standard NAP-25 columns as they were too large to 
pass through. Following Rotary Evaporation, 1 mL aliquots of the opalescent liquid were 




centrifuged at 13,200 rpm for 5 minutes and the resulting pellet re-suspended in 1 mL HEPES 
buffer. This was then repeated a further 2 times and the vesicles stored at 4°C until needed.  
2.2.4.3. Large Unilamellar Vesicle (LUV) preparation 
100 nm LUVs were formed using the film hydration method. Lipid mixtures with a total volume 
of 300 µL were measured from 100 mM lipid stocks in chloroform into sintered glass vials. The 
organic solvent was then evaporated under N2 for 10 minutes, resulting in a uniform lipid film. 
Once dry, 5 mL CF50 buffer was added to each vial and vials were incubated above the Tm at 55 
°C for 10 minutes. After 10 minutes, vials were vortexed and subsequently put through 3 x 
freeze-thaw cycles to increase vesicle encapsulation volume. This resulted in the formation of 
multilamellar vesicles of varied diameter in high yield. 
To form unilamellar vesicles of uniform diameter, vesicles were then extruded using a 
Liposofast™® LF-50 vesicle extruder. In short, the extruder was firstly set up with 2 x 100 nm 
pore extrusion membranes and pre-washed through with HEPES buffer. The vesicle solution was 
then passed through the extruder 3 times or until the solution became clear. All extrusion was 
carried out above the vesicle Tm. 
Vesicle purification was carried out using illustra™ NAP-25 columns (#17-0852, GE Healthcare, 
Little Chalfont, Bucks., UK). Each column was drained and equilibrated with HEPES buffer. 2.5 mL 
vesicle solution was allowed to completely enter the gel bed and 3.5 mL HEPES buffer was then 
added. All eluent of a yellow/orange colour (last 3 mL after HEPES addition) was collected and 
vesicles were then stored at 4 °C until needed. 
For those vesicles containing the cross-linking agent TCDA, vesicles were left overnight (before 
dilution) to equilibrate and then photolysed to crosslink the TCDA. 1 mL of vesicle solution was 
loaded into quartz cuvettes and placed into the middle of a UV CL1000 Crosslinker (254 nm) 
(Ultra Violet Products). Photolysis of vesicles was carried out at timer setting 1 (Approx. 6 
seconds). Vesicles were then diluted 1:2 with HEPES buffer and stored at 4 °C until needed.  
2.2.4.4. Incubation of vesicles with bacterial supernatant 
Supernatant aliquots were thawed to room temperature and 50 µL added to 50 µL vesicle 
solution in a 96-well plate. Plates were then incubated at 37 °C with shaking and the 
fluorescence intensity measured over 2 hours using a Spectrophotometer.  
 




2.2.5. Hydrogel swelling ratio 
Hydrogel swelling studies were carried out by immersing 10 mm gel discs in PBS buffer. Discs 
were incubated in PBS overnight to achieve total swelling. After 18 hours discs were removed, 
blotted to remove excess buffer and weighed (Ws). They were then dried at 60 °C overnight until 








Fourier Transform Infrared Spectroscopy (FTIR) was carried out on a Spectrum 100 FTIR fitted 
with a Universal ATR Accessory (PerkinElmer, USA), using SpectraSuite software to analyse 
spectra.  
Nuclear Magnetic Resonance (NMR) spectra of polymer samples were taken on a 400 MHz 
Bruker Avance III NMR at approximately 10 mg/mL in D2O. Spectra were then analysed using 
SpinWorks 3 software.  
Two separate UV crosslinker setups were used depending on what item was to be crosslinked. 
For TCDA crosslinking in phospholipid vesicles, 1 mL of vesicle solution was loaded into a quartz 
cuvette and placed into the middle of a UV CL1000 Crosslinker (254 nm) (Ultra Violet Products). 
Crosslinking was carried out at timer setting 1 (Approx. 6 seconds). For crosslinking of 
photopolymerisable hyaluronic acid (HAMA), polymer pre-mix was incubated in a Dymax 5000 
Flood curing system (400 W) for the desired time.   
The size distribution of vesicles was analysed using a Zetasizer Nanoscale Dynamic Light 
Scatterer (DLS) (Malvern Instruments, Malvern, UK). Vesicle samples were diluted by F200 in 
HEPES buffer (5 µL vesicle solution in 995 µL buffer) and vortexed; they were then allowed to 
equilibrate for 10 minutes at the set temperature before measurement.  
Absorbance and fluorescence measurements were taken using a SPECTROstar Omega (BMG 
Labtech, UK) microplate reader fitted with a UV/Vis spectrometer. Data measurement and 
analysis was carried out with Omega Data Analysis software and Origin Pro 8.   
 




2.4. General Experimental Theory 
2.4.1. Fluorescence Spectroscopy 
Fluorescent molecules can be used as a useful tool for investigating the dynamics and responses 
of systems such as hydrogels and phospholipid vesicles. Dye molecules can be encapsulated into 
vesicles and are released when the phospholipid bilayer breaks, giving a colour or fluorescence 
change. When added to a hydrogel system, either through direct coupling or entrapment during 
crosslinking, fluorescent molecules can give a greater insight into hydrogel structure and 
diffusion properties, as well as potentially being involved in ‘smart’ triggered release. The 
phenomenon of fluorescence is described by the Jablonski diagram (Figure 2.2). Common non-
toxic, stable dyes used in biological systems include calcein, rhodamine, fluorescein and Alexa 
Fluor® dyes.  
 
The Jablonski diagram describes the electronic states found in molecules and their subsequent 
excitations and transitions3. On absorption of a photon the molecule is excited from the S0 
vibrational ground state to the S2 state. This then transfers to a lower S1 state via intersystem 
crossing. From this state molecule emissions can go one of two ways. Fluorescence occurs when 
the molecule relaxes directly from the S1 state to the S0 state, emitting a photon. 
Phosphorescence occurs when the excited molecule has undergone intersystem crossing. This 
transfers the excited molecule to a state of higher spin multiplicity known as the triplet state. 
The molecule moves to the lowest triplet state T1 and then returns to the ground state by 
Figure 2.2: Jablonski diagram showing fluorescence and phosphorescence from various excited electronic 
states 




emitting a photon as phosphorescence. Fluorescence occurs on a much faster timescale 
compared to phosphorescence - ~10-8 seconds compared to ~1 second respectively.  
The main fluorescent agent used in Chapter 3 was the fluorophore 5(6)-carboxyfluorescein, 
which has an absorption maximum at 480 nm and an emission maximum at 520 nm. It 
fluoresces at low concentrations but is known to self-quench above concentrations of 50 mM 
(Figure 2.3). The mechanism of self-quenching in 5(6)-carboxyfluorescein is not well understood 









2.4.2. UV-visible Spectroscopy 
UV-visible spectroscopy refers to the investigation of the absorption of UV or visible light by 
molecules. It is a widely used technique for the analysis of transition elements, organic 
compounds and biological molecules. Absorbance is easily determined with the use of a 
spectrophotometer, by shining light through a sample and measuring the intensity change.  
Different molecules are able to absorb radiation at different wavelengths, depending on their 
chemical structure and environment, resulting in different colours. On absorption, outer 
electrons (σ, π or lone pair electrons) are promoted from the ground state to the excited state. 
The π to π* transition will be focussed on here as it is the most common transition in organic 
and biological molecules, and its absorption occurs between 200 – 800 nm (the UV-visible 
region). 
Figure 2.3: a) Chemical structure of 5(6)-carboxyfluorescein, b) Left vial containing unquenched 
fluorescing 5 mM dye, right vial containing quenched non-fluorescent 50 mM dye under UV light 
a) b) 




Π to π* transitions occur in molecules which contain unsaturated groups such as double bonds 
and aromatic rings. In protein molecules, absorption occurs at 280 nm due to tryptophan and 
phenylalanine amino acids (both aromatic). The more double bonds and conjugation present, 
the more coloured the compound; for example, the very deeply orange compound β-carotene 
contains an extensively conjugated π-system.  Conjugation (where p-orbital overlap allows 
movement of delocalised electrons) is electronically favourable as it brings the HOMO and 
LUMO π orbitals closer together, lowering the amount of energy required to promote to the 
excited state.  
UV-visible absorption can be described by the Beer-Lambert Law, which states that 
concentration, c, is directly proportional to the absorbance, A, where I0 is the initial intensity, I is 
the transmitted intensity, ε is the molar absorptivity and l is the path length.  
𝐴 =  𝑙𝑜𝑔10
𝐼0
𝐼
=  𝜀 𝑙 𝑐 (2.4 ) 
In this work, absorbance measurements were used in two main ways. Firstly, bacteria are known 
to absorb at 600 nm, and so by measuring the absorbance at 600 nm over the bacterial growth 
cycle, bacterial concentration can be followed. Secondly, a number of colorimetric assays were 
used which either used a coloured stain or produced a colour change in the presence of a certain 
molecule. These included the Carbazole assay (pink/violet = 595 nm), the TNBS assay (orange = 
340 nm), the MTT assay (violet = 570 nm) and the staining of bacterial biofilms with Crystal 
Violet stain (violet = 590 nm). 
2.4.3. Microscopy 
2.4.3.1. Light microscopy 
Light microscopy involves shining white light through a sample at high magnitude in order to 
gain an image. The light is focussed with single or multiple lenses and has a resolution of 
between 100 µm and 0.1 µm. Imaging of eukaryotic and bacterial cells is ideal with light 
microscopy, as these organisms usually have sizes on this scale and it is non-invasive.  
During this research, direct imaging of NIH-3T3 fibroblast cells was carried out using a Zeiss 
AxioCam ERc5s light microscope with no further sample preparation.  
2.4.3.2. Fluorescence microscopy 
Fluorescent microscopes use fluorescence of samples to create an image. Light of a certain 
wavelength is focussed onto a sample that has been previously stained with (or contains) a 
fluorescent compound. The compound is then exited and emits fluorescence of another 




wavelength. This is then detected and an image can be formed. Images can either be purely 














Unlike conventional optical microscopy, fluorescence microscopy gives images with high 
contrast and visibility. Various fluorescent dyes can be used which selectively bind to certain cell 
organelles. For example, in cell culture the fluorescent probe 4',6-diamidino-2-phenylindole 
(DAPI) selectively binds to cell DNA, showing only nuclei as blue in images. One problem 
sometimes found with fluorescence can be the possibility of photo-bleaching, where the 
fluorescent molecule is damaged over the course of excitation and fluorescence gradually fades.  
2.4.3.3. Confocal Laser Scanning Microscopy (CLSM)  
Confocal Laser Scanning Microscopy (CLSM) enables high resolution optical images of 
fluorescently stained samples to be taken on multiple depths. These can then be collated to 
form a 3D picture (z-stack). CLSM has a number of advantages over conventional fluorescence 
microscopy, notably that by using pinhole apertures extraneous light can be filtered out 
resulting in a sharper image.  
CLSM is routinely used for high quality imaging of biological specimens taken from cell biology, 
microbiology and genetics. A Zeiss LSM510 META Confocal Microscope with LSM Image Browser 
Figure 2.4: Schematic diagram of visible light excitation and emission in a 
fluorescent microscope 
 




software was used in this research to image fluorescently tagged phospholipid vesicles in 
solution. 
2.4.3.4. Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) is a high resolution imaging method which uses the 
interaction of high energy electron beams with conductive surfaces. Firstly, an electron beam is 
generated (usually from a tungsten filament cathode) and focussed using electromagnetic 
lenses. To form an image, the focussed electron beam is scanned across the sample under 
vacuum in a raster pattern. The electron beam excites electrons on the surface and emitted 
electrons are detected by a detector. By knowing the position of the sample that has been 
scanned and the intensity of emitted electrons, an image can be formed.  
In order to create an image with SEM, the sample surface must be conductive. In biological or 
non-metallic samples which are not conductive, sputter coating of a thin metal layer (gold, 
platinum, chromium, etc.) is carried out during sample preparation.  
SEM imaging of hydrogels was carried out with help from the University of Bath Microscopy and 
Analysis Suite. 2 x 2 mm hydrogel samples were firstly immersed in liquid nitrogen for 10 
minutes to preserve structure and then freeze dried overnight. Samples were then sputter 
coated with gold using an Edwards S150B sputter coater. SEM images of hydrogels were taken 
under vacuum using a JEOL SEM6480LV SEM.  
2.4.3.5. Transmission Electron Microscopy (TEM) 
Transmission Electron Microscopy (TEM) again uses a high energy electron beam to image at a 
far higher resolution than traditional light microscopy. TEM can be used to image very small 
biological materials which range in size from 1 µm to 1 nm, such as viruses. Electrons are 
emitted at the top of the microscope within a high vacuum and the beam is focussed with 
electromagnetic lenses. The electron beam then passes through the specimen to a viewing 
screen below. Unscattered electrons that have passed through the sample appear as light areas, 
whereas electrons that have been scattered by the sample appear as dark areas.  
In TEM, samples are normally negatively stained with heavy metals; frequently used stains 
include uranyl acetate, osmium tetroxide and phosphotungstic acid. The electron beam then 
interacts with these ions forming an image.  
TEM imaging of bacteriophage was carried out with help from the University of Bath Microscopy 
and Analysis Suite. For sample preparation, glow discharge grids were firstly exposed to ozone 




for 30 minutes to increase surface hydrophilicity. Each grid was then soaked in PEG precipitated 
bacteriophage stock (109 pfu/mL) for 1 minute to allow bacteriophage to adsorb. Excess 
bacteriophage solution was then removed by blotting the edge with filter paper, and the grids 
were then lightly washed with distilled water twice. One drop 1% uranyl acetate solution (pH 4) 
was added to each grid to negatively stain bacteriophage, and the excess was then blotted away. 
The grids were then left to dry overnight. Images were acquired using a Jeol JEM1200EXII TEM 
with Gatan Dualvision Digital Camera. 
2.4.4. Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) is a technique used to calculate the size of nano to micro-sized 
particles such as proteins, polymers, colloids, micelles and vesicles in solution. It can also be 
used to investigate particle size distribution and zeta-potential.   
DLS relies on the underlying Brownian motion of particles in solution to calculate size. A 
monochromatic laser is shone at the sample and light hits the moving particles, causing the 
beam to be scattered. This is known as Raleigh Scattering. If particles were stationary, the 
amount of scattered light would be constant, however as particles are constantly moving 
interference is seen. The change in wavelength of the scattered light in relation to time can be 
measured and is used to calculate the diffusion constant, D. 






where kB is the Boltzmann constant, T is the temperature, η is the dynamic viscosity and r is the 
particle radius. It is important to note that the calculated particle radius is in fact the 
hydrodynamic radius, which includes a thin dipole layer of solvent molecules which surround the 
particle.  
2.5. Polymerisation 
Polymerisation has multiple and far-reaching applications in nearly every aspect of modern life, 
with polymers prevalent in the natural world, as well as the automotive industry, healthcare, 
coatings, adhesives, textiles and packaging. It involves the reaction of small molecules 
(monomers) to form long polymer chains or 3D networks; these can be formed from one or 
many types of monomer.  




Polymer chains which contain only one type of monomer are known as homopolymers. When 
two or more different monomers are involved, copolymers are formed which exhibit varying 
configurations. The main configurations can be seen in Figure 2.5.  
Random copolymers have a random arrangement of monomer units within the chain. 
Alternating polymers are more ordered with regularly alternating units. Block copolymers are 
made up of large blocks of each monomer and are predominantly formed using living 
polymerisation techniques such as ATRP, ROMP and RAFT. In recent years they have come under 
increased investigation due to their interesting phase separation and self-assembly properties4, 5. 
Finally, graft polymerisation results in branched copolymers where one polymer block is grafted 









In bulk polymer matrices, two distinct physical phases can be present: the crystalline and 
amorphous forms. Crystalline structures form when polymers have a regular structure 
(homopolymers or alternating polymers) which can form highly ordered phases, for example, 
polyethylene, and isotactic polypropylene. Amorphous polymers have no crystalline structures 
but form randomly oriented structures with intertwined polymer.  
Polymerisation can occur through chain growth or step growth reactions of monomer units. 
Chain growth polymerisation creates polymers with no by-product molecules formed, whereas 
in step growth polymerisation small molecules such as water or HCl are created as well as the 
growing polymer chain (Figure 2.6). In step growth polymerisation, monomer units are most 
commonly linked through ester, amide and carbonate linkages.  
a) b) c) d) 
Figure 2.5: a) Random copolymer, b) alternating copolymer, c) block copolymer, d) graft copolymer 




Radical, anionic, cationic and coordination polymerisation processes are all classed as chain 
growth polymerisations. In these cases, the monomer unit undergoes polymerisation by forming 
free radicals, carbocations, carbanions or organometallic complexes respectively, which then 
undergo a chain reaction to form polymers. For the purposes of this work, free radical 
polymerisation will be discussed in more detail in Section 2.6. 
 
Polymer molecular weight (and degree of polymerisation) determines the physical properties of 
the polymer in question. It can be described by the number average molecular mass, or the 
weight average molecular mass depending on the number or weight of repeating units. The two 
equations for number average, ?̅?𝑛 and weight average, ?̅?𝑤 molecular weight can be seen in 
below6. Where Ni is the number of molecules and Mi is the molecular weight.  
?̅?𝑛 =  
∑ 𝑁𝑖 𝑀𝑖
∑ 𝑁𝑖









The ratio between ?̅?𝑤and ?̅?𝑛 is known as the (poly)-dispersity index (Ð), which gives an 
indication of the molecular weight range of polymer chains. The smaller the polydispersity, the 
narrower the molecular weight range. If all polymer chains have the same molecular weight, the 
system is described as monodisperse and has a polydispersity of one.  
a) 
b) 
Figure 2.6: a) Chain growth polymerisation of ethene to form poly (ethene), b) Step growth 
polymerisation of 1, 4-phenylene diamine and 1, 4-benzenedicarbonyl chloride to form Kevlar™ and HCl 
by-product 




Figure 2.7: Free radical initiation of monomer unit 
2.6. Principles of Radical Polymerisation 
Free radical polymerisation is a chain growth addition polymerisation which creates polymers 
through the sequential addition of monomer to an active free radical centre at the chain end 
(suitable monomers consist of vinylic monomers). It is a successful method for large scale 
production of polymers; more than 70% vinyl polymers (polymers formed from vinylic 
monomers) have been industrially produced this way7a. Although relatively non-specific (e.g. it 
gives little control over polymer tacticity or polydispersity), it has a number of advantages over 
other methods as it forms polymers of a high molecular weight very quickly without the 
formation of by-products. The process occurs in four distinct steps: initiation, propagation, chain 
transfer and termination7b.  
2.6.1. Initiation 
Initiation describes the initial production of radical species which go on to create the radical 
centres involved in polymerisation. Initiators are frequently small molecules which form radicals 
after decomposition with either heat or light. These include peroxides, azo compounds (AIBN), 
redox initiators and photoinitiators (peroxides and azo compounds can dissociate photolytically, 
as well as benzophenone based molecules).  
After dissociation, the primary radical species reacts with a monomer unit, M, to form initiating 
radicals, which then go on to react with more monomer units in a chain reaction (Figure 2.7). 
Reaction mainly occurs in a “head-to-tail” orientation, from the least sterically hindered and 








Where ki is the rate constant for initiator decomposition, f is initiator efficiency and [I] is initiator 
concentration. 
Initiation is frequently not ideal; a number of side reactions, rearrangements and fragmentations 
can occur in competition with the ideal initiation seen in Figure 2.7.  Initiator concentration (with 




respect to monomer concentration) also governs polymer chain length; a high initiator 
concentration (compared to monomer concentration) eventually yields shorter chains, whilst a 
low initiator concentration gives longer chains.  
2.6.2. Propagation 
Propagation is the process in which polymers increase chain length by sequential addition of 
monomers (Figure 2.8). After the radical initiator has reacted with the monomer unit, the 
monomer radical sequentially attacks each new monomer (usually at bonds which stabilise the 
radical such as π-bonds), forming a new polymer repeating unit and a radical at a new position. 
This process will continue until there are no more monomers, or a termination event occurs. 
 
𝑟𝑎𝑡𝑒 𝑝𝑟𝑜𝑝 = − 
𝑑[𝑀]
𝑑𝑡
=  𝑘𝑝[𝑀][𝑅𝑀𝑛 ∙] 
 
Where kp is the rate constant for chain propagation, [M] is monomer concentration and [M·] is 
monomer radical concentration. 
Chain transfer is the side reaction to propagation, and is the transfer of a radical from a growing 
polymer chain either to a monomer, another radical species, another polymer or the solvent. 
This results in the formation of both a terminated polymer and a new radical species.  
Chain transfer agents are small molecules that can be added to a polymerisation to induce chain 
transfer through abstraction of a hydrogen or halogen atom. In general, the addition of small 
amounts of these species forms polymers of reduced molecular weight and polydispersity.  The 
most commonly used chain transfer agents are thiol derivatives and halocarbons because of 
their weak S-H and C-halogen bonds8 
2.6.3. Termination 
There are two main termination events which stop the polymerisation reaction: combination of 
two growing polymers (combination), or termination by disproportionation (Figure 2.9). In 
combination, two radical polymer chains combine together to form one long polymer chain 
linked with a σ-bond. In radical disproportionation, two radical polymer chains transfer a proton 
to form two separate non-radical products. The most common disproportionation reaction 
Figure 2.8: Propagation of polymer chains in free radical polymerisation 




occurs when a hydrogen atom is taken from one chain by another, forming one hydrogen-











𝑤ℎ𝑒𝑟𝑒    𝑘𝑡 =  𝑘𝑡𝑐 +  𝑘𝑡𝑑   
 
Where kt is the rate constant for chain termination, ktc is the rate constant for combination 
termination, ktd is the rate constant for disproportionation termination and [M.] is radical chain 
concentration. 
Termination is the major disadvantage of free radical polymerisation compared to other 
processes. Because the reaction with radical chains is so fast, chains can react quickly and easily 
with other growing chains. This results in the formation of polymers with a very broad 
polydispersity and different molecular weights7. In order to overcome this, in recent years 
chemists have turned to controlled radical polymerisation techniques such as atom transfer 
radical polymerisation (ATRP)9 and reversible addition-fragmentation chain transfer (RAFT)10, 11, 
which give a very narrow relative polydispersity 12-15. 
2.6.4. Kinetics of radical polymerisation 
The rate equations for initiation, propagation and termination can be combined into a simplified 
rate equation by using the steady-state approximation. This assumes that during the reaction, 
the concentration of the intermediate species, RMn. concentration does not change significantly 







Figure 2.9: Combination and Disproportionation termination mechanisms in free radical polymerisations 




After an induction period, the rate of initiation and termination become equal: 
2𝑓𝑘𝑖[𝐼] = 2𝑘𝑡[𝑀𝑛
.]2      (2.8) 
which rearranges to: 
[𝑅𝑀𝑛





By substituting in the rate equation for propagation, we can get an equation for the overall loss 
of the initial monomer species: 








which can simplify to Equation 2.11, where k is the overall rate constant for reaction: 
𝑟𝑎𝑡𝑒 𝑝𝑟𝑜𝑝 = 𝑘√[𝐼][𝑀] (2.11) 
Therefore, by monitoring the monomer concentration over time, the general rate of reaction 
can be calculated.  
2.6.5. Thermodynamics of radical polymerisation 
In free radical polymerisation, polymerisation is favoured enthalpically (ΔH = negative), but dis-
favoured entropically (ΔS = negative). The reaction will take place provided that the change in 
Gibbs free energy (ΔG) is negative (Equation 2.12); in order for this to occur the enthalpy change 
must be large and negative, making the process exothermic.  
𝛥𝐺 =  𝛥𝐻 − 𝑇𝛥𝑆 < 0 (2.12) 
In general, the driving force of polymerisation is the enthalpy change, which in turn is dependent 
on a number of factors. These include the bond energy difference between the monomer and 
polymer (e.g. if the double bonds on the monomer or polymer are stabilised by resonance), 
steric effects and electronic effects. As temperature increases, the entropic contribution to the 
system becomes more important.  
 
 





= polymer chain 
2.7. Principles of Hydrogel Chemistry 
As mentioned earlier in Chapter 1, hydrogels are crosslinked polymer networks formed from 
natural or synthetic polymers which contain over 90% water. They can be highly hydrophilic, 
superabsorbent, biocompatible and non-toxic, as well as displaying similar structural and 
mechanical properties to human tissues. It is due to these reasons that in recent years, 
hydrogels have become widely used in biotechnology (e.g. in tissue engineering, wound 
dressings, medical devices and cell culture).   
Hydrogels encompass a vast range of structures and chemistries, and so can be classified 
depending on varying parameters16: 
- Charge: anionic, cationic, ampholytic or neutral 
- Preparation method: homo-polymer networks, multi-polymer ‘blended’ networks, 
interpenetrating networks or copolymers 
- Chemical composition: natural or synthetic polymers 
- Structure: amorphous, semi-crystalline or supramolecular networks 
- Nature of crosslinks: chemical hydrogels = covalent bonds, physical hydrogels = Van der 
Waals, molecular entanglements, metal complexes or hydrogen bonds 
 
Either radiation (to induce a chain reaction) or chemical reaction can be used to crosslink 
polymers into networks. Radiation crosslinking is predominantly through UV irradiation, but can 
also be through X-rays, γ-rays or electron beams. With ‘reactive’ chemical crosslinking, small 
molecular weight molecules can be reacted with polymer chains to form di- or multi- crosslinks. 






Figure 2.10: Structure of ideal crosslinked polymer network for use in hydrogels 
?̅?𝑐 




Ideally, a crosslinked polymer network should comprise tetra-functional crosslinks with small 
size distribution of length between crosslinks, Mc. However, more commonly ideal behaviour is 
not seen and other crosslinked structures can be present. Polymer chains can be looped 
together or entangled, or there could be unreacted functionalities or dangling chain ends.  
2.7.1. Rheology 
The most common method of measuring the viscoelastic mechanical properties of hydrogels is 
through rheology, using dynamic mechanical analysis, DMA. Rheology is the science of 
deformation and flow of liquids and semi-solids in response to an applied force. In DMA, the 
hydrogel is clamped between two plates and a sinusoidal shear strain is applied to one side 
through rotation of one plate; on the other side, a detector measures stress imparted to the 
hydrogel (Figure 2.11) 17, 18. Shear force is a force applied to a sample parallel to the surface. 
From this measurement, two important parameters can be calculated: the shear storage (elastic) 
modulus, G’, and the shear loss (viscous) modulus, G’’ 16, 19, 20. In general, G’ describes the 






On initial testing of the sample, the material is subjected to sinusoidal strain, described by 
Equation  (2.13), where γ0 is the shear strain amplitude and ω is the oscillation frequency: 
𝛾 = 𝛾0 sin  (𝜔𝑡) (2.13) 
On interaction with the sample, the wave becomes out of phase with the strain applied by a 








Figure 2.11: (left) Diagram of hydrogel sample between one rotating and one stationary plate in DMA, 
(right) shearing of a hydrogel block by a force, F 
Hydrogel 




stress, this can be described by the equation below, where σ is the shear stress and G* is the 
shear modulus: 
𝜎 = 𝐺∗ (𝜔) 𝛾0 sin  (𝜔𝑡 + 𝛿) (2.14) 
If we separate this into an “in-phase” and “out-of-phase” component, and if we define: 
𝐺′(𝜔) =  𝐺∗ cos(𝛿) (2.15) 
𝐺′′(𝜔) =  𝐺∗ sin(𝛿) (2.16) 
Then, we can obtain an equation to describe G’ (the elastic modulus) and G’’ (the viscous 
modulus): 
𝜎 = 𝛾0 (𝐺
′(ω) sin  (𝜔𝑡) + 𝐺′′(𝜔) cos (𝜔𝑡)) (2.17) 
The ratio of the energy lost to the energy stored by the hydrogel during the plate rotation is 
described by the loss tangent: 





In general, the technique provides a good indication of the viscoelastic properties of a hydrogel; 
however for the purposes of this work, rheology of hydrogels was not investigated in detail. 
2.7.2. Swelling  
The swelling ratio of a hydrogel in a certain solvent can give valuable information on its 
structure, density and diffusion properties. The most widely used method of investigating the 
internal structure of a hydrogel is the use of the Flory-Rehner equation21. Florey-Rehner analysis 
assumes the hydrogel structure to be a neutral and tetra-functionally crosslinked network. 
Although the theory is quite general, it offers a useful indication of hydrogel properties in an 
ideal system.  
A simplified version of the Flory-Rehner equation can be seen in Equation (2.19)22, where Qv is 
the volumetric swelling ratio, ?̅?  is the specific volume of the dry polymer,  ?̅?𝑐is the average 
molecular weight between crosslinks, V1 is the molar volume of solvent and χ is the Flory 
polymer solvent interaction parameter.  
𝑄𝑣
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The volumetric swelling ratio can be determined by standard swelling measurements described 
in Section 2.2.5. Subsequently, a number of hydrogel characteristics can be calculated. The 
effective crosslink density of the hydrogel, Ve, can be calculated using Equation (2.20), where ρp 
is the polymer density: 





The mesh size of the hydrogel, ξ, can also be calculated using Equation (2.21), where ?̅?2 is the 
distance between crosslinks: 
ξ =  𝑄𝑣
1
3 √?̅? 2  (2.21) 
By knowing these parameters, the diffusional characteristics of the hydrogel can be understood. 
A highly swelling hydrogel would have a large pore size, giving faster diffusion, whereas in low 
swelling hydrogels which are denser, slow diffusion is seen.  
2.8. Enzyme kinetics 
Enzymes are biological protein molecules which act as extremely specific catalysts in chemical 
reactions by lowering the activation energy of the system. Here, enzymes act as mediators in the 
transition state between reactants (in the case of enzymes they are referred to as substrates) 
and products. The enzyme lowers the activation energy, ΔE, required to overcome the energy 
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Figure 2.12: ΔE change difference in catalysed and uncatalysed reactions 




presence of no enzyme, substrate molecules would not have enough thermal energy to 
overcome this energy barrier to be converted to products. In general, catalysts increase the rate 
of reaction from substrate to product.  
A schematic of substrate interaction with an enzyme, and subsequent reaction can be seen in 
Figure 2.13. On initial reaction, the enzyme and the substrate bind in equilibrium with the 
enzyme-substrate complex. The enzyme contains a region, known as the active site, which is 
completely complementary to the substrate in size, shape and chemical composition. On binding 
the enzyme-substrate complex lowers the activation energy and promotes the rapid conversion 







The enzyme-substrate reaction can be described by the Equation (2.22), where E is the enzyme, 
S is substrate, ES is the enzyme-substrate complex and P is the products:   
 
𝐸 + 𝑆 ⇌ ES → 𝐸 + 𝑃 (2.22) 
 
Taking this equation, the overall rate of reaction can be calculated as described by the Michaelis-
Menten equation, where ν is the rate, Vmax is the maximum rate achieved by the system, and KM 
is the Michaelis constant: 










Figure 2.13: a) initial reversible binding of enzyme to substrate, b) conversion of substrate to products in 















Experimentally, Vmax is calculated by measuring the rate of product formation versus the 
substrate concentration. The Vmax is the maximum rate at which substrate is converted too 
product. KM is then subsequently calculated as ½ Vmax. 
In general, the Michaelis-Menten constant can describe two properties of an ES system. Firstly, 
KM is the concentration of substrate at which half the active sites are filled. In this way the 
concentration of substrate needed for significant catalysis to occur can be calculated. Also, KM 
gives an indication of how well an enzyme is able to complex with a substrate. If the rate of 
product formation, k2, is much smaller than the rate of dissociation, k-1, KM is equal to the 
dissociation constant for the ES complex. Here, if KM is high, binding is weak, and if KM is low, a 
strong binding is seen.  
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The initial preliminary work on this project focussed on the use of phospholipid vesicles for 
triggered release. In recent years, vesicles (formed from either phospholipids or more commonly 
amphiphilic block copolymers) have been used to encapsulate a range of biologically active 
molecules including peptides, enzymes, viruses, antimicrobials and drugs1-4, as well as in 
imaging.  
As previously mentioned in Chapter 1, when growing, bacteria secrete a number of small 
molecule virulence factors into their surrounding environment. The structure of the 
phospholipid bilayer of vesicles is very similar to that of the cell membrane, giving them very 
similar responses to these virulence factors5.Previous research within the group has investigated 
how S. aureus and P. aeruginosa virulence factors cause triggered release of dye and 
antimicrobial molecules from phospholipid vesicles (Figure 3.1) 6.  
 
As bacteria grow, these small molecules are able to degrade the phospholipid bilayer of the 
vesicle in the same way as with cell membranes. This causes the vesicle to burst, and depending 
on what is encapsulated inside the vesicle, a different response is seen. If vesicles contain 
encapsulated self-quenched fluorescent dye such as 5(6)-carboxyfluorescein, the dye will be 
released into the surrounding environment and diluted, allowing it to fluoresce. This can be seen 
as a fluorescent glow under UV light. If antibiotics or other antimicrobials are encapsulated, 
triggered killing is seen. In the presence of toxic bacteria, the antimicrobials are released and go 
Figure 3.1: Schematic of antimicrobial or dye filled vesicles which become degraded by bacterial virulence 
factors, leading to the killing of bacteria or the release of dye molecules 





on to kill the surrounding bacteria. In non-toxic species, the vesicles remain intact and no killing 
is seen.  
Triggered breakdown of vesicles (and subsequent cargo release) is understood to be due to 
secreted δ-toxin in S. aureus and rhamnolipids in P. aeruginosa7, 8.  δ-toxin is a potent, low 
molecular weight peptide which causes cell (and vesicle) damage through insertion into the cell 
membrane phospholipid bilayer. On insertion, the protein forms pore-like barrel structures in 
the membrane, allowing efflux of water and ions. At higher concentrations the peptide is also 
thought to cause solubilisation of the membrane in a similar way to surfactant9, 10. Rhamnolipids, 
on the other hand, are rhamnose based glycolipid biosurfactants which solubilise the 
phospholipid cell membrane11. 
The aim of this chapter was to encapsulate bacteriophage into phospholipid vesicles to create a 
system which gives triggered release by bacterial virulence factors. In the presence of 
pathogenic bacteria, the vesicles would become lysed and bacteriophage would be released into 
the system (killing infecting bacteria). When there is no infection, or the bacteria present are not 
pathogenic, no vesicle lysis is seen and so bacteriophage are not released. In this way, the 
constant release of therapeutic is prevented, lowering the selection pressure on bacteria to 
become resistant. Because of the highly aqueous nature of the vesicles, in order to remain active 
the vesicles would then be embedded into a hydrogel matrix. 
3.2. Preliminary Results and Discussion 
Proof of concept was carried out using LUVs previously researched by the group. 100 nm 
phospholipid LUVs (size verified with DLS) containing DPPC, DPPE, cholesterol and the 
crosslinker TCDA were formed containing 50 mM 5(6)-carboxyfluorescein. These vesicles were 
then incubated with bacterial supernatant of pathogenic strains (S. aureus RN6390B, lac and 
MSSA 476 and P. aeruginosa PAO1) and non-pathogenic strains (S. aureus RN9611 and E. coli 
DH5α), as well as positive and negative controls (the surfactant Triton X100 and buffer). 
As seen in Figure 3.2, in the presence of surfactant or pathogenic bacteria, the vesicles become 
lysed and a fluorescent switch-on was seen. In the presence of non-pathogenic bacteria, no 
fluorescent response was seen, implying the vesicles were not lysed. From these results we 
could show that vesicles were able to give triggered release of encapsulated molecules only in 
the presence of pathogenic bacteria and Triton X100 surfactant.  





With this in mind, it was initially proposed to use this selective lysis of vesicles by bacterial 
virulence factors to create a vesicular system for triggered release of the bacteriophage. The 
vesicles would provide a stable, aqueous environment to protect the bacteriophage, and on lysis 
by secreted virulence factors, bacteriophage would be released into the system to infect and kill 
bacteria. Some investigations have been previously carried out into bacteriophage encapsulation 
by other researchers, however none had used phospholipid vesicles, and none had reported 
triggered release12, 13.  
Here, the extruded 100 nm LUVs used for the majority of previous research were unsuitable, as 
they were too small; instead Giant Unilamellar Vesicles (GUVs) formed by rotary evaporation 
were used which generally have a diameter of over 1 µm14, 15.  GUVs were initially formed 
containing 80% DPPC 20% cholesterol encapsulating 5(6)-carboxyfluorescein and then imaged 
using confocal microscopy (Figure 3.3).  
Because GUVs are relatively heavy, they were able to sink down onto the bottom of the glass 
coverslip; 3D confocal images of these were then formed using z-stacks.  The majority of GUVs 
formed were approximately 1 µm in diameter; however some of up to 10 µm were apparent. 
Although fluorescence microscopy did give an idea of the size distribution, it did not allow 
further investigation of vesicle structure, e.g. lamellarity. Also many vesicles appeared 
aggregated and non-spherical in shape.  
Figure 3.2: (left) Fluorescence intensity of 5(6) carboxyfluorescein vesicles incubated with bacterial 
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The phospholipid bilayer was then doped with Texas Red labelled phospholipid DHPE in order to 
visualise the lipid bilayer in more detail. Vesicles with this were formed with encapsulated of 5 
mM 5(6)-carboxyfluorescein and then imaged using confocal microscopy (Figure 3.4).  
As expected, the Texas Red labelled DHPE (excitation = 595 nm, emission = 613 nm) aggregated 
into the phospholipid bilayer, allowing the GUV bilayer to be seen. Under excitation, the Texas 
Red emits a red colour only from the phospholipid membrane. Under excitation at 488 nm 
however, the encapsulated 5(6)-carboxyfluorescein is seen emitting a green colour from the 
vesicle inside.  
Figure 3.3: Confocal microscopy images of DPPC GUVs containing 5 mM 5(6)-carboxyfluorescein (left) from 
the z direction and (right) from the x direction 
Figure 3.4: a) red, b) green and c) combined laser images of 5(6)-carboxyfluorescein GUVs doped with 
Texas Red labelled DHPE. Scale bar = 2 µm 
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Figure 3.5: (left) Fluorescence intensity of 5(6) carboxyfluorescein GUVs incubated with bacterial 
supernatant over 2 hours, (right) Endpoint fluorescence intensity after 2 hours 
In general, the imaging showed that GUVs could successfully be formed using rotary 
evaporation; however this technique formed vesicles with a broad size distribution with little 
control over vesicle lamellarity or shape. Also, the concentration of GUVs formed was very low 
and the majority of GUVs imaged were small and aggregated. Despite this, the majority of 
vesicles formed had a diameter of approximately 1 µm, which was sufficient for bacteriophage 
encapsulation.  
GUVs containing self-quenched 50 mM 5(6)-carboxyfluorescein were then incubated with 
bacterial supernatant in a similar way to LUVs (Figure 3.5).  
 
After two hours incubation, GUVs generally exhibited the same response to LUVs, with 
pathogenic strains showing a higher fluorescent response than non-pathogenic strains or buffer 
solution. However, far higher background fluorescence was seen, with negative controls 
exhibiting approximately 10 times more fluorescence intensity than with LUVs; this implied 
either poor vesicle purification or inherent vesicle instability in solution. Also, the GUVs were not 
responsive to P. aeruginosa PAO1, a strain that secretes rhamnolipid virulence factors which 
were earlier shown to break down LUVs (Figure 3.2).   
As the bacteriophage used was not active against P. aeruginosa, this was not necessarily an 
issue, so GUVs containing encapsulated Bacteriophage K were still investigated. GUVs were 
found to be successfully purified by centrifugation, as the viral particles did not sediment 
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compared to GUVs. The bacteriophage were also stable in the elevated temperatures seen 
during rotary evaporation, as well as being stable in the presence of the organic solvents 
(chloroform and methanol) used to dissolve the phospholipids. As now a fluorescent marker was 
not incorporated into the GUVs, lysis was followed using absorbance of bacteria at 600 nm. 
When incubated with bacteriophage GUVs, bacterial virulence factors would again lyse the 
vesicle, but this time bacteriophage would be released and a drop in absorbance would be seen 
as bacteria are lysed.  
Here, bacteriophage GUVs were incubated with two S. aureus strains which were both sensitive 
to Bacteriophage K (data shown in Chapter 4), however they had differing abilities to lyse GUVs. 
S. aureus MSSA 476 was used as a strain sensitive to Bacteriophage K, and able to lyse vesicles, 
whereas S. aureus RN9611 was sensitive to Bacteriophage K but unable to lyse vesicles 
compared to positive and negative controls in 5(6)-carboxyfluorescein GUVs.  
With bacterial strains which were sensitive to Bacteriophage K, killing should only be seen in 
strains which are also able to lyse vesicles (if bacteriophage have been efficiently encapsulated 
into GUVs). With strains which do not lyse GUVs (e.g. RN9611) but are still sensitive to 
bacteriophage, normal growth should be seen. If normal growth is seen, in all cases the 
bacteriophage concentration was too low to cause significant bacterial killing; this would either 
be due to the reaction conditions killing bacteriophage, or GUVs not being encapsulated inside 
GUVs in a high enough concentration. Overnight incubation results can be seen in Figure 3.6. 
 
 
Figure 3.6: (left) S. aureus MSSA 476 and (right) S. aureus RN9611 incubated with GUVs containing 
Bacteriophage K 
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In S. aureus MSSA 476 normal responses to Bacteriophage K and Bacteriophage K GUVs were 
seen, with bacterial lysis in all cases. With S. aureus RN9611 however, again bacterial lysis was 
seen in all cases; a small re-emergence in growth apparent after approximately 12 hours growth 
can be attributed to bacterial mutation and subsequent resistance to bacteriophage occurring.  
From the results of live culture experiments, no triggered release was seen; instead killing was 
seen in both S. aureus species. To assess why this occurred, bacteriophage were tagged with a 
fluorescent label. By imaging the bacteriophage GUVs using fluorescence confocal microscopy, 
we could ascertain if bacteriophage were assembling inside the vesicles or in the phospholipid 
bilayer.  
Fluorescent tagging of bacteriophage was carried out by reacting amine groups on the 
bacteriophage capsid head (predominantly arginine and lysine) with fluorescent labels. 5-
carboxyfluorescein N-succinimidyl ester (CF-NSE) and fluorescein isothiocyanate (FITC) were 
investigated, with CF-NSE the most successful (Figure 3.7).16, 17 
  
 
After purification, the successful tagging of bacteriophage was confirmed using spectroscopy, 
with the maximum intensity in the emission spectrum of the dye shifting by approximately 10 
nm to a lower wavelength (Figure 3.8). This is known as hypsochromic (blue) shift and occurs 
when the fluorophore is in a different chemical environment, implying attachment to the capsid 
head. 
Figure 3.7: Reaction scheme for the fluorescent tagging of bacteriophage capsid primary amines with (5)-
carboxyfluorescein N-succinimidyl ester 





Figure 3.9: a) red, b) green and c) combined laser images of Texas Red labelled DHPE GUVs containing 
CF-NSE labelled bacteriophage 
  
The tagged bacteriophage were encapsulated into GUVs through rotary evaporation. Texas Red 
labelled DHPE was also added in order to label the phospholipid bilayer. Confocal images of the 
vesicles can be seen in Figure 3.9, where separate images of the labelled phospholipid (a) and 
bacteriophage (b), as well as combined together in one vesicle (c) are shown.  
 
Spherical GUVs could be visualised under confocal microscopy by exciting the Texas Red dye at 
543 nm, as seen in image a) in Figure 3.9. When a 488 nm excitation was then used, the 
carboxyfluorescein labelled bacteriophage could also now be seen (image b), showing where the 
a) b) c) 
Figure 3.8: Emission spectra of pure 5-carboxyfluorescein N-succinimidyl ester and 5-
carboxyfluorescein N-succinimidyl ester tagged Bacteriophage K 
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bacteriophage in the GUVs could be found. This showed that when formed into GUVs, the 
bacteriophage aggregated into the phospholipid layer instead of selectively being encapsulated. 
This could be confirmed by overlaying both images (image c)), where both the phospholipid 
bilayer and the bacteriophage were in exactly the same position. This meant that on incubation 
with bacteria, bacteriophage were still free to infect and lyse bacteria as they were not 
separated by the GUV membrane. Therefore triggered release was not possible by using GUVs. 
A recent paper by Nieth et al has similarly described their investigations into the encapsulation 
of bacteriophage into phospholipid vesicles, however in their case vesicles were used to 
facilitate cellular uptake21. They encountered similar issues with a lack of control of vesicle size 
and lamellarity, and only gained significant bacteriophage loading by using alternative 
techniques (gel-assisted GUV formation or inverse emulsion).  These techniques could be utilised 
in order to form more homogenous, stable and highly loaded bacteriophage GUVs for future 
work.  
3.3. Conclusions 
Although previous work by the group has used LUVs successfully for triggered release of 
antimicrobial and dye molecules, this was not as effective when used with GUVs. The sensitivity 
to bacterial virulence factors and long term stability (data not shown) were significantly poorer 
than in LUV systems. Also, the control of size distribution and lamellarity was not as precise. On 
the formation of bacteriophage GUVs, bacteriophage were found to associate with the 
phospholipid bilayer instead of being isolated in the inside of the vesicle.  
Because of this, it was decided not to continue with the use of vesicular systems for the 
triggered release mechanism of bacteriophage. Instead, an alternative approach was chosen 
using hydrogels. Hydrogels offer a number of advantages over vesicle systems. Firstly, as 
described in Chapter 1, they are already commonly and effectively used in medical devices to aid 
and promote would healing; they can additionally be incorporated with a variety of additives to 
extend this further. The highly aqueous environment is generally robust to drying effects 
compared to vesicles, which lyse and collapse on even small amounts of drying. Lastly, hydrogels 
give excellent control of structure and reactivity through tailoring polymer chemistry. The 
stabilisation of bacteriophage by hydrogel matrices and their subsequent therapeutic use has 
been reported; however these systems did not incorporate a triggered release mechanism but 
instead gave sustained release 18-20. 





In recent years, the use of hydrogels for triggered release by using external stimuli-responsive 
chemistry has been widely reported (e.g. pH, temperature, enzymes or light), as discussed in 
Chapter 1. In a bacterial system, the use of enzyme-sensitive hydrogels is apt and has been 
shown to give triggered release, and so the triggered release of bacteriophage from a hydrogel 
system by bacterial virulence factors was subsequently investigated. 
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This chapter will focus on the immobilisation and diffusion of bacteriophage in hydrogel 
matrices. Hydrogels offer a protective environment for bacteriophage which prevents virion 
desiccation during storage, as well as creating an optimal environment for wound healing.  The 
aim of this chapter was to investigate a range of hydrogel formulations which could be used in 
wound dressings, and to determine if incorporation of bacteriophage affected activity. 
Bacteriophage will passively diffuse out of the hydrogel and, on bacterial infection, will be able 
to cause bacterial lysis (Figure 4.1).  
 
Bacteriophage are the natural viral predators of bacteria, and so due to the increase in 
resistance to conventional antibiotics, have in recent years become a promising alternative to 
antibiotics. The relative advantages and disadvantages of bacteriophage therapy have been 
discussed in detail in Chapter 1. In order to be a viable therapeutic for use in medical 
applications a bacteriophage must exhibit certain characteristics. Firstly, bacteriophage can be 
extremely specific, with one bacteriophage sometimes only able to infect one bacterial strain; in 
this case a bacteriophage with a wide host range (able to infect multiple strains of a species) 
must be chosen, or used in combination with other phages with different infectivity in a phage 
cocktail. Secondly, the bacteriophage must contain no toxic elements within its genome1; this 
can be remedied through whole genome sequencing. The bacteriophage must also have good 
temperature stability in order to survive use at room and body temperature, as well as during 
incorporation into hydrogel matrices. In this investigation Bacteriophage K was used as it is 
Figure 4.1: Bacteriophage diffusion out of hydrogel matrices and subsequent killing of bacteria 




known to have a broad host range against S. aureus, as well as having its entire genome 
sequenced.  
In this system, the hydrogel layer will not only provide a highly hydrated environment which 
prevents bacteriophage desiccation, but it will also be a semi-solid framework that retains 
bacteriophage whilst still allowing bacteriophage diffusion and infection at a slowed rate. This 
can be achieved by altering the crosslinking density, chemical structure or composition.  
A vast number of polymeric systems can be used to form hydrogels to immobilise bacteriophage, 
however two were focussed on during this study; the synthetic polymer poly(vinyl alcohol) and 
the natural biopolymer agarose. In both cases the hydrogel is formed through physical, as 
opposed to chemical means. This was to minimise possible damage to bacteriophage through 
reaction with chemical crosslinkers, solvents or curing techniques.   
Poly (vinyl alcohol), PVA, was chosen as it is non-toxic and biocompatible. The polymer is 
available in a range of molecular weights meaning that hydrogel properties could be altered 
easily. Gelation is primarily carried out through freeze/thawing to form a solid, durable, highly 
flexible hydrogel that is clear to opaque depending on polymer concentration.  
Agarose is a natural polysaccharide biopolymer derived from seaweed which is already widely 
used in biological applications (e.g. agarose gel electrophoresis). It is again non-toxic and 
biocompatible, and forms highly hydrated hydrogels with relatively low polymer concentrations. 
Hydrogels are formed though cooling of agarose solution, which again forms clear to opaque 
hydrogels depending on polymer concentration. Agarose hydrogels are solid and retain 
structure, however are not flexible at high concentrations which can lead to cracking and 
shearing.  
4.2. Materials and Methods 
4.2.1. Formation of PVA 
PVA (Mw = 146,000 – 186,000) solutions were made up in SM buffer and heated to 95 °C until 
dissolved. The solutions were then allowed to cool to room temperature. To form bacteriophage 
or non-bacteriophage hydrogels, 900 µL PVA solutions were added to either 100 µL 
bacteriophage lysate or 100 µL SM buffer respectively. The final polymer concentrations in 
solution were 2%, 5% and 10% w/v PVA. Once mixed, 1 mL hydrogel mix per well was added to a 
12-well plate and frozen at -20 °C for 18 hours. Hydrogels were then allowed to thaw at room 
temperature for 2 hours before use.  
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4.2.2. Formation of agarose 
Agarose (low gelling temperature) solutions were made up in SM buffer and heated to above 95 
°C in a microwave until dissolved. The liquid hydrogels were then cooled, and kept at 50 °C until 
needed. To form bacteriophage or non-bacteriophage hydrogels, 900 µL agarose solutions were 
added to 100 µL bacteriophage lysate or 100 µL SM buffer respectively. The final polymer 
concentrations in solution were 0.2%, 0.4%, 0.7%, 1.4% and 2% w/v agarose. Once mixed, 1 mL 
mix per well was added to a 12 well plate and allowed to cool for 1 hour at room temperature. 
Plates were then cooled further at 4 °C overnight before use.  
4.2.3. Bacteriophage methods 
The standard protocols for bacteriophage harvesting, isolation, purification and quantification 
can be found in Chapter 2.  
4.2.4.1. Disc diffusion assay 
Agarose and PVA hydrogel discs containing 108 pfu/mL Bacteriophage K were formed as 
described in Section 4.2.1. and 4.2.2.. Bacterial lawn plates were formed as previously described 
with S. aureus H560 as the host bacterium. 8 mm discs were then cut with a cork borer and 
placed on the bacterial lawn plates. The plates were incubated at 37 °C overnight. The zone of 
inhibition caused by bacteriophage diffusing from the hydrogel was measured as the whole zone 
diameter (including 8 mm hydrogel disc) in triplicate. 
4.2.3.2. Temperature Stability of Bacteriophage K 
In brief, 100 µL bacteriophage lysate solution (108 pfu/mL) was placed in a 1.5 mL Eppendorf 
tube and incubated in a heating block at 25, 37, 45 and 60 °C for 1 hour with mild shaking. After 
1 hour vials were cooled in ice for 5 minutes and kept at 4 °C until needed. The concentration of 
viable bacteriophage after heating was then calculated using previously described methods.  
4.2.4.3. UV stability of Bacteriophage K 
400 µL Bacteriophage K lysate solution (108 pfu/mL) was placed in a 12-well plate and exposed 
to 30, 60, 120 and 300 seconds of UV irradiation (UV flood lamp, Dymax 5000 Flood curing 
system (400 W). The plate was then placed at 4 °C for 5 minutes to cool and bacteriophage 
concentration calculated using previously described methods. 
 








4.3. Results and Discussion 
4.3.1. Bacteriophage 
4.3.1.1. Bacteriophage isolation and plaque morphology 
Bacteriophage K was propagated and isolated using S. aureus H560 as a host bacterium. The 
bacteriophage was chosen as it has been well investigated, is lytic (as opposed to lysogenic), has 
a broad host range and has its entire genome sequenced, and so is contains no toxic elements2. 
On incubation with host bacteria, bacteriophage create clear ‘plaques’ where bacteria have been 
lysed (Figure 4.2). Plaques formed were small and circular in shape, with a size of approximately 
1 – 1.5 mm in diameter. As bacteriophage lysate was diluted, single isolated plaques could be 
seen and so could be used for concentration calculation.   
 
4.3.1.2. TEM imaging of bacteriophage  
Although Bacteriophage K morphology has already been documented by O’Flaherty et al, TEM 
imaging was still carried out to verify bacteriophage size, type and structure3. The protocol for 
TEM imaging of bacteriophage particles is explained in Section 2.4.3.5. Bacteriophage were 
immobilised on hydrophilised TEM grids and then negatively stained using 1% uranyl acetate 
solution (pH 4). Images can be seen in Figure 4.3. 
Figure 4.2: a) Bacteriophage K dilutions used for concentration calculation with 10-3, 10-4, 10-5 and 10-6 
phage lysate dilutions. b) Individual Bacteriophage K plaques 












TEM images of Bacteriophage K show it to be part of the most common bacteriophage family, 
the Myoviridae. The bacteriophage comprises an icosahedral capsid head of approximately 100 
nm in diameter and a long contractile tail of approximately 400 nm in length, as well as short tail 
fibres. In Figure 4.3, Bacteriophage with tails in both the relaxed (left) and contracted state 
(right) can be seen. The contracted tail also shows the central tail tube, which is used for the 
injection of genetic material through the cell membrane into the host bacterium (see arrow). To 
a certain extent, the protein subunits that make up the bacteriophage tail structure can also be 
seen as organised lines made up of small globular units. This is limited by the photographic 
resolution of the TEM, and could be improved by better sample clean-up before staining, 
different negative stains or the use of cryo-TEM.  
4.3.1.3. Bacterial sensitivity to bacteriophage 
The sensitivity of a number of bacterial species to Bacteriophage K was determined by the steak 
test. For a bacteriophage to be a useful therapeutic, it is important that the virus has activity 
against a broad range of strains within a species. In a clinical setting it is often time-consuming to 
initially identify the species, let alone the strain responsible for infection. A broad spectrum 
bacteriophage has a higher chance of eradicating infection than a bacteriophage that only has 
activity against a small number of strains within a species.  
Figure 4.3: TEM images of Bacteriophage K stained with 1% uranyl acetate. Bacteriophage K with 
extended tail (left), Bacteriophage K with contracted tail and injection mechanism (right). Imaging carried 
out by Diana Alves 




As Bacteriophage K is primarily an S. aureus infecting virus, the bacteriophage was tested against 
86 S. aureus strains, as well as other clinically relevant pathogens including S. epidermidis, E. coli 
and P. aeruginosa. Streaks of bacterial overnight culture were allowed to dry on agar plates, and 
then 10 µL spots of Bacteriophage K lysate solution (108 pfu/mL) were added to the bacterial 
streak. The sensitivity of the strain to Bacteriophage K was then assigned depending on the 
amount of bacterial killing seen after overnight incubation at 37 °C.  
Strains that exhibited total killing by Bacteriophage K were assigned as “Susceptible” to phage 
infection (Figure 4.4, left). Large, clear areas of killing were seen in the area where the lysate 
solution had been placed, with no resistant colonies being present. Strains with “Intermediate” 
killing by Bacteriophage K showed areas of slight but not total killing by the bacteriophage 
(Figure 4.4, centre). A characteristic spotted pattern is seen where some bacteria have been 
killed, but other resistant colonies are present. Where no killing at all is seen, these strains were 
assigned as “Resistant” to Bacteriophage K (Figure 4.4, right). The bacteriophage have no activity 
against the strain, allowing normal bacterial growth to occur.  
 
In general, the majority of S. aureus strains tested with Bacteriophage K were found to either be 
completely sensitive, or intermediately sensitive. Of the 86 strains tested, only five strains were 
completely resistant (Table 4.1). 59% strains showed total killing, whilst 35% showed 
intermediate killing; these strains encompassed hospital and community acquired strains with 
varying susceptibility to methicillin. There appeared to be no correlation between country of 
origin, or susceptibility to methicillin, and sensitivity to Bacteriophage K.  
Non S. aureus strains were also tested to determine sensitivity to bacteriophage in other species 
(Table 4.2). In the 7 Staphylococcus species tested, all showed intermediate killing by 
Bacteriophage K, meaning that the bacteriophage has a broader spectrum than most other 
phages. However, in E. coli DH5α and P. aeruginosa PAO1 no killing was seen, with strains being 
completely resistant to Bacteriophage K. This was expected, as the strains are Gram-negative, so 
Figure 4.4: Streak test examples of S. aureus strains deemed susceptible (left), intermediate (centre) and 
resistant (right) to Bacteriophage K infection. 
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contain different bacteriophage receptor molecules, and are completely unrelated to 
Staphylococci in morphology, genome and outer membrane structure. 
























































































Table 4.1: Sensitivity of S. aureus species to Bacteriophage K. Tests were carried out jointly by Jessica Bean 
and Diana Alves 
Intermediate Resistant 
S. epidermidis 12228 
S. epidermidis RP62A 
S. xylosus ATCC29971 
S. chromogenes CCM3387 
S. arlettae N910-254 
S. simulans N920-197 
S. sciuri subsp. Sciuri ATCC29062 
E. coli DH5α 
P. aeruginosa PAO1 
Table 4.2: Sensitivity of other bacterial species to Bacteriophage K. Tests were carried out by Diana Alves 
The broad spectrum of Bacteriophage K makes it an ideal candidate for use in the proposed 
hydrogel system. In the bacterial screen, 94% S. aureus strains assessed showed complete or 
intermediate killing by Bacteriophage K. In cases where complete killing is seen, all infective 




Figure 4.5: Overnight bacterial growth curves of a) 
Bacteriophage K sensitive S. aureus H560, b) 
Bacteriophage K intermediate sensitivity S. aureus 
RN6390B and c) Bacteriophage resistant S. aureus 
ST239 µ2 











































































bacteria can be effectively removed by the phage. Even in cases where only intermediate killing 
is seen, the bacteriophage can still reduce bacterial numbers, which could aid the treatment of 
infection when used in combination with other phage (in phage cocktails) or antibiotics. Further 
research in the group by Diana Alves has developed a novel phage cocktail containing 
Bacteriophage K and another bacteriophage, DRA88 with increased S. aureus activity compared 
to pure Bacteriophage K4.  
4.3.1.4. Bacteriophage growth curves in liquid culture  
S. aureus strains that had been assigned as “Susceptible”, “Intermediate” or “Resistant” to 
Bacteriophage K by the streak assay were then incubated overnight in liquid culture. The optical 
density at 600 nm was measured and so the growth curves of the bacteria in solution could be 
followed.  
Chapter 4: Diffusion and Infection of Bacteriophage K in Hydrogel Matrices 
93 
 
The S. aureus strains used were H560 (Susceptible), RN6390B (Intermediate) and ST239 µ2 
(Resistant). The strains were also incubated with a range of Bacteriophage K concentrations (102 
– 108 pfu/mL) to determine the minimum concentration needed for complete killing. 
Overnight growth curves for S. aureus H560, RN6390B and ST239 µ2 incubated with varying 
concentrations of Bacteriophage K can be seen in Figure 4.5. In general, killing by Bacteriophage 
was seen in Susceptible and Intermediate strains, whereas in S. aureus ST239 µ2, which is 
resistant to Bacteriophage K, no killing was seen in live culture. 
In S. aureus H560, a characteristic dilution dependent killing by Bacteriophage K is seen. 
Between dilutions of 105 and 108 pfu/mL bacteriophage, there is no growth after 18 hours 
implying that the bacteriophage have successfully infected and lysed all bacteria. Bacterial 
growth does occur until approximately 4 hours; this is due to the fact that bacteriophage are 
most able to infect actively growing bacteria in the exponential cycle, and lysis is slow before this 
point. In 104 and 103 pfu/mL, the bacteriophage concentration is sufficient to cause a slight 
reduction in bacterial growth; however bacteria are still present in high concentrations after 18 
hours. By 102 pfu/mL, there are not sufficient bacteriophage to cause significant killing and 
growth follows the normal bacterial growth curve (black).  
In the intermediately sensitive S. aureus RN6390B, a similar pattern is seen to that observed for 
S. aureus H560, however growth is only prevented by far higher bacteriophage concentrations. 
Where killing was seen down to 105 pfu/mL, here killing is only seen in 108 and 107 pfu/mL 
Bacteriophage K. In fact in 107 pfu/mL bacteriophage, after initial killing growth is able to restart 
after 8 hours. Here, either not all bacteria were killed in the first place or resistant cells had 
evolved which are not killed by Bacteriophage K. This mirrors what is seen in in the streak test, 
where resistant clusters of bacteria are present after incubation with bacteriophage. In all lower 
dilutions, normal bacterial growth was seen.  
S. aureus ST239 µ2 exhibits complete resistance to Bacteriophage K, with normal bacterial 
growth seen in all cases after 18 hours incubation. In bacteria incubated with 108 pfu/mL lysate, 
a slight slowing of the rate of bacterial growth is seen in the exponential phase, however after 
10 hours the same final concentration is still reached.  
4.3.1.5. Temperature stability of Bacteriophage K 
Although bacteriophage are extremely resilient and capable of existing in a range of 
environments, their protein structure makes them temperature sensitive. Normally 
bacteriophage lysate solutions are stored for years at 4 °C without a significant loss in titer. It is 




also possible to freeze bacteriophage at –80 °C, or liquid nitrogen, or freeze/dry them5, 6. 
However, each bacteriophage has a different sensitivity to freezing.  
High temperatures can cause more serious, irreversible damage to bacteriophage than lower 
temperatures7. Heat is able to denature bacteriophage proteins and (especially due to damage 
of the delicate tail fibres) causes a loss in bacteriophage infectivity. In 2012, Qiu et al were able 
to examine the heat-induced disassembly of Bacteriophage λ using DSC, SLS and Electron 
Microscopy. Above approximately 68 °C they found that proteins in the capsid head began to 
melt, releasing bacteriophage DNA into the surrounding environment8. It is important to note 
that some bacteriophage (e.g. isolated from hot springs) have exhibited higher stability in higher 
temperatures9. 
Bacteriophage K was incubated in a heating block at 25, 37, 45, 60 and 70°C for one hour to 
determine if a significant loss in titer would be seen. The solution was also frozen at -20 °C to 
assess bacteriophage damage by freezing. The bacteriophage titer after one hour incubation can 
be seen in Figure 4.6: 
 
Bacteriophage K virions were found to be stable after one hour incubation at 4, 25, 37 and 45 °C; 
no significant change in titer was seen which implies that the bacteriophage were not damaged 
by heating at these temperatures. Also, after freezing at -20 °C the bacteriophage were similarly 
Figure 4.6: Titer of Bacteriophage K solutions incubated at -20, 4, 25, 37, 45, 60 and 70 °C for 
one hour 
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unaffected, with a concentration of 108 pfu/mL being seen. At 60 °C however, a significant loss in 
bacteriophage concentration occurred, with titer dropping from 108 to 102 pfu/mL. No 
bacteriophage were detected after incubation at 70 °C, as bacteriophage particles had become 
damaged and unable to infect. 
4.3.1.6. UV stability of Bacteriophage K 
Bacteriophage are also inherently susceptible to damage by UV light. In fact, irradiation by UV is 
a common method for the bacteriophage sterilisation of microbiological flow hoods and 
instruments. The highly energetic radiation affects bacteriophage in many ways. DNA and 
proteins which make up bacteriophage virions are known to be physically altered or damaged by 
UV irradiation; this can be through mechanisms such as reaction with reactive oxygen species, 
genetic mutation, crosslinking with aromatic amino acid residues or formation of single strand 
breaks in DNA10-12. Damage can also be due to an increase in temperature caused by the 
radiation13. This reduces the ability of bacteriophage to infect and multiply.  
 
Bacteriophage K was irradiated in a UV flood curer for 30, 60, 120 and 300 seconds to ascertain 
if a significant loss in bacteriophage titer would be seen (Figure 4.7). This was important to 
determine, as (if Bacteriophage K were to be incorporated into a device) UV may be needed in 
other processes such as polymer crosslinking or bacterial sterilisation. 
Figure 4.7: Titer of Bacteriophage K exposed to UV flood irradiation for 30 seconds, 1, 2 and 5 minutes 





































































As expected, after 300 seconds of UV exposure a high loss of bacteriophage concentration was 
seen, with an initial concentration of 108 pfu/mL dropping to approximately 106 pfu/mL. A high 
rate of loss was seen until 60 seconds, where the rate of loss then slowed with increasing time. 
The quantity of UV irradiation that bacteriophage were exposed to was sufficient to affect 
concentration of viable virions.  
In general, it is unlikely that UV experiments involving bacteriophage or polymers will exceed 60 
seconds in length, as prolonged UV exposure results in increased temperature as well as physical 
damage and breakdown of materials. Therefore, a loss bacteriophage titer of approximately a 
factor of 10 after 60 seconds is not high enough to be regarded as considerable. From 
experiments carried out in Section 4.3.1.4., 107 pfu/mL Bacteriophage K is still sufficient to cause 
significant killing in “Susceptible” and “Intermediate” S. aureus strains. 
In truth, in a commercial setting any irradiation of a bacteriophage with UV would be 
discouraged, as it would not be possible to ensure that the bacteriophage genome was not 
damaged or mutated into a possibly dangerous species. 
4.3.1.7. Use of Bacteriophage K for further development 
In general, Bacteriophage K is an ideal bacteriophage candidate for use in an antimicrobial 
wound dressing. The bacteriophage has a broad spectrum over S. aureus and other 
Staphylococci, meaning that there is a higher chance that on bacterial infection, the 
bacteriophage will be active. The whole genome of the bacteriophage has also been sequenced 
which allows examination of possible toxic genetic elements. For incorporation into a hydrogel 
matrix, the bacteriophage has high temperature and UV stability, allowing a range of hydrogel 
formulations to be tested. Despite this, high temperatures, desiccation, chelating ligands, 
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4.3.2. Bacteriophage K in poly(vinyl alcohol) (PVA) hydrogels 
PVA hydrogels were the first hydrogel candidates to be investigated. The structure of the 
polymer can be seen in Figure 4.8. PVA is a synthetic, biocompatible hydrogel that forms solid, 
flexible gels under mild conditions. It is available in a range of molecular weights; in this 







4.3.2.1. PVA hydrogels 
PVA hydrogels were formed by heating varying concentrations of polymer in SM buffer until 
dissolved. Once cooled, the dissolved polymer remained liquid when kept at room temperature. 
PVA can be crosslinked to form solid hydrogels chemically (with sodium tetraborate or dimethyl 
sulphoxide) or physically (with freeze/thawing)14, 15. Here, freeze/thawing was chosen as it does 
not introduce potentially harmful chemicals into the hydrogel which could damage the 
bacteriophage.  
On freeze/thawing dissolved PVA undergoes physical crosslinking between chains. The 
formation of ice crystals during freezing is thought to push polymer chains together, allowing 
hydrogen bonds to form between hydroxyl groups16. There is high control over PVA gelation with 
freeze thawing, as the polymer solution remains liquid until it is frozen. The porosity and 
strength of cast hydrogels can also be altered by changing the number of freeze/thaw cycles, 
addition of salts or altering PVA molecular weight.   
Cast 2%, 5% and 10% PVA hydrogels after one freeze/thaw cycle can be seen in Figure 4.9. The 
formed hydrogels are strong and flexible, with the hydrogel resistant to cracking or breaking. 
The hydrogels were also slightly opaque in appearance. Structural rigidity of hydrogels increases 
with polymer concentrations; 2% PVA hydrogels are highly hydrated, with structure collapse 
seen, whereas 10% hydrogels appear less hydrated and are extremely strong and robust. 
Figure 4.8: Structure of PVA repeating unit 


































The swelling ratio of 2%, 5% and 10% PVA hydrogels was calculated using previously described 
methods. In general, the swelling ratio decreases sharply with increasing polymer concentration 











The swelling ratio for 2% PVA mirrored the highly hydrated, weak hydrogel that was seen after 
freeze/thawing. The high concentration of absorbed water causes the structure to become soft 
Figure 4.9: 10 mm discs of freeze/thawed hydrogels containing (left to right) 2%, 
5% and 10% PVA 
Figure 4.10: Swelling ratio measurements of 2%, 5% and 10% PVA hydrogels 
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and unstructured. In 5% and 10% PVA hydrogels, the swelling ratio decreased significantly 
compared to 2% PVA, with swelling ratios of approximately 30 and 16.4 being seen respectively. 
These ratios imply a denser, less hydrated, more crosslinked network. 
The weight loss of 5% PVA hydrogels was assessed by incubating hydrogels at varying 
temperature to determine the extent of water evaporation (Figure 4.11). This was important to 
understand if the hydrogel is to be used as a dressing; significant water loss during use could 










In general, weight loss due to water evaporation occurred at a higher rate as temperature 
increased. At 4 °C the rate of water loss was comparatively slow, with a loss of approximately 3 
%/hr. At room temperature (25 °C), water loss rate increased to 8 %/hr, whilst at body 
temperature (37 °C) water loss occurred at 15.4 %/hr. In hotter temperatures, the rate of water 
loss increased sharply, with water loss occurring at 37 %/hr at 45 °C and 62 %/hr at 60 °C. 
Although these results were significant, it is important to note that in a clinical setting, the 
hydrogels would not be stored or used at elevated temperatures, and would be covered in a 
protective plastic cover to prevent water loss. 
4.3.2.2. SEM imaging of PVA hydrogels 
SEM images of freeze/dried PVA hydrogels were taken to analyse the internal structure of the 
hydrated hydrogel (Figure 4.12). Although there is a certain amount of hydrogel collapse during 
Figure 4.11: Water loss measurements of 5% PVA hydrogels at 4, 25, 37, 45 and 60 °C 




the freeze/drying process, this is the same in all cases and so differences due to PVA 







In general, as PVA concentration increased the hydrogel pore size decreased; all hydrogels 
exhibited a highly porous internal structure. In 2% PVA hydrogels pores were very large (> 5 µm) 
with uneven size distribution, reflecting the high swelling ratio seen in Section 4.3.2.1. In 5% PVA 
hydrogels the hydrogel had a significantly smaller pore size (1 – 0.2 µm) with a more uniform 
porosity. By 10% PVA hydrogels appeared almost solid in nature, with a highly compact porosity 
of < 200 nm pores. In both 5% and 10% PVA the highly dense porous structure is reflected in the 
low swelling ratio observed in swelling measurements.  
For the immobilisation of Bacteriophage K in these hydrogels, it was expected that the porosity 
would play a key factor in diffusion of the bacteriophage. In 2% PVA the large pore structure 
would allow near-free diffusion of the bacteriophage, whereas in 10% PVA very low or no 




Figure 4.12: SEM images of a) 2%, b) 5% and c) 10% 
PVA hydrogels formed by freeze thawing at -20 °C. 
Scale bar = 5 µm. 
c) 
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4.3.2.3. Release of bacteriophage from PVA hydrogels 
The diffusion of bacteriophage from PVA hydrogels was investigated by measuring the 
concentration change over time (Figure 4.13). 1 mL PVA solutions (2%, 5% and 10% PVA) 
containing 108 pfu/mL Bacteriophage K were cast into a 12-well plate and freeze/thawed to form 
crosslinked hydrogels. 1 mL SM buffer per well was then added and the concentration of 
bacteriophage calculated at determined timepoints. 
 
In general, a faster diffusion of bacteriophage was seen in less concentrated hydrogels; 2% PVA 
exhibited a very fast ‘burst’ of bacteriophage release, whereas in 10% PVA hydrogels a slower 
release was seen. In 2% and 5% PVA hydrogels a final concentration of approximately 5 x 105 
pfu/mL was seen, whereas in 10% a lower concentration of 104 pfu/mL was determined.  
In all cases, a low percentage of bacteriophage appeared to be released compared to the initial 
loading concentration. Bacteriophage concentration reached a plateau at approximately 5 x 105 
pfu/mL from a hydrogel concentration of 108 pfu/mL. This could be due to a number of factors. 
Firstly, the highly dense pore structure of 5% and 10% PVA hydrogels seen in SEM images (Figure 
4.12) implies that the structure significantly restricts the free movement of bacteriophage; 
however if this was the case, in networks with a larger pore size such as 2% would show an 
increased concentration of released bacteriophage. Also, the freezing process in the presence of 
Figure 4.13: Bacteriophage release from 2%, 5% and 10% PVA hydrogels 



































polymer could damage bacteriophage and prevent them from infecting, and so the number seen 
in this experiment could be the number of virions that were able to survive the conditions. From 
Section 4.3.1.5, it was known that freezing at -20 °C did not cause a significant reduction in 
bacteriophage titer, however this was only after one hour freezing. A prolonged exposure could 
be sufficient to damage bacteriophage, especially if immobilised in a polymer network that 
prevents movement and expansion. 
4.3.2.4. Kinetics of bacteriophage release 
The kinetics of bacteriophage diffusion and the diffusion coefficient of bacteriophage in varying 
concentrations of PVA was then analysed using Fick’s Law17, 18. The apparent diffusion 
coefficient, Dapp, is obtained from the slope of Ct/C0 versus time plots, where Ct is the 
bacteriophage concentration at time t, C0 is the initial bacteriophage concentration, S is the 








The concentration of bacteriophage released was measured as previously described before the 
system reached the steady state. This can be seen in Figure 4.14.  
 
 
Figure 4.14: Graph of Ct/C0 of 2%, 5% and 10% PVA hydrogels 


















y = 0.0002x + 0.0005
y = 2E-05x - 0.0001
y = 2E-06x - 4E-06
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Figure 4.15: Diffusion coefficient values (10-11 m2sec-1) for 2%, 5% and 10% PVA 
The slopes calculated in Figure 4.14 were then used to calculate Dapp for each concentration of 
PVA (Figure 4.15 and Table 4.3). Here, the solution volume, V, was 1 x 10-6 m3 and membrane 
thickness, X, was 2.6 x 10-3 m for all measurements. The diffusion area, S, was calculated from 
the 12-well plate well diameter as 3.8 x 10-4 m2.  
% PVA 
(w/v) 
Ct/C0 V (10-6 m3) X (10-3 m) S (10-4 m2) t (secs) Dapp(m2sec-1) 
2 0.0002 1 2.6 3.8 1800 7.6E-13 
5 0.00002 1 2.6 3.8 1800 7.6E-14 
10 0.000002 1 2.6 3.8 1800 7.6E-15 
Table 4.3: Dapp calculations for Bacteriophage K diffusion from 2%, 5% and 10% PVA hydrogels 
 
In general, the Dapp values calculated for Bacteriophage K in PVA were extremely low. The 
diffusion constant for bacteriophage decreases significantly as % PVA (and so hydrogel density) 
increases. The more concentrated polymer network physically slows diffusion of bacteriophage 
particles. 2% PVA, being the most fluid and least rigid hydrogel showed the highest Dapp of 7.6 x 
10-13 m2sec-1. With more concentrated PVA hydrogels Dapp values decreased by a factor of 10 
each time, with 7.6 x 10-14 m2sec-1 for 5% PVA and 7.6 x 10-15 m2sec-1 for 10% PVA.  
 
 























This is thought to be due to the shape of bacteriophage particles; Bacteriophage K is a long tailed 
phage of approximately 100 nm x 400 nm in size. The long tail is more likely to become 
entangled in the polymer matrix, or prevent movement through smaller pores. Also, as PVA 
crosslinks through physical interactions of the polymer chains, semi-crystalline domains in the 
hydrogel could entrap bacteriophage more strongly than in amorphous regions.  
4.3.2.5. Zones of inhibition 
PVA hydrogels containing 108 pfu/mL Bacteriophage K were incubated on bacterial lawns 
containing S. aureus H560 to assess bacteriophage diffusion out of the hydrogel. Bacteriophage 
are able to diffuse through the matrix into the bacterial lawn where they are able to infect in 








The zone of inhibition seen around bacteriophage-containing PVA hydrogels decreased with 
increasing polymer concentration. In 2% a very high diffusion was seen of approximately 22 mm 
in diameter. This correlates well with the diffusion experiments in Section 4.3.2.3. where 2% PVA 
showed a significantly faster and higher bacteriophage release compared to more concentrated 
hydrogels. In 5%, 7% and 10% PVA, the zone of inhibition was smaller with 11.5, 11, 10 mm 
respectively. 
 
Figure 4.16: (left) Zone of inhibition measurements of 8 mm diameter PVA hydrogels containing 108 
pfu/mL Bacteriophage K on S. aureus H560. (right) Image of zone of inhibition surrounding 7% PVA 
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4.3.2.6. Bacteriophage hydrogels in overnight culture 
2%, 5% and 10% PVA hydrogels containing Bacteriophage K were formed into 24-well plates with 
500 µL per well. The hydrogels were crosslinked by freezing overnight at -20 °C and subsequent 
thawing at room temperature for one hour. The hydrogels were then incubated with actively 
growing bacteria in liquid culture to determine if enough bacteriophage were able to diffuse to 
initiate bacterial killing (Figure 4.17). From the diffusion experiments carried out in Section 
4.3.2.3., bacteriophage were able to diffuse, however in 5% and 10% PVA hydrogels, the 
concentration released could not be high enough to cause sustained killing.  
 
A high background in bacteriophage hydrogels was seen during the experiment, as with 
increasing PVA concentration hydrogels became more opaque which interfered with absorbance 
measurements. As this was constant throughout the experiment, it was not significant when 
following bacterial growth. Similarly, a higher starting OD600 was seen in bacteriophage 
containing hydrogels compared to standard PVA as the lysate solution also contributes to a 
change in the opacity of the hydrogels. 
Killing of S. aureus H560 was seen in all concentrations of PVA compared to PVA hydrogels 
containing no bacteriophage. A higher baseline OD600 was seen with increasing PVA 
concentration, however as previously discussed this was due to the hydrogel opacity and not a 
Figure 4.17: Growth curves of S. aureus H560 liquid cultures incubated with 2%, 5% and 10% PVA 
containing 108 pfu/mL Bacteriophage K. 
 









 2% PVA + PhK
 5% PVA + PhK











Figure 4.18: Incubation of S. aureus H560 with 5% PVA containing 108 pfu/mL Bacteriophage K which has 
been irradiated with flood UV for 10, 30 and 60 seconds 


















loss in bacterial killing. In all hydrogels, active bacteriophage were able diffuse out of the 
hydrogel into bacterial solution in a high enough concentration (> 105 pfu/mL) to initiate killing. 
A characteristic “bump” in bacterial growth is seen at approximately 4 hours, where bacteria 
begin to grow and then are killed again. This is frequently seen in bacteriophage infection curves 
(see Section 4.3.1.4.). Killing by bacteriophage only begins to occur in the exponential phase, 
when bacteria are actively metabolising and reproducing. The bacteria start to grow, increasing 
the OD600, and then bacteriophage begin to lyse bacteria once the exponential phase is reached, 
causing a decrease in OD600.  
4.3.2.7. UV irradiation  
Bacteriophage can become damaged in UV light, as reactive radical species generated by UV can 
react with the delicate protein structure. In Section 4.3.1.6. it was shown that UV irradiation 
caused a loss of infective bacteriophage titer, with up to 103 pfu/mL loss after 5 minutes 
irradiation. The effect of UV irradiation on bacteriophage in PVA hydrogels was measured to 
determine if the hydrogel protected or damaged further immobilised bacteriophage. Here, only 
5% PVA hydrogels containing 108 pfu/mL were investigated with UV irradiation for 10, 30 and 60 
seconds. 2% and 10% PVA hydrogels were not taken on for further development; 2% hydrogels 
did not show a strong enough structure after crosslinking, and uncrosslinked 10% PVA was too 
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In general, as exposure of bacteriophage PVA hydrogels to UV increased, the lytic ability of 
immobilised bacteriophage significantly decreased (Figure 4.18). With no UV irradiation, normal 
killing of S. aureus H560 was seen compared to the normal growth curve. Even after 10 seconds 
of UV exposure, bacteriophage damage was seen with a shift in the initiation of bacterial lysis 
from four to five hours. Similarly, this was shifted further after 30 seconds irradiation to six 
hours. Despite this, overall bacterial killing was seen in both cases. After 60 seconds UV 
irradiation no bacterial killing was seen compared to normal bacterial growth, implying that 
bacteriophage had become damaged and unable to infect.  
This could be due to a number of reasons. Firstly, after 60 seconds UV irradiation the local 
temperature of the hydrogel was significantly increased. High temperatures are known to 
damage bacteriophage proteins and nucleic acids, as well as altering the more complex virion 
structure. Secondly, in the case of PVA the polymer is known to form highly reactive free radical 
species on UV irradiation, as described by Niki et al19. These species can not only cause damage 
to bacteriophage particles through absorption of photons by DNA and proteins and subsequent 
oxidation, but on reaction with PVA, acidic species can be formed which lower the local pH 20. 
4.3.2.8. Overview 
In general, PVA hydrogels were a promising vehicle for the immobilisation of bacteriophage. The 
optimum PVA concentration was determined as 5% PVA, as this formed a strong, flexible 
hydrogel that retained structure whilst allowing high bacteriophage diffusion. The highly 
hydrated matrix provided an environment where bacteriophage could diffuse and successfully 
infect live bacterial culture on incubation. However, the loss of bacteriophage infectivity seen 
after UV irradiation would prevent the use of PVA where UV is required (e.g. for 











4.3.3. Bacteriophage K in agarose hydrogels 
Agarose was the second candidate for use as a hydrogel to embed Bacteriophage K. The 
structure of agarose can be seen in Figure 4.19. The polymer was chosen as it is natural, non-






4.3.3.1. Agarose hydrogels 
Agarose hydrogels were formed by heating varying % low melting point agarose in SM buffer at 
95 °C until dissolved. The liquid mixture sets into a solid hydrogel on cooling at different rates 
depending on agarose concentration; solidification usually occurs below 30 °C.  
Agarose is ideally suited for bacteriophage immobilisation. It forms a highly hydrated, non-toxic 
hydrogel that is able to hold its shape at relatively low polymer concentrations. The hydrogels 
are clear to slightly opaque depending on polymer concentration (Figure 4.20), meaning they 
can be seen through, and the polymer itself is a natural polysaccharide requiring no additional 
molecules for hydrogel formation. The hydrogel is already commonly used in molecular biology 
for the analysis of proteins and nucleic acids in gel electrophoresis.  
One drawback of agarose hydrogels is that they are mechanically quite fragile. They are not 
flexible and form into solid blocks that are irreversibly damaged on crushing or bending. There is 
also less control over gelation than with PVA hydrogels. The agarose must be kept above the 
setting temperature to mix in bacteriophage particles, but not so hot as to cause bacteriophage 
damage. In highly concentrated mixtures (e.g. > 1.5% w/v agarose) solidification can occur 
before bacteriophage have been mixed in and the agarose solution has been transferred to the 
desired mould. This can result in solidification in situ, either in the mixing vessel, the pipette tip 
or in a half filled mould.  Because bacteriophage are temperature sensitive, it is not possible to 
reheat agarose to the pre-solidified state in these cases.  
Figure 4.19: Structure of agarose repeating unit 
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The swelling ratios of agarose hydrogels were again determined by swelling measurements 
(Figure 4.21). Compared to PVA hydrogels, in general agarose hydrogels were more hydrated 
and exhibited higher swelling ratios. Due to the poor structure of 0.2% agarose gels, the swelling 
ratio is significantly higher than more concentrated gels. Once the hydrogel has been swollen 
overnight the gel must be blotted to remove excess water; in 0.2% agarose gels the water 
content is so high that the structure is delicate and easily damaged when blotted. With 0.4%, 
0.7%, 1.4% and 2% agarose hydrogels the structure is far more solid and the swelling ratio is 
more accurately measured. As agarose concentration increases, the swelling ratio decreases, 











Figure 4.20: 10 mm discs of hydrogels containing (from left to right) 0.2%, 0.4%, 0.7%, 1.4% and 2% 
agarose 
Figure 4.21: Swelling ratio measurements of 0.2%, 0.4%, 0.7%, 1.4% and 2% agarose hydrogels 




0.7% agarose hydrogels were incubated at various temperatures to measure the % weight loss 
due to water evaporation of the hydrogel (Figure 4.22). As expected, weight loss occurred at a 
faster rate as temperature increased, in a linear fashion. At 4°C, weight loss decreased at a rate 
of approximately 7 %/hr, at room temperature (25 °C) weight loss occurred at 12 %/hr and at 
body temperature (37 °C) weight loss occurred at 30 %/hr. At higher temperatures, weight loss 
was far faster; at 79 %/hr for 45 °C and 95 %/hr for 60 °C. Again it is noted that in a clinical 
setting, any hydrogels used would be protected by a plastic cover to prevent water loss.  
In comparison to PVA hydrogels, the rate of water loss seen in agarose is far higher. This is 
thought to be due to the higher porosity of agarose hydrogels, which allows water molecules to 
evaporate from a greater surface area of hydrogel compared to PVA. 
 
4.3.3.2. SEM imaging of agarose hydrogels 
SEM images of agarose hydrogels were taken to analyse the internal structure of agarose 
hydrogels (Figure 4.23). Here, 0.2%, 0.4%, 0.7%, 1.4% and 2% agarose hydrogels were cast and 
allowed to set. 2 x 2 mm samples were then cut and freeze dried to preserve the hydrated 
structure. In all cases, images taken were of the internal cut side of the hydrogel, not the air-
facing top.   
Figure 4.22: Water loss measurements of 0.7% agarose hydrogels at 4, 25, 37, 45 and 60 °C 
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Figure 4.23: SEM images of a) 0.2%, b) 0.4%, c) 
0.7%, d) 1.4 and e) 2% w/v agarose hydrogels. Scale 





Agarose hydrogels formed showed a less obvious pore structure than that seen in PVA 
hydrogels. In general, hydrogels appeared more solid as agarose concentration increased, with 
1.4% and 2% agarose hydrogels showing no pores, even at high magnification (x 10,000, images 
not shown). The gelation mechanism of agarose in solution is generally thought to be via a 
liquid-liquid phase separation that occurs in the sol-gel trasition on cooling21. Polymer chains are 
able to aggregate in the polymer-rich phase, surrounded by a polymer-poor phase. The agarose 









Figure 4.24: Bacteriophage release from 0.2%, 0.7% and 2% agarose hydrogels 








































In 0.2% agarose, a flaked appearance was seen with pores of approximately 5 µm.  0.4% agarose 
also exhibited this, however the hydrogel seemed less porous with a more solid structure. In 
0.7% agarose, the flaked appearance has given way to a solid structure which was interdisperced 
with a low number of larger pores of approximately 10 µm in diameter. 1.4% and 2% agarose 
hydrogels appeared as solid sheets with a rouge surface but no visible pores. This was most 
likely not that the hydrogel had an absence of pores, but that they were too small to be seen by 
SEM; with SEM very small pores could be hidden or filled during sputter coating.  
4.3.3.3. Release of bacteriophage from agarose hydrogels 
To analyse bacteriophage release from agarose hydrogels, 1 mL of agarose (0.2 – 2% w/v) 
containing 108 pfu/mL bacteriophage was cast in triplicate in a 12-well plate and allowed to set 
overnight at 4 °C. The concentration of released bacteriophage was then measured after the 












In general, a higher concentration of released bacteriophage was seen in agarose hydrogels 
compared to PVA. A burst release of bacteriophage was seen, with the majority of 
bacteriophage being released in less than 10 minutes in most agarose concentrations (Figure 
4.24). The lowest concentration (and so most porous) 0.2% agarose hydrogel exhibited very fast 
release, with bacteriophage concentration reaching a plateau after 7.5 minutes. In 0.7% 
hydrogels, release was slightly slower but the majority of bacteriophage had been released by 10 
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y = 0.0163x + 0.0012
y = 0.0043x - 0.0065
y = 0.0002x - 0.0001
minutes. The more concentrated 2% agarose hydrogel showed a far shallower release curve, 
with eventually 107 pfu/mL bacteriophage released.  
4.3.3.4. Kinetics of bacteriophage release from hydrogels 
To analyse the fast diffusion of bacteriophage from agarose, the concentration of bacteriophage 
released was assessed over a shorter timeframe (Figure 4.25). Here, 0.2% agarose was chosen as 
a highly porous, highly hydrated hydrogel, 0.7% was chosen as a porous, solid hydrated hydrogel 
and 2% agarose was chosen as a dense, less hydrated hydrogel. 1 mL SM buffer was then added 
per well and the bacteriophage concentration again measured at various timepoints before the 
system had reached the steady state. The kinetics of bacteriophage diffusion in agarose were 











The slopes calculated in Figure 4.25 were then used to calculate Dapp for each concentration of 
agarose. Here, solution volume, V, was 1 x 10-6 m3 and membrane thickness, X, was again 2.6 x 
10-3 m for all measurements. The diffusion area, S, was calculated from the 12-well plate well 
diameter as 3.8 x 10-4 m2.  
% agarose 
w/v 
Ct/C0 V (10-6 
m3) 
X (10-3 m) S (10-4 m2) t (secs) Dapp(m2sec-1) 
0.2 0.0163 1 2.6 3.8 450 2.48E-10 
0.7 0.0043 1 2.6 3.8 1800 1.63E-11 
2 0.0002 1 2.6 3.8 1800 7.60E-13 
Table 4.4: Dapp calculations for Bacteriophage K diffusion from 0.2%, 0.7% and 2% agarose hydrogels 
Figure 4.25: Graph of Ct/C0 0.2%, 0.7% and 2% agarose hydrogels 













As expected, again the diffusion constant for bacteriophage decreases significantly as % agarose 
(and so hydrogel density) increases (Table 4.4 and Figure 4.26). The more concentrated polymer 
network physically slows diffusion of bacteriophage particles. The Dapp values calculated 
correlate extremely well with those reported by Hu et al in 2010, where they analysed the 
diffusion of T4 phage in agarose17, 23. In this case, 0.2% agarose (the most porous gel that could 
form a solid gel) showed the highest Dapp of 2.48 x 10-10 m2sec-1. As agarose concentration 
increased, Dapp values decreased with 1.63 x 10-11 m2sec-1 for 0.7% agarose and 7.60 x 10-13 
m2sec-1 for 2% agarose. In general all agarose hydrogels showed significantly higher release and 
Dapp values than PVA hydrogels.  
This could be due to the nature of each hydrogel gelation mechanism. In PVA the gel forms semi-
crystalline areas which are highly packed and could entrap bacteriophage. With agarose the 
structure is more homogenous, meaning a less tight entrapment. 
4.3.3.5. Zones of inhibition 
 
Agarose hydrogels containing 108 pfu/mL Bacteriophage K were incubated on bacterial lawns 
containing S. aureus H560 to assess bacteriophage diffusion out of the hydrogel. Again the 
diameter of bacteriophage lysis around the hydrogel disc was measured.  
Figure 4.26: Diffusion coefficient values (10-11 m2sec-1) for 0.2%, 0.7% and 2% agarose 




























The ability of bacteriophage to diffuse out of agarose hydrogels was reduced with increasing 
agarose concentration (Figure 4.27). However in all cases, bacteriophage were able to diffuse 
and infect bacteria present in the agar plate. In 0.2% a very high diffusion was seen of 
approximately 20 mm in diameter. This correlates well with the diffusion experiments in Section 
4.3.3.3. where 0.2% agarose showed very high release of Bacteriophage K after one hour. In 
more concentrated hydrogels the zone of inhibition appears significantly smaller with 12.2, 10.3, 
9.8 and 9 mm for 0.4%, 0.7%, 1.4% and 2% hydrogels respectively. 
 
4.3.3.6. Bacteriophage hydrogels in overnight culture 
0.4%, 0.7%, 1.4% and 2% agarose hydrogels containing 108 pfu/mL Bacteriophage K were formed 
into 24-well plates with 500 µL per well. 0.2% agarose was not investigated further as its lack of 
structure retention, high swelling ratio and fast bacteriophage diffusion meant that it would not 
be suitable for further development. The hydrogels were allowed to set overnight at 4 °C and 
then incubated with S. aureus H560 subculture. Now that the diffusion of bacteriophage from 
agarose hydrogels into buffer solution and bacterial lawns had been assessed, it was again 
important to measure the bacteriophage infectivity in actively growing liquid culture. The 
growth of the bacteria overnight was measured to determine if bacteriophage were still 
infective against actively metabolising and replicating bacterial culture once immobilised in the 
hydrogel matrix (Figure 4.28).  
Figure 4.27: (left) Zone of inhibition measurements of 8 mm diameter agarose hydrogels containing 108 
pfu/mL Bacteriophage K on S. aureus H560. (right) Image of zone of inhibition surrounding 0.4% agarose 





































Bacteriophage immobilised in 0.4%, 0.7%, 1.4% and 2% agarose all exhibited complete killing of 
S. aureus H560 in solution compared to agarose containing no bacteriophage (in this case 0.7% 
but the bacterial growth curve was the same in all agarose concentrations). It was already 
understood from Section 4.3.3.3. that after one hour, bacteriophage were able to diffuse 
enough into SM buffer from all agarose concentrations to exhibit a high enough concentration to 
kill bacteria (> 105 pfu/mL). This was seen in practice here, as killing was observed in all cases. 
The “bump” seen at approximately two hours is again characteristic of bacteriophage infection 
as described in Section 4.3.2.5.  
4.3.3.7. UV irradiation  
Once immobilised in agarose, it was again important to determine that on UV irradiation the 
polymer structure did not generate reactive radicals which would lower bacteriophage 
infectivity (as was seen in PVA). S. aureus H560 was incubated with agarose hydrogels that had 
been exposed to flood UV curing for 10, 30 and 60 seconds. 
Bacteriophage K immobilised in agarose hydrogels were successfully able to prevent bacterial 
growth after UV irradiation (Figure 4.29). This implied that the more complex polysaccharide 
Figure 4.28: Growth curves of S. aureus H560 liquid cultures incubated with 0.4%, 0.7%, 1.4% and 2% 
agarose containing 108 pfu/mL Bacteriophage K. 
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Figure 4.29: Incubation of S. aureus H560 with a) 0.4%, b) 0.7%, c)1.4% and d)2% agarose containing 108 
pfu/mL Bacteriophage K which has been irradiated with flood UV for 10, 30 and 60 seconds 
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structure of agarose is less susceptible to radical formation in the presence of UV, or that 











In general, the extent of S. aureus killing by Bacteriophage K was again reduced with more UV 
irradiation. In all cases killing was seen with Bacteriophage K hydrogels that had been UV cured 
for 0, 10 and 30 seconds; by 60 seconds bacterial killing was only seen in 1.4% and 2% agarose 
hydrogels. It was hypothesised that the concentration of the agarose hydrogel exhibits a 
protective effect over the bacteriophage, shielding the viral particles from damaging UV 









concentrated hydrogels (0.4% and 0.7%) after prolonged UV irradiation a loss of bacteriophage 
activity is seen compared to more concentrated hydrogels.  
In 1.4% and 2% agarose hydrogels, killing was also initiated at later stages as irradiation time 
increased. For example after 10 seconds UV irradiation, killing started at the beginning of the 
exponential phase at 2 hours. After 30 seconds UV irradiation killing commenced later at 4 
hours. By 60 seconds UV irradiation killing only commenced after 5 hours. This is thought to be 
due top UV damage of the bacteriophage slowing or reducing the infectivity of bacteriophage.  
4.3.3.8. Overview 
Overall, agarose hydrogels were found to be good vehicles for the immobilisation of 
bacteriophage. Agarose gels showed high swelling and allowed bacteriophage to diffuse at 
varying rates depending on polymer concentration. Bacteriophage were also able to successfully 
infect live bacteria on plates and in liquid culture. Additionally, the hydrogel actually showed 
protective properties over bacteriophage when UV irradiated. 
4.4. Conclusions 
In this chapter, the therapeutic use of Bacteriophage K as an active bacteriophage against 
Staphylococcus aureus infections was investigated. Here, agarose and PVA hydrogel systems 
were also used in order to immobilise the bacteriophage in a protective, highly aqueous 
environment. Although some research has been carried out into bacteriophage in agarose 
hydrogel matrices, immobilisation in poly (vinyl alcohol) has not been reported. In both cases 
the hydrogels were assessed for activity against live bacterial cultures. This chapter set out to 
answer a number of questions: 
 Is Bacteriophage K a suitable bacteriophage for use in S. aureus infections? 
 Can bacteriophage be immobilised in hydrogel matrices?  
 Are bacteriophage able diffuse through the matrices, and if so, how? 
 Once diffused out, are bacteriophage able to remain active against S. aureus? 
 
Bacteriophage K proved to be a highly active bacteriophage with a broad host range against S. 
aureus. Diffusion of the bacteriophage in both hydrogels was investigated with diffusion 
significantly higher in agarose hydrogels. Furthermore, it could be successfully immobilised in 
both agarose and PVA hydrogels whilst retaining infectivity.  
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Chapter 5 : Development of Crosslinkable Hyaluronic Acid and 
Subsequent Sensitivity to Staphylococcal Hyaluronidase 
 
5.1. Introduction 
This section will focus on the development of an enzymatically degradable upper layer which will 
be added to the top of the bacteriophage hydrogel (described in Chapter 4) to create a ‘smart’ 
release wound dressing. On bacterial infection, the upper layer will be degraded by secreted S. 
aureus virulence factors, exposing the lower bacteriophage hydrogel. The bacteriophage can 






The upper hydrogel layer ideally needs to include a number of key properties; the hydrogel 
needs to be flexible, dense and enzymatically sensitive, whilst also promoting wound healing: 
 Flexibility: A flexible hydrogel is required to prevent the wound dressing degrading or 
breaking during normal patient movement.  
 High crosslinking density: In order to form a sturdy barrier to prevent release of 
bacteriophage from the lower layer, the hydrogel must be highly crosslinked without 
excess swelling.  
 Enzyme sensitivity and selectivity: The trigger mechanism of this dressing is introduced 
by forming the upper layer from a polymer that is selectively degradable by S. aureus 
virulence factors. The polymer must be very sensitive to bacterial enzymes; a low 
amount of enzyme must be able to cause considerable degradation. Selectivity is also 
Figure 5.1: Schematic diagram of bilayered hydrogel system: upper hydrogel layer containing degradable 
crosslinked HA. 




important as the polymer must be broken down by an enzyme that is not produced by 
all bacterial species.  
 Wound healing: Ideally the dressing must also promote wound healing. In the presence 
of S. aureus, the layer will degrade and bacteriophage will be released, but in the 
presence of no infection, the upper layer polymer must still aid healing as this is the 
layer in contact with the wound.  
 
Hyaluronic acid was chosen as the enzyme-sensitive polymer which makes up the upper layer. 
The polymer is natural, non-immunogenic, non-toxic and is known to aid wound healing. Its 
structure also contains a number of chemically active groups which can be used to crosslink the 
polymer into hydrogel networks. The enzyme hyaluronidase (which breaks down HA) is known 
to be mainly secreted by S. aureus, meaning that the upper layer will only be degraded in the 
presence of that species.  
HA must be crosslinked in order to form a solid hydrogel. A number of crosslinking methods 
were investigated to find an optimal HA formulation which encompassed the majority of desired 
characteristics. Alongside this, HAase expression and reactivity was investigated in S. aureus to 
ensure that HAase expressed was active, secreted in high enough concentrations and also that it 
was secreted by the majority of strains.  The crosslinked hydrogels were tested with purified and 
Staphylococcal HAase and the structural breakdown during degradation followed through SEM 
and quantitatively with the Carbazole assay.  
5.2. Materials and Methods 
Hyaluronic acid sodium salt from Streptococcus equi (Mw = 1.8 x 106 g/mol), EDC, sodium 
periodate, ethylene glycol, tert-butyl carbazate, trichloroacetic acid, trinitrobenzene sulphonic 
acid solution (TNBS), adipic dihydrazide, glycidyl methacrylate, triethylamine (TEA), tetrabutyl 
ammonium bromide (TBAB), Irgacure 2959, PEG diacrylate (Mn = 575), PEG diglycidyl ether (Mn = 
500), sodium azide, sodium chloride, hyaluronidase from bovine testes (Type I-S, 400-1000 
U/mL), N-acetyl glucosamine, sodium tetraborate, p-dimethylaminobenzaldehyde (DMAB), 
acetic acid and hydrochloric acid were purchased from Sigma-Aldrich (Poole, Dorset, UK). 
Phosphate buffered saline (PBS) was purchased from Oxoid (Basingstoke, Hamps, UK) 
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5.2.1. Carbodiimide crosslinking  
40 mL 2% w/v HA solution was dissolved overnight and then sonicated to remove air bubbles. 
The solution was then poured into a 120 x 120 mm square petri dish and the solution was 
allowed to settle to form an even distribution. The dish was incubated at 37 °C overnight to form 
a dry HA film. The film was then cut into 10 x 10 mm squares for further tests.  
To crosslink, dried HA films were immersed in acetone:H2O solution (80:20) containing EDC and 
HCl, as well as varying concentrations of PEG diglycidyl ether (0.5 – 20 equivalents) overnight at 
room temperature. Films were then washed in acetone:H2O and allowed to air dry.  
5.2.2. Aldehyde/adipic dihydrazide crosslinking 
5.2.2.1. Synthesis of oxidised HA (oxi-HA) 
Oxidisation of HA was carried out using a modified method based on the work described by Yeo 
et al1, 2. 1 g HA was dissolved in 100 mL distilled water (1% w/v) at room temperature until 
homogenous. 5 mL 0.5 M sodium periodate was then added and thoroughly mixed. The reaction 
was carried out for 2 hours at room temperature in the dark. The reaction was then terminated 
with the addition of 500 µL ethylene glycol to quench the reaction. Oxidised HA was purified by 
dialysis in deionised water for 3 days, with water changes every 12 hours. The product was then 
freeze dried and stored at -20 °C until needed. Oxi-HA structure was confirmed using FTIR and 
the TNBS assay. 
5.2.2.2. TNBS assay  
The TNBS assay was used to determine the degree of oxidisation of oxi-HA3. In brief, 25 µL 0.6% 
oxi-HA in water was added to 25 µL tert-butyl carbazate (t-BC) solution (30 mM tert-butyl 
carbazate in 1% w/v aqueous trichloroacetic acid) in a 1.5 mL Eppendorf tube and reacted at 
room temperature for 24 hours. 0.5 mL TNBS solution (6 mM TNBS, 0.1 M borate buffer, pH 8) 
was then added to each vial and allowed to react for a further hour at room temperature. 50 µL 
of the final mixture was then removed and placed in a 96-well plate, where it was diluted with 
200 µL 0.5 M HCl per well. Absorbance was measured at 340 nm. A standard calibration curve of 
aqueous t-BC (5 – 30 mM) was used to calculate the concentration of unreacted t-BC in the test 
solution, and subsequently concentration of aldehyde groups per molecule. All experiments 
were done in triplicate.   
 




5.2.2.3. Crosslinking of oxi-HA with adipic dihydrazide 
Oxi-HA and adipic dihydrazide (ADH) were allowed to thaw for 1 hour at room temperature 
before use. Separate solutions were then made of oxi-HA (6% w/v) and ADH (8% w/v) in 
deionised water, and the solutions allowed to dissolve until homogenous. To form crosslinked 
hydrogels, 200 µL ADH solution was added to 800 µL oxi-HA solution and immediately vortexed. 
A solid hydrogel was seen to form after approximately 30 seconds. Hydrogel crosslinking was 
confirmed with FTIR.  
5.2.3. Photopolymerisation crosslinking 
5.2.3.1. Synthesis of hyaluronic acid methacrylate (HAMA) 
Photo-crosslinkable HA methacrylate (HAMA) was prepared using the method described by 
Leach et al4. In brief, 1 g of HA (Mw = 1.8 x 106 g/mol) was dissolved in water overnight to form a 
1 % w/v solution. 2.2 mL TEA, 4.4 mL glycidyl methacrylate and 2.2 g TBAB were then added 
sequentially, with each reagent fully dissolved before the addition of the next. The solution was 
stirred at room temperature for 24 hours, followed by 1 hour incubation at 60 °C. HAMA was 
then recovered by precipitation with acetone (20 x volumes) and re-dissolved in distilled water 
to remove excess reactants. The HAMA was lyophilised and stored at 4 °C until needed. 1H NMR 
was used to determine the percentage of methacrylation. HAMA samples were dissolved in D2O 
and spectra were recorded with a Bruker 450 MHz NMR.  
5.2.3.2. Photopolymerisation of HAMA 
Solutions of varying concentration of HAMA (0.5 – 5% w/v) and PEG diacrylate (0 – 10% v/v) 
were dissolved in deionised water overnight to form a homogenous mixture. The photoinitiator 
Irgacure 2959 was then added, the solution mixed, and then incubated at 50 °C for 5 minutes to 
aid solvation. The mixture was then kept in the dark at room temperature for up to 2 weeks until 
needed. To photocrosslink the HAMA mix, 400 μL mix was added per well to a 12-well plate with 
the plates then incubated under UV light (Dymax 5000 Flood curing system, 400 W) for 60  
seconds. 
5.2.4. Carbazole assay 
The concentration of HA breakdown products after breakdown by HAase was quantified using a 
modified version of the Carbazole assay described by Makris et al5. Bacterial overnight cultures 
(approximately 109 cfu/mL) in TSB broth were centrifuged at 4,000 rpm for 15 minutes and the 
supernatant filter sterilised with 0.22 µm filters. 125 µL supernatant was then added to 250 µL 
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pre-warmed HA solution (0.6 % HA, 1 % NaN3 and 200 mM NaCl). The vials were mixed and 
incubated at 37 °C for 2 hours with mild shaking (120 rpm). After this time, 125 µL was removed 
and added to vials containing 125 µL water and 25 µL 0.8 M sodium tetraborate. The vials were 
then boiled at 95 °C for 3 minutes to stop further enzyme activity. Samples were cooled and 
stored at 4 °C until needed. A standard curve was simultaneously carried out using 125 µL N-
acetyl-glucosamine (0.5 - 0.05 mM) mixed with 125 µL water and 25 µL 0.8 M sodium 
tetraborate.  Vials were boiled at 95 °C for 3 minutes and again allowed to cool.  
A colour change was seen on the addition of 750 µL 0.1x DMAB reagent (10% w/v DMAB, 12.5 % 
v/v 10 M HCl, 87.5 % v/v glacial acetic acid) and subsequent incubation at 37 °C for 20 minutes. 
The absorbance at 544 nm was measured on a BMG SPECRAstar spectrometer. 
5.2.5. Hyaluronidase production in biofilms 
5.2.5.1. S. aureus biofilm formation 
S. aureus biofilms were formed using previously reported methods6. In brief, 10 µL bacterial 
overnight culture was added to 10 mL TSB broth supplemented with 1% D-(+)-glucose. 1 mL 
solution was then added per well to a 12-well plate, as well as three wells containing TSB broth 
as a negative control; the plates were then incubated at 37 °C with no shaking to form biofilms.  
Biofilm plates were removed at 6, 24 and 48 hours to determine HAase concentration and 
biofilm biomass. Biofilm supernatant was removed, centrifuged and filter sterilised with a 0.22 
µm to remove any planktonic bacteria. HAase concentration of the sterilised supernatant was 
then measured using the Carbazole assay (Section 5.2.4).  
5.2.5.2. Crystal violet assay 
Biofilm biomass was quantified using the Crystal Violet assay. After the removal of supernatant 
for HAase analysis, each well was washed twice with PBS to remove planktonic bacteria. Plates 
were then dried for one hour at 50 °C. After drying, 500 µL 0.1% crystal violet staining solution 
was added and the plates left at room temperature for 20 minutes. The stain was then removed 
and the wells washed twice again with PBS. To dissolve the dye, 1 mL ethanol was added per 








5.3. Results and Discussion 
5.3.1. Crosslinking of HA 
5.3.1.1. Carbodiimide crosslinking 
One of the most common methods of crosslinking HA with itself is through the use of water 
soluble diimides such as EDC. Here, dried HA films were immersed in acidified 80:20 
acetone:water containing EDC, HCl and PEG diacrylate; the acetone:water mixture here allowed 
for solvation and reaction of EDC without further solvation of the HA film. PEG diglycidyl ether 
was also introduced as a crosslinker in order to form more crosslinks with the HA, and to also 
improve hydrogel properties by increasing hydrogel strength. An example reaction scheme for 





Carbodiimides are the most popular, best understood and most versatile methods for the 
chemical crosslinking or functionalisation of carboxylic acids, with the water soluble EDC the 
most commonly used. On reaction of HA with EDC, the EDC reacts with HA carboxylic acid 
groups to form an active O-acylisourea intermediate. This group can then go on to react in a 
number of different ways to form crosslinks (Figure 5.3). Both the carboxylic acid and secondary 
alcohol groups can attack the intermediate forming zero-length HA-HA crosslinks. With the 
addition of other molecules, such as diethers or diamines, longer crosslinks can be formed. 
Figure 5.2: Reaction scheme for the crosslinking of HA with EDC and PEG diglycidyl ether 




The crosslinking of HA films in acetone:water containing EDC and crosslinker resulted in the 
formation of highly crosslinked hydrogel films. On crosslinking, the dry hydrogel films did not 
appear different from native HA films; they were slightly flexible and easily cut with scissors 
(Figure 5.4). After hydration, crosslinked HA films did not swell to high amounts, and although 
very flexible, could be easily ripped and were prone to curling into tubes.  
 
Firstly, a previously reported standard crosslinking mix was assessed to crosslink HA using 10 
mM EDC, 10 mM HCl and 250 mM PEG diglycidyl ether crosslinker. The structure of crosslinked 
HA was confirmed by FTIR, with the appearance of a new C=O ester stretch at approximately 
1730 cm-1 compared to non-crosslinked HA (Figure 5.5). It was not possible to tell from FTIR 
Figure 5.3: Reaction mechanism for the EDC mediated crosslinking of HA 
Figure 5.4: a) dry HA film before crosslinking, b) crosslinked HA film (10 mM EDC, 10 mM HCl, 250 mM PEG 
diglycidyl ether) after swelling in PBS buffer overnight 





































A screen of reaction conditions was carried out to analyse how changing EDC, HCl and PEG 
diglycidyl ether concentration would affect the hydrogel swelling ratio (Table 5.1).  Here, HA 
films were immersed overnight with varying concentrations of EDC (1 – 100 mM), HCl (10 – 50 
mM) and PEG diglycidyl ether (25 – 500 mM). Mixtures containing no EDC and no PEG diglycidyl 





Figure 5.5: FTIR spectrum of HA and HA sheets crosslinked with 10 mM EDC, 10 mM HCl and 250 mM PEG 
diglycidyl ether. 
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 EDC (mM) HCl (mM) PEGDE (mM) Swelling ratio 
1 0 10 250 no crosslinking 
2 1 10 250 7.9 ± 1.3 
3 2 10 250 4.8 ± 0.1 
4 5 10 250 2.6 ± 0.1 
5 10 10 250 1.8 ± 0.1 
6 50 10 250 1.2 ± 0.2 
7 100 10 250 0.7 ± 0.2 
8 10 0 0 1.4 ± 0.1 
9 10 10 0 no crosslinking 
10 10 10 25 16.2 ± 1.2 
11 10 10 50 4.5 ± 0.4 
12 10 10 100 2.6 ± 0.2 
13 10 10 250 1.5 ± 0.2 
14 10 10 500 1.2 ± 0.03 
15 0 10 0 no  crosslinking 
16 10 10 250 2.1 ± 0.1 
17 10 20 250 2.9 ± 0.1 
18 10 50 250 3.7 ± 0.3 
19 0 0 0 no crosslinking 
Table 5.1: Swelling ratio calculations for HA sheets crosslinked with EDC (1 – 100 mM), HCl (10 – 50 mM) 
and PEG diglycidyl ether (0 – 500 mM) 
 
Firstly, swelling ratio generally decreased with increased concentration of EDC or PEG diglycidyl 
ether. With EDC, swelling ratio reduced from 7.9 ± 1.3 for 1 mM to 0.7 ± 0.2 for 100 mM. With 
PEG diglycidyl ether a similar trend was seen, with a reduction of 16.2 ± 1.2 for 25 mM to 1.2 ± 
0.03 for 500 mM. This implied that in both cases the number of crosslinks was increasing as 
more crosslinking species were available. The concentration of HCl was also assessed, with a 
slight increase in swelling ratio as concentration increased (2.1 ± 0.1 for 10 mM, 2.9 ± 0.1 for 20 
mM and 3.7 ± 0.3 for 50 mM). This could be due to hydrolysis of HA repeating units causing a 
breakdown of polymer structure at low pH.  
In all samples where no EDC was present (samples 1, 15, and 19), no crosslinking of HA films was 
seen, showing that EDC was essential for successful crosslinking. In sample 15, only HCl was 
present to determine if crosslinking could occur through acid catalysed esterification, however 
this proved unsuccessful.  
In general, although strong highly crosslinked HA hydrogels were formed through crosslinking 
with carbodiimides, the films were not chosen for further development due to the fact that the 
hydrogel could not be crosslinked in situ. For the proposed sandwich hydrogel, it would not be 




possible to add second layers to the hydrogel once crosslinked. Also the presence of an 
acetone:water based crosslinking solution would damage any bacteriophage virions immobilised 
in the second layer. 
5.3.1.2. Aldehyde/adipic dihydrazide crosslinking  
Next, sodium periodate was chosen to oxidise certain groups on HA, as although it results in the 
degradation of HA primary structure (unlike Dess-Martin periodinane or TEMPO oxidation), the 
reaction is fast and the number of aldehydes formed per repeating unit is two as opposed to one 
(Figure 5.6). The viscosity of the HA reaction solution was visibly reduced after 24 hours, 
implying breakdown of the HA ring structure. 
 
On reaction of oxi-HA with adipic dihydrazide, the nucleophilic ADH amine attacks the 
electrophilic oxi-HA aldehyde groups. This goes on to form a stable imine bond, through a 
carbinolamine intermediate, between one aldehyde group and one end of the ADH molecule. 
Because the ADH molecule is a diamine, it can act as a crosslinker which reacts with two sites on 
one HA molecule, or with two different molecules. The reaction mechanism for oxidised HA 
crosslinking with dihydrazide groups can be seen in Figure 5.7.  
Figure 5.6: Reaction scheme for the oxidation of HA by sodium periodate 
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Figure 5.8: FTIR spectrum of HA, oxidised HA and oxidised HA crosslinked with adipic dihydrazide, 
aldehyde groups, and subsequent HA crosslinking 
Figure 5.7: Reaction mechanism for the nucleophilic addition of adipic dihydrazide to oxi-HA 




Figure 5.9: Standard curve of OD340 measurements of 0 – 30 mM tert-butyl carbazate used to calculate 
aldehyde concentration in oxidised HA 
HA was oxidised by reaction with sodium periodate, which opens the glucuronic acid ring and 
forming two aldehyde groups per ring. FTIR was used to confirm the presence of aldehyde 
groups in oxi-HA (Figure 5.8). The appearance of a new peak at 1730 cm-1 showed the presence 
of a C=O aldehyde stretch. After crosslinking with adipic dihydrazide, the hydrogel was dried 
overnight at 50 °C. The crosslinked structure was again confirmed by FTIR with the simultaneous 
appearance of a peak at 1560 cm-1 (N-H stretch) and loss of the C=O peak at 1730 cm-1. 
The TNBS assay was used to calculate the degree of oxidation of oxi-HA, as the aldehyde groups 
were not stable with other quantitative methods such as NMR. A standard curve of tert-butyl 
carbazate was initially formed, and the concentration of t-BC remaining after reaction with oxi-
HA subsequently quantified. The calculated number of aldehyde groups was then divided into 
the number of repeating units of HA, giving an approximate degree of oxidation of 70%. 
 
Oxi-HA/ADH hydrogels were formed by mixing 6% oxi-HA with 8% ADH in aqueous solution. 
Crosslinking occurred extremely quickly after mixing at room temperature, with a solid hydrogel 
being seen after approximately 30 seconds compared to the viscose liquids of the reactants 
(Figure 5.10). The hydrogel formed was clear and elastic, with polymerisation occurring so 
quickly that air bubbles became entrapped in the matrix. On removal of the gel from the 
reaction vessel hydrogel shape was kept slightly, however it did not retain a defined structure.  
















y=0.165 exp (x/14.5) + 0.85




In general, although a fast and reliable way of crosslinking HA without the addition of toxic 
crosslinking agents, this approach was not investigated further. This was primarily due to the 
speed of crosslinking; although this could be altered by tailoring the % oxidation of oxi-HA or the 
concentration of ADH, the removal of entrapped air bubbles would still be an issue. 
5.3.1.3. Photopolymerisation crosslinking 
A photo-crosslinkable HA was next investigated as crosslinking with UV light offers a number of 
benefits over purely chemical crosslinking; the degree and time of polymerisation can be 
controlled, and hydrogels can be crosslinked in situ. The polymer can also be crosslinked in 
aqueous solution and can be co-polymerised with other photoactive or inert polymers. This also 
offers the opportunity of forming interpenetrating polymer networks (IPNs) where a polymer 
scaffold is soaked in a photocrosslinkable polymer mixture and then UV crosslinked forming an 
interlaced framework.  
The methacrylation of HA to form a photoactive HA is predominantly carried out using 
methacrylic anhydride or glycidyl methacrylate, however the use of methacrylic anhydride gives 
low control of methacrylation and can yield methacrylic acid by-products4, 7, 8. HAMA was 
synthesised by reacting HA with 10 molar equivalents of glycidyl methacrylate in an excess of 
TEA and TBAB. In the presence of TEA, the basic conditions favour the ring-opening of glycidyl 
methacrylate epoxide by the secondary alcohol on the N-acetyl glucosamine unit of HA, as 
opposed to the glucuronic acid carboxylate (which is favoured at pH 3.5)9. The reaction scheme 




Figure 5.10: a) 6% oxi-HA solution, b) 8% ADH solution and c) oxi-HA/ADH crosslinked 





Once purified, aqueous HAMA solution was UV crosslinked with the use of the photoinitiator 
Irgacure 2959; this was chosen predominantly because of its low cytotoxicity10. In UV light 
Irgacure 2959 homolytically cleaves to form two different radical species. The benzaldehyde 
radical species then goes on to attack the methacrylate double bond, initiating polymerisation 
(Figure 5.12). Diacrylates were also introduced as a crosslinker to strengthen gel and increase 









Figure 5.12: Reaction mechanism of radical formation of Irgacure 2959 by UV light and subsequent 
polymerisation initiation of HAMA. 
Figure 5.11: Reaction scheme for the methacrylation of HA using glycidyl methacrylate 
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HAMA hydrogels containing 1, 2 and 5% diacrylate were crosslinked for 1 minute in a UV reactor. 
As seen in Figure 5.13, hydrogels crosslinked with the longer chain PEG diacrylate were clear, 
whereas those crosslinked with ethylene glycol dimethacrylate and ethylene diacrylate were 
opaque. A clear hydrogel layer is advantageous in this system, as in a wound dressing it is 
beneficial to be able to see the progression of healing without disturbing the dressing. A clear 
gel means that wound healing instead can be assessed by looking through the hydrogel. Because 









FTIR analysis of HAMA verified methacrylation with peaks at 1455 cm-1 corresponding to C=C 
stretching (Figure 5.14). The structure of HAMA was also confirmed by 1H NMR. Resonances at 
5.6 and 6.2 ppm verified the presence of methylene protons coupled to the grafted 
methacrylate (Figure 5.15). The integration ratio of methacrylate methylene protons and the N-
acetyl glucosamine methyl proton peak allowed the approximate % methacrylation to be 





Figure 5.13: Crosslinked HAMA hydrogels containing 1% w/v Irgacure 2959 and 1%, 2% and 5% a) PEG 
diacrylate, b) ethylene glycol dimethacrylate and c) ethylene diacrylate after 1 minute UV irradiation 























































Figure 5.14: FTIR spectra of hyaluronic acid and hyaluronic acid methacrylate (HAMA) 
Figure 5.15: 1H NMR spectrum of HAMA in D2O. Resonances at 5.6 and 6.2 ppm verified the presence of 
methylene protons. 
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2% w/v HAMA was co-crosslinked with a range of concentrations of PEG diacrylate, along with 
1% Irgacure 2959 photoinitiator through free radical polymerisation. The hydrogels could be 
crosslinked for up to 1 minute without visible signs of degradation (e.g. yellowing, structure 
breakdown or fluid exudate).  
The swelling ratio of hydrogels changed inversely with the concentration of PEG diacrylate 
(Figure 5.16). For 0, 1, 5 and 10% w/v PEG diacrylate, the swelling ratio was determined as 
67.4±3.9, 41.5±0.7, 14.6±0.1 and 7.7±0.3 respectively (n=3). This indicates an increased 
crosslinking density and a smaller hydrogel mesh size.  This could also be due to the increasing % 
of PEG in the hydrogel compared to HA. As HA is more hydrophilic than PEG, and is thought to 
hold more water molecules per chain than PEG, this could contribute to a lower interaction of 












A better understanding of hydrogel networks can be found using Florey-Rehner calculations, 
however in this case the heterogeneity of the system meant a too simplistic approximate was 
given. For 0% PEG diacrylate HA hydrogels (a one component system well explained by Florey-
Rehner), the mesh size was found to be approximately 6.6 µm, with a crosslink density of 1.65 x 
10-8 mol/cm3. On the addition of PEG diacrylate however, Florey Rehner cannot now be reliably 
used. An indication of mesh size and crosslink density can be gained from swelling data by 
utilising the Florey parameter and specific dry polymer volume of HA throughout. By doing this, 
Figure 5.16: Swelling ratio measurements of 2% HAMA hydrogels containing varying % PEG 
diacrylate with 1% initiator and 1 minute UV exposure 




a mesh size of 3.1, 0.6 and 0.2 µm respectively was seen for 1%, 5% and 10% PEG diacrylate 
hydrogels; however this was not completely illustrative of the real system. 
SEM images of 2% HAMA hydrogels containing 0, 1, 5, and 10% PEG diacrylate were taken to 
assess internal structure and mesh size (Figure 5.17). In general, as PEG diacrylate concentration 
increased hydrogel structure became more ordered, implying that the long PEG chains are 
orienting together. A definite columnar structure is seen in hydrogels containing 5 and 10% PEG 
diacrylate.  
After investigation of structure and swelling properties of HA crosslinked by various methods, it 
was decided that photocrosslinked  2% HAMA hydrogels co-crosslinked with 1% PEG diacrylate 
and 1% Irgacure 2959 was an optimal formulation to take on for further testing. The hydrogels 
formed were robust, and had a significantly small pore size and swelling ratio to ensure the 
retention of active molecules stored in the lower hydrogel layer. HAMA could be easily 
polymerised in situ, with good control of the hydrogel properties and without the fast gelation 
time seen with oxi-HA/ADH gels. The HAMA gels formed were then analysed for their reaction 
with HAase, both purified and from S. aureus cultures.  
0% PEGDA 
Figure 5.17: Side-on SEM images of 2% HAMA hydrogels containing 0, 1, 5 and 10% v/v PEG diacrylate 
with 1% initiator and 1 minute UV exposure. 
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JE2         hys-      TW20      µ2         µ20  
Figure 5.18: 2% agarose gels of hysA gene in JE2, NE334 (hys-), TW20, ST239 µ2 and ST239 µ0. Ladder =1 
kB 
5.3.2. Hyaluronidase production by S. aureus 
5.3.2.1. Screen of bacterial hyaluronidase activity 
A screen of 116 clinical strains was carried out to assess HAase expression in a wide range of 
bacterial strains and species (Figure 5.19), which gave an 82.7% overall activity and 86% activity 
in S. aureus. These included hospital and community acquired MSSA and MRSAs, coagulase 
positive and negative S. aureus, as well as other medically important species such as E.coli, P. 
aeruginosa, and S. epidermidis. An additional screen of 33 Proteus mirabilis strains was also 










HAase activity was calculated using the Carbazole assay, by incubating HA solution with bacterial 
supernatant. In brief, the assay involves the reaction of HA NAG at the reducing end with borate 
to form a monoanhydro sugar. On subsequent addition of acidified p-
dimethylaminobenzaldehyde (DMAB), the DMAB is able to react with the sugar to form a 
red/purple complex with maximum absorbance at 544 nm.  
The level of activity between strains ranged up to approximately 1.2 mM NAG in 2 hours. There 
was no apparent correlation between bacterial virulence and HAase activity. This also did not 
appear to be determined by methicillin resistance or origin of species. 
 





 Figure 5.19: HAase activity screen of 116 bacterial strains 
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A number of S. aureus strains were found to show no HAase activity. S. aureus NE334 (hys-) is 
distinctive from other HAase negative S. aureus strains found in the screen, as it has been 
genetically engineered to exhibit no HAase activity by insertion of a transposon. Bacterial DNA 
was extracted and then analysed for the hysA gene, to asses if hysA is removed in non-
engineered strains (Figure 5.18). Alongside hys-, JE2 was analysed as the parent strain of hys- 
(which does show activity). Also, ST239 µ2 and µ20 were analysed alongside their parent strain 
TW20. In all cases, the hysA gene was present.  
S. aureus NE334 (hys-) does not exhibit HAase activity as the inserted transposon prevents the 
correct gene transcription. In other cases this also could be true; however it is more likely that 
the gene is downregulated by other mechanisms (e.g. the gene is silenced or repressed).  
5.3.2.2. Hyaluronidase expression during S. aureus growth 
The secretion of HAase was monitored over the growth cycle of both HAase positive (H560) and 
negative (ST239 µ2) S. aureus strains (Figure 5.20 and Figure 5.21). Bacterial subcultures were 
grown in 50 mL centrifuge tubes in a shaking incubator at 37 °C. Samples were then removed at 
certain timepoints; for each timepoint the bacterial OD600 and the HAase activity ([NAG] ml-1min-
1OD600-1) was measured using the Carbazole assay.  
 
 
Figure 5.20: HAase production during the growth of S. aureus H560 

























































In S. aureus H560, HAase expression was predominantly seen in the early exponential phase of 
bacterial growth, with a peak after 4 hours growth, followed by a gradual decrease in expression 
once the stationary phase was reached. This was consistent with HAase being a spreading factor 
involved in early bacterial invasion of hosts, and also mirrored the results of Makris et al5, 11. In 
HAase negative S. aureus ST239 µ2, no expression of HAase was detected at any timepoint. 
5.3.2.3. Expression of hyaluronidase by S. aureus biofilms 
S. aureus biofilms were formed using a high HAase producing strain (C3), a low HAase producing 
strain (H560) and a non-producing strain NE334 (hys-). It was also recently reported by Hart et al 
that mutant bacteria deficient of HAase activity showed no significant change in biofilm 
production12. In that case however, HAase activity was only measured using zone of inhibition 
diameters. 
HAase activity and biofilm biomass measurements can be seen in Figure 5.22. It is important to 
note that the three strains tested are example strains, and in order to get a better understanding 
of HAase expression in biofilms, more strains must be analysed. At different stages of biofilm 
formation, the biofilm biomass and concentration of HAase secreted was measured to 
determine three things. Firstly, if HAase was expressed differently in a biofilm compared to 
planktonic bacteria, and secondly, if HAase was expressed at different times over the biofilm 
growth cycle and finally, if there was a correlation between biofilm and HAase production.  
Figure 5.21: HAase production during the growth of S. aureus ST239 µ2 




Firstly, comparing HAase activity at 24 hours in planktonic and biofilm systems, it was found that 
especially for strains that showed a high HAase activity as planktonic cells, a reduction was seen 
once in a biofilm. In S. aureus C3, HAase activity was reduced from approximately 0.9 mM NAG 
to 0.125 mM. Strains which exhibited a lower HAase activity in planktonic culture, such as H560, 
did not change significantly once in a biofilm. In both growth environments, S. aureus hys- 
showed no HAase activity. It is widely understood that bacteria in biofilms behave completely 
differently compared to planktonic bacteria. They have vastly different metabolism and 
susceptibility to antibiotics, as well as being phenotypically different exhibiting varied gene 
expression13, 14. S. aureus C3 could be exhibiting a genetic ‘compromise’ when forming a biofilm; 
overly high HAase expression could be downregulated to concentrate on biofilm formation.  
Figure 5.23: (left) HAase activity and (right) biofilm biomass in S. aureus C3, H560 and hys- 













































Figure 5.24: Concentration of NAG from 2% HAMA /1% PEGDA gels, after incubation with PBS, 0.01, 0.1 
and 1 mg/mL HAase 






















Secondly, it was shown that in both HAase positive cases, HAase expression continued for 
approximately 24 hours until a sharp reduction was seen by 48 hours. HAase, as primarily an 
invasion enzyme, is likely to be downregulated after the initial invasion period (~ 24 hours) in 
order to concentrate bacterial resources in other areas.  
Finally, normal biofilm production was seen in all three strains, implying that there is no 
correlation between biofilm and HAase production; production was seen in both HAase positive 
and negative strains. Biofilm biomass increased with time, as bacteria replicated and began to 
secrete EPS to form mature biofilms.  
5.3.3. Sensitivity of HAMA-co-PEG films to hyaluronidase  
HAMA-co-PEG hydrogels were incubated in a range of concentrations of HAase (Figure 5.23). 
Purified HAase was obtained from bovine testes; although this is not derived from microbial 
producers, it still degrades HA through hydrolysis of the sugar at the same position that would 
be seen after bacterial degradation. The enzyme is approximately 55 kDa and has a calculated 
size of 52 x 44 x 39 nm15 - although large for an enzyme, this is still small enough to diffuse into 
the HAMA network based on theoretical mesh size calculations. 
The concentration of the HA breakdown product NAG was quantified, however in the case of 
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On incubation with HAase, an increase in the concentration of NAG was seen compared to 
hydrogels incubated with PBS buffer solution, showing that although modified with 
methacrylate, HAMA was still susceptible to enzymatic degradation. Hydrogels were also seen to 
disappear by 6 hours in all HAase concentrations, with degradation continuing past this time as 
longer polymer chains were made smaller. 
The degradation process was analysed through SEM after 2 hours incubation with HAase at 37 °C 
(Figure 5.25). On incubation with PBS no damage to hydrogel morphology was seen; gel 
homogeneity and a general absence of cavities implied the gel does not undergo significant 
hydrolysis with buffer. Hydrogels incubated with 0.01 mg/mL HAase showed small pores of 
approximately 5 μm in diameter, which were consistent throughout the gel. An increased 
concentration of 1 mg/mL gave considerably larger pores of 15-20 μm, with evidence of collapse 
between the layers also being apparent. 
 
HAMA hydrogels containing a range of PEG diacrylate concentrations were then incubated with 
HAase, and the extent of breakdown of the cross-linked hydrogel measured after 24 hours 
Figure 5.25: Top view SEM images after 2 hour incubation of 1% PEG diacrylate + 2% HAMA hydrogels with 
a) PBS, b) 0.01 mg/mL HAase and c) 1 mg/mL HAase 





























through the measurement of the formation of NAG breakdown product, using the Carbazole 
assay (Figure 5.26). 
It can be seen that an increase in HAase concentration increases breakdown of cross-linked 
HAMA; an increase in the relative proportion of PEG-diacrylate however decreases the 
susceptibility of the cross-linked polymer to HAase. The breakdown of 10% PEG diacrylate co-
gels was roughly a third of that seen for pure HAMA gel. It was hypothesised that in high co-
polymer hydrogels, the viscosity of the polymer gel greatly increases slowing diffusion of HAase 
into the matrix. 
 
5.3.4. Sensitivity of HAMA-co-PEG films to S. aureus supernatant 
HAMA-co-PEG hydrogels were also then incubated with overnight bacterial supernatant for 2 
hours. Top view SEM images of the hydrogels after incubation showed significant differences in 
hydrogel morphology (Figure 5.27). HAMA hydrogels incubated with strains known to secrete 
HAase (images a), b), c)) all exhibited clear visual signs of enzymatic degradation. Large areas of 
hydrogel loss were seen that permeated through the entire matrix. This enzymatic hydrolysis 
leads to increased permiability and eventual dissolution of the gel.  
Hydrogels were also incubated with S. aureus strains which showed no HAase activity in the 
initial strain screen. S. aureus hys- (image d) showed no changes compared to the negative 
Figure 5.26: Degradation of HAMA hydrogels containing 0%, 1%, 5% and 10% PEGDA by HAase. 
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control (TSB growth medium, image f)). The hydrogel top layer remained confluent with no pores 
formed.) On incubation with ST239 µ2 (image e), a phenotypic mutant where despite hysA being 
present, no activity was seen in the strain screen, small circular pores were seen in some parts of 
the hydrogel. This could have been due to low levels of HAase being present which were 




Figure 5.27: SEM images of HAMA hydrogels after 2h incubation with S. aureus supernatant. HAase positive 
strains: a) RN6390B, b) H560, c) lac. HAase negative strains: d) hys-, e) ST239 µ2, and f) TSB. 


























Again the concentration of NAG breakdown products on incubation with supernatant were 
measured over the course of 24 hours (Figure 5.28). Firstly, no significant breakdown was seen in 
HAase negative strains (ST239 µ2 and hys-) compared to the negative control (TSB). With strains 
known to produce HAase however, the concentration of NAG breakdown products increases as 
the polymer was broken down. The rate at which this was done is different between strains. High 
HAase producers RN6390B, H560 and lac exhibited relatively fast breakdown with a plateau seen 
after 6 hours. Visually, hydrogels were completely dissolved after incubation with HAase positive 














This chapter focussed on the interactions of hyaluronic acid, HA and the enzyme hyaluronidase, 
HAase, a virulence factor of S. aureus. HA was chosen as an enzyme-sensitive release mechanism 
for immobilised bacteriophage as it already is widely used in medical therapeutics. It was 
crosslinked into hydrogel matrices of varying strength and flexibility. The secretion of HAase by 
116 bacterial strains (predominantly S. aureus) was also assessed with the Carbazole assay to 
confirm that the enzyme was secreted by the majority of strains. Finally, crosslinked HAMA-co-
PEG hydrogels were degraded by commercially available and bacterial HAase, as well as with S. 
aureus mutants with no activity.  The degradation of these hydrogels was then analysed using 
Figure 5.28: Degradation of HAMA hydrogels by HAase positive (green) and HAase negative 
(red) S. aureus supernatant. 
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SEM imaging and quantitatively. In conclusion the final crosslinked HA formulation was found to 
be selectively degraded by Staphylococcal HAase, making it a viable hydrogel mechanism for 
triggered release. 
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Chapter 6 : A Bilayered Hydrogel System for Triggered Release of 
Bacteriophage K by Staphylococcal Hyaluronidase 
 
6.1. Introduction 
This chapter will focus on the combination of work described in Chapters 4 and 5 to create a 
bilayered hydrogel system which gives triggered release of Bacteriophage K on incubation with 
hyaluronidase. This bilayered hydrogel comprises two hydrogel matrices: firstly an agarose or 
PVA hydrogel containing immobilised Bacteriophage K, and secondly a crosslinked hyaluronic 
acid layer which will become degraded in the presence of Staphylococcal hyaluronidase.  
On infection with hyaluronidase secreting bacteria (S. aureus), the HA-based upper layer will be 
degraded, allowing bacteriophage to be released into the surrounding environment and 
subsequently go on to infect and lyse live bacteria. In this way, bacteriophage are released only 
in the presence of pathogenic bacteria and by doing so the development of bacterial resistance 
to bacteriophage will be reduced. A diagram of triggered bacteriophage release from bilayered 
hydrogels can be seen in Figure 6.1.   
 
With non-pathogenic or non S. aureus species, no hyaluronidase is expressed and so the upper 
HAMA layer does not break down, causing no bacteriophage to be released. As the 
bacteriophage used (Bacteriophage K) only has efficacy against S. aureus, this is not an issue as 
even if the bacteriophage were released they would not cause lysis. Bacteriophage are only 
released by bacteria that are susceptible to them.  
Figure 6.1: Schematic diagram of bilayered hydrogel system: degradation of the upper HAMA layer causes 
release of immobilised bacteriophage, causing bacterial death 




Bilayered hydrogels have been used in a number of biomedical applications. Firstly, they are 
commonly used in tissue engineering in order to build up stratified hydrogels which mimic the 
structure and mechanical properties of tissue1-4. These are predominantly tissues which already 
exhibit a highly ordered structure in the body, such as dermal or osteochondral tissue5, 6.  
Secondly, double or triple network hydrogels can be used to increase the mechanical strength of 
a hydrogel7-10. These are referred to as interpenetrating polymer networks, IPNs, and can 
demonstrate dramatically different properties from their constituent polymers11. The IUPAC 
definition of an IPN is “a polymer comprising two or more networks which are at least partially 
interlaced on a molecular scale but not covalently bonded to each other and cannot be 
separated unless chemical bonds are broken”12.  In general to form IPNs, firstly one polymer is 
crosslinked into a matrix and then another is crosslinked around it in situ. 
6.2. Materials and Methods 
6.2.1. Formation of bilayer hydrogel 
Bilayered hydrogels were formed in 12-well (for hyaluronidase and supernatant tests) and 24-
well (for live bacteria tests) cell culture plates. Different hydrogel volumes were used for each 
plate, retaining the same hydrogel volume ratio: 
 12-well plate = 1 mL lower layer + 400 µL HAMA 
 24-well plate = 500 µL lower layer + 200 µL HAMA 
 
Lower layer hydrogel formation has been previously described in Chapter 4, whilst upper layer 
development has been described in Chapter 5. In all experiments, HAMA mix (2% HAMA, 1% 
Irgacure 2959, 1% PEG diacrylate) was crosslinked in a UV flood crosslinker.  
A schematic representation of bilayer hydrogel formation can be seen in Figure 6.2. Lower layer 
hydrogels containing SM buffer or 108 pfu/mL Bacteriophage K were cast and allowed to set; for 
agarose, plates were cooled overnight at 4 °C, for PVA, plates were frozen overnight at – 20 °C 
and then thawed at room temperature for 1 hour. HAMA mix was then added and allowed to 
completely cover and seal the lower hydrogel. Plates were then exposed to UV irradiation to 
crosslink the upper layer and used immediately.  
 
 









6.2.2. Measurement of bacteriophage release by hyaluronidase 
Triggered bacteriophage release from bilayered hydrogels by hyaluronidase was measured by 
casting bacteriophage containing hydrogels into a 12-well plate, as shown in Figure 6.3. Column 
1 contained control bacteriophage hydrogel with no HAMA layer, and columns 2 and 3 
contained bacteriophage hydrogel with a HAMA layer. 1 mL per well SM buffer was then added 
to columns 1 and 2, and 1 mL 1 mg/mL was added to column 3.  
 
     
    
    
 
Figure 6.3: 12-well plate layout for 1 mg/mL hyaluronidase breakdown measurements of bilayer hydrogel 
experiments 
Plates were incubated at 37 °C with 120 rpm shaking. Time point measurements at 2, 4 and 6 
hours were taken after addition of hyaluronidase, and (100 µL) samples were stored at 4 °C until 
required. After removal, liquid was replaced by SM buffer or HAase solution to keep test volume 
constant. Bacteriophage concentration was measured using standard protocols described in 
Chapter 2.  
6.2.3. Measurement of bacteriophage release by bacterial supernatant 
Triggered bacteriophage release from bilayered hydrogels by bacterial supernatant was 
measured by casting bacteriophage containing hydrogels into a 12-well plate, as shown in Figure 


























Figure 6.2: Schematic diagram of bilayer hydrogel formation 
UV 




columns 2, 3 and 4 bacteriophage hydrogel with a HAMA layer. 1 mL per well TSB was then 
added to columns 1 and 2, whilst 1 mL S. aureus C3 supernatant was added to column 3 and 1 








Plates were again incubated at 37 °C with 120 rpm shaking. Time point measurements at 1, 2 
and 4 hours were taken after addition of hyaluronidase, and (100 µL) samples were stored at 4 
°C until required. After removal, liquid was replaced by TSB or bacterial supernatant to keep test 
volume constant. Bacteriophage concentration was measured using standard protocols 
described in Chapter 2.  
When incubating the bilayered hydrogel systems with bacterial supernatant instead of HAase, a 
faster timeframe was analysed as the concentration of HAase in bacterial supernatant was much 
higher than 1 mg/mL. As the enzyme was able to work faster, triggered release was seen at an 
earlier time. Also, as seen in Section 5.3.2.2., peak HAase production in S.aureus is seen in the 
early exponential phase, at approximately 4 hours.  
6.2.4. Live culture with bilayer hydrogels 
Bilayer hydrogels (with and without Bacteriophage K) were cast in a 24-well plate as previously 
described. Lower layers with no HAMA layer were also included to determine non-triggered 
response. S. aureus H560 and hys- subculture was formed by mixing 10 µL overnight culture with 
10 mL TSB. Broth for growth of S. aureus hys- strains was additionally supplemented with 5 
µg/mL erythromycin. 500 µL per well was then added to each well and OD600 measurements 
were taken during the overnight incubation at 37 °C with shaking.  
    
    
    







































6.3. Results and Discussion 
6.3.1. Bilayer hydrogels   
 
Bilayered hydrogel systems could be formed easily with both agarose and PVA solutions (Figure 
6.5). With agarose, an inflexible hydrogel was seen that formed a solid system with defined 
layers; an opaque agarose layer and a clear HAMA layer. With PVA, a more elastic hydrogel was 
formed with could be bent without breaking. The bilayered system again formed two defined 
layers however the hydrogels were clearer, with a higher binding between the two layers.  
6.3.2. Optimisation of HAMA crosslinking 
As the main cause of bacteriophage killing during the hydrogel making process is UV exposure, 
the shortest time needed to effectively crosslink HAMA without the loss of the structure seen in 
Chapter 5 was determined. Here, the swelling ratios and rate of degradation by HAase were 
measured to assess if the hydrogel properties were altered. In general, all HAMA hydrogels 
became solid (“fully-crosslinked”) after a minimum of 10 seconds. Because of this, hydrogels 
were irradiated for 10, 20, 30 and 60 seconds to determine if there was a significant change 
from lowering the crosslinking time from 60 to 10 seconds.  
Firstly, the swelling of hydrogels crosslinked for varying times was measured; this gives an 
indication of the extent of crosslinking. If crosslinking has not gone to completion, the hydrogels 
would exhibit a higher swelling (and higher pore size). If crosslinking is completed by 10 seconds, 
the same swelling should be seen in all cases. Swelling ratio values for 10, 20, 30 and 60 seconds 
UV exposure can be seen in Figure 6.6. In general, the swelling ratio values measured for HAMA 
did not change with irradiation time, implying total crosslinking had occurred before 10 seconds.  
Figure 6.5: (left) Bilayered 2% agarose hydrogel with HAMA layer, (right) bilayered 5% PVA hydrogel with 
HAMA layer 





















Figure 6.6: Swelling ratio measurements of HAMA hydrogels after 10, 20, 30 and 60 sec UV irradiation 
The HAMA hydrogels were then incubated with 1 mg/mL HAase solution to determine if 
changing the crosslinking time affected the rate of enzymatic degradation Figure 6.7. In general, 
hydrogels exhibited a slightly slower initial degradation when irradiated for 10 seconds 
compared to longer exposure times. However, by 45 minutes incubation, the concentration of 
breakdown products (NAG) present had become equal. By 1 hour there was no significant 
difference in NAG concentration, implying that the rate of degradation was not dependent on 
irradiation time. This again implies that crosslinking had gone to completion at or before 10 
seconds.  





































Figure 6.7: Degradation of HAMA hydrogels crosslinked for 10, 20, 30 and 60 seconds with 1 mg/mL HAase 




It was decided that 10 seconds UV exposure would be sufficient to completely crosslink HAMA 
hydrogels judging by swelling and enzymatic degradation results. It was then important to 
determine if this UV irradiation time was damaging to bacteriophage in the lower layer. 
6.3.3. Optimisation of agarose hydrogels 
From Chapter 4, it was known that after UV irradiation of bacteriophage immobilised in 5% PVA 
of up to 30 seconds, sufficient bacteriophage remained to cause lysis and killing of bacterial live 
culture. However, even 10 seconds of UV irradiation was found to affect the onset of lysis 
compared to non-irradiated samples. This, combined with the general knowledge that UV is 
highly damaging to bacteriophage and their genetic material when combined with PVA, meant 
that PVA was not used as the lower layer hydrogel.  
Instead, agarose was used for lower layer development. Agarose is not thought to form (as many 
of) the highly damaging radicals seen in PVA during UV exposure. When agarose systems were 
incubated with live culture, a less extreme effect was seen compared to PVA, with full lysis 
occurring in all cases, except those with a very long exposure time and a very low polymer 
concentration (60 seconds, 0.4% and 0.7% agarose). In fact with agarose the polymer appeared 
to shield the bacteriophage from UV.  
In this respect, it was firstly important to determine the concentration of bacteriophage 
remaining in agarose hydrogels after 10 seconds UV exposure. Hydrogels containing 108 pfu/mL 
Bacteriophage K were formed using standard protocols and then exposed to UV for 10 seconds. 
SM buffer was then added to each well and the plates were incubated with slight shaking for 4 
hours (the time S. aureus normally takes to reach the early exponential phase; the phase where 
bacteriophage are most infective). The bacteriophage concentration present after 4 hours was 





















































 10 sec UV
Figure 6.6: Bacteriophage K concentration released from agarose hydrogels exposed to no and 10 sec UV 
after 4 hours 
After 10 seconds UV exposure, the concentration of infective bacteriophage released into the 
SM buffer from agarose hydrogels decreased by approximately a factor of 10 compared to non-
exposed hydrogels. In hydrogels exposed to no UV, a concentration of approximately 108 pfu/mL 
was seen, with a slight decrease as agarose concentration increased. This mirrors the results 
seen in Chapter 4, where the higher polymer concentration slows the diffusion of bacteriophage 
particles out of the hydrogel. When exposed to 10 seconds of UV, the bacteriophage 
concentration present was lower (107 pfu/mL), implying a certain amount of bacteriophage 
damage. However, this was still a high enough concentration to cause complete killing of 
infecting bacteria in live culture.  
6.3.4. 0.4% agarose bilayer hydrogel 
0.4% agarose based hydrogels were first investigated. From previous experiments, it was known 
that the hydrogel exhibited extremely high bacteriophage diffusion whilst retaining hydrogel 
structural stability. The more bacteriophage able to diffuse, the more that can go on to infect 
pathogenic bacteria.  
6.3.4.1. Triggered release of Bacteriophage K by hyaluronidase 
Bilayered 0.4% agarose/HAMA hydrogels were incubated with 1 mg/mL hyaluronidase solution 
and bacteriophage concentration measurements taken at 2, 4 and 6 hours (Figure 6.9). 
 





Firstly, in wells where only bacteriophage-containing agarose was present (no HAMA layer) a 
very high concentration of bacteriophage (almost 108 pfu/mL) was seen after two hours, which 
was constant throughout the experiment. From this, it could be confirmed that a high 
concentration of bacteriophage were able to diffuse out of 0.4% agarose (as also seen in Chapter 
4).  
Once the HAMA layer was added, bacteriophage release became significantly reduced compared 
to pure agarose. The HAMA was able to form a barrier to prevent or slow bacteriophage 
movement. When SM buffer (no HAase) was added, a low number of bacteriophage were 
released, whereas in comparison HAase addition caused a significantly higher release (106 
pfu/mL). A significant difference between SM buffer and HAase, especially after two hours 
incubation, implied that the HAMA had an active role in triggered release. The HAase was able to 
successfully degrade the HAMA layer quickly, even after two hours.  
On the other hand, after two hours, a high concentration of bacteriophage were found in 
samples incubated with SM buffer. The HAMA layer did not give selective release of 
bacteriophage, most probably due to the passive diffusion of bacteriophage from the agarose 
matrix. The high diffusion in 0.4% agarose meant that too many bacteriophage were able to 









































 HAMA + SM
 HAMA + HAase
Figure 6.7: Bacteriophage titer after hyaluronidase degradation of bilayer 0.4% agarose / HAMA hydrogel 




6.3.4.2. Triggered release of Bacteriophage K by bacterial supernatant 
Bilayered 0.4% agarose/HAMA hydrogels were then incubated with HAase positive S. aureus 
supernatant (C3) and HAase negative S. aureus supernatant (NE334 (hys-)), as well as TSB 
growth medium. Bacteriophage concentration measurements were then taken at 1, 2 and 4 
hours (Figure 6.10).  
 
Again, control wells containing bacteriophage agarose but no HAMA layer showed a high release 
of bacteriophage, with 106 pfu/mL after 1 hour and 107 pfu/mL after 2 hours. In hydrogels 
containing the HAMA layer, no bacteriophage were detected when incubated with TSB or S. 
aureus hys- supernatant (both contain no HAase). However, when incubated with S. aureus C3 
supernatant (HAase positive) bacteriophage were found, albeit in low concentrations.  
After 4 hours incubation, the unspecific release of bacteriophage seen with HAase was again 
seen with bacterial supernatant. Approximately 104 pfu/mL bacteriophage were detected in 
HAase negative wells, implying that passive diffusion was seen. Despite this, a significant 
difference in bacteriophage concentration was seen between S. aureus C3 and hys- supernatant, 
implying that the HAMA layer was forming a HAase sensitive barrier to release.   
 
Figure 6.8: Bacteriophage titer after S. aureus C3 and hys- supernatant degradation of bilayer 0.4% 
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6.3.5. 0.7% agarose bilayer hydrogel 
0.7% agarose based hydrogels were then investigated as the more concentrated hydrogel shows 
slower bacteriophage diffusion. In this way, passive release of bacteriophage would be 
prevented, allowing the degradation of HAMA to be the only way of causing bacteriophage 
release.  
6.3.5.1. Triggered release of Bacteriophage K by hyaluronidase 
Bilayered 0.7% agarose/HAMA hydrogels were incubated with 1 mg/mL hyaluronidase solution 
and bacteriophage concentration measurements taken at 2, 4 and 6 hours.  
In wells where only bacteriophage-containing agarose was present a high concentration of 
bacteriophage (107 pfu/mL) was still seen after two hours, which was constant throughout the 
experiment. Bacteriophage were able to diffuse out of 0.7% agarose (as again seen in Chapter 4) 












In hydrogels containing the HAMA layer, after two hours incubation triggered release was seen, 
with bacteriophage only detected in systems containing HAase. After 4 hours this was still 
generally the case; however a low concentration of bacteriophage was detected after SM 
incubation. After 6 hours, 103 pfu/mL bacteriophage was detected after SM incubation. In both 
cases, 106 pfu/mL bacteriophage were released after incubation with HAase, meaning a 
Figure 6.9: Bacteriophage titer after hyaluronidase degradation of bilayer 0.7% agarose / HAMA 
hydrogel. # = no bacteriophage detected 
# 











































 HAMA + TSB
 HAMA + C3
 HAMA + hys-
significant difference was seen between SM and HAase. In this respect triggered release was still 
apparent; however passive bacteriophage diffusion was still seen. 
6.3.5.2. Triggered release of Bacteriophage K by bacterial supernatant 
Bilayered 0.7% agarose/HAMA hydrogels were again incubated with HAase positive S. aureus 
supernatant (C3) and HAase negative S. aureus supernatant (NE334 (hys-)), as well as TSB 
growth medium. Bacteriophage concentration measurements were then taken at 1, 2 and 4 













In this system, control hydrogel wells with no HAMA layer showed a high bacteriophage release, 
however understandably slightly less than in 0.4% agarose. The rate of bacteriophage diffusion 
however appeared to be significantly slower, as after 1 hour no bacteriophage were detected in 
HAMA layer hydrogels, even in HAase positive strain supernatant. After 2 hours, triggered 
release was seen, with 104 pfu/mL bacteriophage released by S. aureus C3 (HAase positive) and 
none found in control or S. aureus hys- (HAase negative) wells.  
Although initially promising, after 4 hours unspecific release was seen with bacteriophage 
present after incubation with HAase negative S. aureus hys- supernatant. In this case however, 
no bacteriophage were found after addition of TSB. The difference in concentration between C3 
Figure 6.10: Bacteriophage titer after S. aureus C3 and hys- supernatant degradation of bilayer 0.7% 
agarose / HAMA hydrogel. # = bacteriophage not detected 
# # # # # # 





















































































AFigure 6.11: Bacteriophage titer after 4 hour incubation of bilayered 0.7% agarose / HAMA hydrogels with 
8 HAase positive and 8 HAase negative strains. # = no bacteriophage detected 
and hys- was significant, and far higher than in 0.4% agarose systems. The use of 0.7% agarose 
enabled a reduction in passive diffusion of bacteriophage whilst retaining HAase sensitivity.  
6.3.5.3. Triggered release of Bacteriophage K by multiple bacterial supernatants 
Due to the promise of the 0.7% agarose system, it was assessed with more S. aureus strain 
supernatants (8 HAase positive strains and 8 HAase negative strains). Strains were chosen from 
the strain screen carried out in Chapter 5 which exhibited very high or no HAase activity. HAase 
positive strains were S. aureus RN6390B, Not380, H050960412, D98, Cuba4005, CDC201078-
USA300, C3 and CAN6820-0616. HAase negative strains were S. aureus 963Small, D470, D473, 
HT2001-634, hys-, HT2002-0635, MRSA378 and C154.  
After 4 hours incubation with bacterial supernatant, bacteriophage concentration was measured 
for each strain (Figure 6.13). Here, all HAase positive strains were coloured in green, and all 












When incubated with HAase positive S. aureus strains, in all cases a high concentration of 
approximately 105 to 106 pfu/mL bacteriophage were released from bilayered 0.7% agarose 
# # # # # 




based hydrogels. In HAase negative strains, out of 8 strains tested, 5 strains showed no 
bacteriophage release after 4 hours and 3 strains released 102 pfu/mL. Although some strains 
did exhibit some phage release, in all cases HAase positive strains caused a significant release of 
bacteriophage compared to HAase negative strains. In this respect, triggered release was seen. 
6.3.6. 2% agarose bilayer hydrogel 
2% agarose based were finally assessed as the hydrogel exhibits very low bacteriophage 
diffusion. Even though this may result in fewer bacteriophage available to infect and lyse 
pathogenic bacteria, killing should still be possible for two main reasons. Firstly, killing of S. 
aureus is seen by Bacteriophage K in concentrations as low as 105 pfu/mL. Secondly, 
bacteriophage multiply in number as they infect, so a low initial concentration results in 
exponential-type growth, resulting in millions of further bacteriophage progeny.  
6.3.6.1. Triggered release of Bacteriophage K by hyaluronidase  
Bilayered 2% agarose/HAMA hydrogels were incubated with 1 mg/mL hyaluronidase solution 
and bacteriophage concentration measurements taken at 2, 4 and 6 hours (Figure 6.14). 
Firstly, in this experiment 2% agarose hydrogels which contained no HAMA layer exhibited a high 








































 HAMA + SM
 HAMA + HAase
Figure 6.12: Bacteriophage titer after hyaluronidase degradation of bilayer 2% agarose / HAMA hydrogel. # 
= no bacteriophage detected 
# # # 




hydrogels (106 pfu/mL) due to the dense nature of such concentrated agarose. The 
bacteriophage concentration would still be sufficient to cause high levels of S.aureus killing.  
Triggered release of Bacteriophage K by HAase was seen in all timepoints. In Bilayer hydrogels 
incubated with SM buffer, no bacteriophage were released as the lower agarose layer was now 
dense enough to retain bacteriophage and prevent passive leakage. When incubated with pure 
HAase, a high concentration of bacteriophage were detected with concentrations of 5 x 105 
pfu/mL after 6 hours. This significant difference in release was initially purely because of HAMA 
layer degradation by the HAase enzyme.  
6.3.6.2. Triggered release of Bacteriophage K by bacterial supernatant  
Bilayered 2% agarose/HAMA hydrogels were incubated with HAase positive S. aureus 
supernatant (C3) and HAase negative S. aureus supernatant (NE334 (hys-)), as well as TSB 
growth medium. Bacteriophage concentration measurements were then taken at 1, 2 and 4 
hours (Figure 6.15).  
  
Generally, bacteriophage release was significantly lower in this experiment compared to tests 
with pure HAase and tests with less concentrated agarose. In 2% agarose hydrogels containing 
no HAMA layer, only 105 pfu/mL bacteriophage were detected after 4 hours. This may be due to 
Figure 6.13: Bacteriophage titer after S. aureus C3 and hys- supernatant degradation of bilayer 2% 
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Figure 6.14: Bacteriophage titer after 4 hour incubation of bilayered 2% agarose / HAMA hydrogels with 8 
HAase positive and 8 HAase negative strains. # = no bacteriophage detected 
a combination of the high agarose concentration and the bacterial growth medium (TSB) 
composition slowing bacteriophage diffusion.  
Despite this, triggered release of Bacteriophage K by HAase positive S. aureus supernatant was 
seen at all time points. On incubation of bilayered hydrogels with TSB growth medium or S. 
aureus hys- supernatant, no bacteriophage release was seen. However when incubated with C3 
supernatant, a high bacteriophage concentration was eventually seen. Bacteriophage release 
was initially slow, but increased with time as HAase enzymes degraded the HAMA layer.  
6.3.6.3. Triggered release of Bacteriophage K by multiple bacterial supernatants 
The S. aureus strains assessed in Section 6.3.5.3. were then incubated again with the 2% agarose 
based bilayer hydrogel. The 8 HAase positive and 8 HAase negative strain supernatants were 
added to the bilayered hydrogels and incubated for 4 hours, and the concentration of 
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Figure 6.15: 2% agarose/ HAMA bilayer hydrogels containing Bacteriophage K incubated with (left) S. 
aureus H560 and (right) S. aureus hys- live culture 
On incubation with HAase positive strains, a release of bacteriophage was seen in all cases. This 
concentration, although low (104 – 105 pfu/mL) compared to 0.7% based systems, would still be 
enough to elicit a therapeutic effect. With added time this would also increase. In HAase 
negative strains, no bacteriophage were detected after incubation in all cases. From this, it can 
be said that triggered release was seen only by S. aureus strains which were known to secrete 
HAase.  
 6.3.6.4. Incubation with live S. aureus culture 
After the success of triggered release seen in incubation of 2% agarose bilayer hydrogels with 
hyaluronidase and bacterial supernatant, the hydrogels were then assessed using live bacterial 
liquid culture. Bilayer hydrogels were formed in 24-well plates with and without Bacteriophage 
K. They were then inoculated with S. aureus H560 (HAase positive) and hys- (HAase negative) 
live subculture and incubated at 37 °C for 18 hours. The OD600 was measured to assess bacterial 
growth and the graphs plotted can be seen in Figure 6.16.   
Here, as bacteria grow, levels of HAase will increase as HAase is secreted into the surrounding 
environment (as examined in Chapter 5). The HAase will then degrade the HAMA layer causing 
release of Bacteriophage K and killing of S. aureus H560. In the case of hys-, no HAase is 










In S. aureus H560, systems were found to respond as expected. In hydrogels with no 
bacteriophage present (with and without HAMA) normal bacterial growth was seen. A slightly 
higher growth was seen with bilayer systems, as the additional HAMA provides a superb energy 
source for the growing bacteria. In both hydrogels that contained bacteriophage, killing was 
seen. The bacteriophage were able to diffuse out of the 2% agarose in a high enough 
concentration to cause killing. In the bilayered system, the HAMA layer was degraded by HAase 
produced by H560, and so bacteriophage were released.  
In S. aureus hys- however, the same result was seen. Normal growth was seen in hydrogels 
containing no bacteriophage, and in both hydrogels (with and without HAMA) which contained 
bacteriophage bacteria were killed. This indicated that the HAMA layer was not able to cause 
triggered release of bacteriophage, as if this was the case normal bacterial growth would be 
seen in bilayered hydrogels.  
It is most probable that passive diffusion of bacteriophage was apparent in the system; this 
could be due to a number of reasons. The seal between the well and the hydrogel, or the HAMA 
and agarose layer could not be intact or sealed enough to prevent bacteriophage diffusion over 
18 hours. In Section 6.3.6.1., no bacteriophage were detected after 6 hours of incubation in SM 
buffer (no HAase), however after this time bacteriophage in low numbers could eventually 
diffuse out. Also, the shaking of the plate reader used for live experiments was far more 
aggressive than the shaking used for HAase and supernatant experiments; this could dislodge 
the HAMA layer causing un-triggered bacteriophage release.  
6.4. Conclusions 
In conclusion, this chapter combined work carried out in Chapters 4 and 5 to create a bilayered 
hydrogel comprising of a lower bacteriophage-containing layer and an upper layer formed of 
crosslinked HAMA. PVA was not investigated, as when exposed to UV the polymer is known to 
form highly damaging free radicals which can harm bacteriophage. Instead, agarose was used as 
a biocompatible, non-toxic hydrogel. HAMA was crosslinked in situ on top of the set agarose 
layer for a shorter time than in previous experiments in order to minimise bacteriophage 
damage.  
The aim of this chapter was to form a hydrogel system which selectively gave triggered release 
of bacteriophage only in the presence of HAase. In this way, bacteriophage are only released in 
the presence of bacterial infection, therefore reducing the unnecessary release of bacteriophage 
and the possibility of resistance evolving.   




The bilayered hydrogel system was assessed with varying concentrations of agarose in order to 
tune the triggered release. The system was then assessed with pure HAase, bacterial 
supernatant and live cultures. The 2% agarose system was found to be most sensitive, with 
bacteriophage only released when HAase was present (either from pure commercially available 
HAase or bacterial supernatant).  
The system was then taken on for further assessment with HAase positive and negative S. aureus 
live culture to see if HAase secreted during the normal growth cycle was capable of initiating 
triggered release of bacteriophage (and so triggered killing of the HAase positive strain).When 
incubated with live culture, bacterial killing was seen in all cases where bacteriophage were 
present compared to normal growth curves. In this case it was most probable that 
bacteriophage were able to diffuse out of the hydrogel due to a poor seal with the culture well. 
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Chapter 7 : Nano-imprint lithography of photocrosslinkable 
hyaluronic acid/gelatin hydrogels for cell proliferation 
 
7.1. Introduction 
In a similar fashion to prokaryotes, eukaryotic cells are inherently driven to bind to surfaces 
during growth. Because of this, it is important to assess the growth and interactions of 
eukaryotic cells on a device if it is to be used as a therapeutic. Hydrogels have been widely used 
in cell culture for a number of years, either as scaffolds to immobilise cells, or as platforms to 
grow cell sheets on top of. The hydrogel chemical structure greatly determines the extent of cell 
binding and can be incorporated with polymers, proteins (e.g. growth factors) or other additives 
which promote cell growth. Also, the polymer structure can be altered to make the hydrogel 
more or less hydrophilic, and so changing how cells adhere to the surface.  
In this chapter, firstly the growth of NIH-3T3 mouse fibroblast cells on hydrogels derived from 
HA and gelatin was investigated. Fibroblasts are cells which secrete the extracellular matrix and 
collagen found in the skin and connective tissues; because of this they are critical for wound 
healing. A number of studies have reported the beneficial effect HA has on fibroblast growth1, 2. 
The cells are also known to have a number of cell-binding receptors for HA (CD44, RHAMM) 
which have been discussed previously in Chapter 1. Because of its close structural similarity to 
collagen, gelatin interacts with cells through the same receptors; the most prevalent of which 
are integrins and the RGD (Arg-Gly-Asp) amino acid sequence3, 4.  
In this investigation, nano-imprint lithography was also used to form printed hydrogels for use in 
cell culture. It was proposed that lithography of hydrogels could impart a surface roughness that 
could aid cell adherence, or direct cell growth (depending on print size and shape). The effect of 
surface roughness has been investigated at the nano and micro scale in hydrogels, as well as on 
implant surfaces, with positive results5-7. Cells have been successfully grown in a directed way 
with a high control over cell growth using lithography of a range of biocompatible hydrogels8-11. 
Here, hydrogels were printed with a pre-patterned stamp, with cells either incorporated into the 
hydrogel structure or subsequently being grown on top.  
A schematic representation of this process can be seen in Figure 7.1. Polypropylene moulds can 
be formed with surface patterns in a variety of shapes and sizes. These then can be placed on 
top of a pre-polymer solution that when exposed to UV light, can be crosslinked to form a solid 




hydrogel (a) which contains a print. On removal of the mould, an inverted print is seen in the 
hydrogel surface (b). 
 
Due to the previous work carried out on UV crosslinkable HA, it was decided that this mix would 
be the foundation for lithographic printing and fibroblast cell tests.  
7.2. Materials and Methods 
7.2.1. Cast moulding of lithographic prints through Hot Embossing 
A UV-reactive photoresist AZ125 was firstly spin-coated onto a clean silicon wafer. The coated 
wafers were then baked on a hot plate at 65 °C for 3 minutes followed by a second bake at 95 °C 
to remove organic solvents. A mask was placed on top of the wafer with the required design and 
the photoresist exposed to UV light. Post-exposure baking was performed for 1 minute at 65 °C, 
followed by a second bake for 3 minutes at 95 °C. Un-crosslinked photoresist was then washed 
away using developer and dried under nitrogen.  
PDMS (Polydimethylsiloxane) moulds used for hot embossing were formed using the PDMS mix 
Sylgard® 184 in the ratio 1:9 curing agent:PDMS. PDMS mix was degassed under vacuum for 30 
minutes and 1 mL poured over the spin-coated silicon pre-mould. Moulds were then incubated 
at 60 °C for 2 hours to cure. Hot Embossing was used to form durable prints for hydrogel nano-
imprinting. Polystyrene sheets were cleaned to remove contaminating dust and placed over the 
PDMS mould. They were then heated in an Obducat Eitre 3 Hot Embosser to 140 °C at 5 bar for 
120 seconds, and then allowed to air cool for 100 seconds.        
7.2.2. Crosslinking of hydrogels 
Casting of hydrogels was carried out in a similar way to that described in Chapter 5. 1 mL 
hydrogel mixture containing photoinitiator was added per well in a 12 well cell culture plate. In 
Figure 7.1: Diagram of nano-imprint lithography using PDMS moulds to emboss photo-crosslinkable 
polymers. Diagram by Ping Li 
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non-printed hydrogels, gels were left and allowed to form a flat surface; in printed hydrogels, 
the cooled polystyrene print was placed on top of the hydrogel (with the printed side exposed to 
the hydrogel). Plates were then crosslinked using a UVP CL-1000 UV Crosslinker. 
7.2.3. Characterisation of polystyrene prints and imprinted hydrogels 
Light microscopy of polystyrene prints, printed hydrogels and all cell imaging was carried out on 
a Zeiss AxioCam ERc5s light microscope. Printed polystyrene patterns were gold sputter coated 
and Scanning Electron Microscopy (SEM) images were taken using a Carl Zeiss AG Zeiss Ultra 55 
FESEM.  
7.2.4. Cell culture on HAMA hydrogels 
In brief, passaged NIH-3T3 fibroblasts were adjusted to 104 cells/mL with culture medium, and 
1.5 mL added to precast hydrogels in a 12-well plate. Plates were then incubated for up to 48 
hours at 37 °C at 5% CO2.  
7.2.5. Preparation of GelMA 
Gelatin methacrylate (GelMA) was synthesised as described by Chen et al12. In brief, 2 g type A 
porcine gelatin was dissolved in 20 mL PBS at 60 °C to make a 10% w/v solution. Once gelatin 
was fully dissolved, 1.6 mL methacrylic anhydride was added at a rate of 0.1 mL/min with 
stirring. The mixture was then allowed to react at 50 °C for 3 hours and the reaction stopped by 
the addition of 60 mL PBS. The GelMA mixture was dialysed against deionised water to remove 
unreacted methacrylate and by-products using 50 kDa MWCO dialysis membrane for 7 days at 
40 °C. The purified GelMA was then frozen at -80 °C, lyophilised and stored at 4 °C until needed. 
Methacrylation was confirmed by 1H NMR using a Bruker 400 MHz NMR.  
7.2.6. Cytotoxicity of Irgacure 2959 
Cytotoxicity of Irgacure 2959 to NIH-3T3 fibroblasts was investigated using the method 
described by Williams et al13. Passaged NIH-3T3 fibroblasts were adjusted to 64,000 cells/mL 
with growth medium and seeded at 500 µL/well in a 24 well plate. Photoinitiator stock solutions 
were formed by dissolving 0, 0.03, 0.05 and 0.1 g Irgacure 2959 in 1 mL 70% ethanol. The 
solutions were then removed from light and kept at room temperature until needed. 
Immediately after seeding, 5 µL Irgacure 2959 solution was added to each well which exposed 
cells to a final initiator concentration of 0, 0.03, 0.05 and 0.1 % w/v. Plates were then incubated 
for 24 hours at 37 °C and 5 % CO2. Control wells contained cells incubated with 5 µL 70% ethanol 
solution only.  




7.2.7. MTT assay 
In vitro cytotoxicity was assessed through the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl 
tetrazolium bromide) assay. This involves the conversion of the water soluble MTT to insoluble 
formazan (Figure 7.2). After incubation with test chemical for the appointed time, medium was 
removed and replaced with 600 µL fresh DMEM medium. Standard curve wells were also 
included containing 500 – 128,000 cells/mL. 60 µL MTT solution (5 mg/mL in PBS) was then 
added per well and the plate incubated for 4 hours at 37 °C.  
 
After 4 hours, 600 µL SDS solution (100 mg/mL in 0.01 HCl) was then added per well, the 
solutions mixed, and the plate incubated overnight at 37 °C. Solutions were mixed again 
thoroughly and the absorbance measured at 570 nm. 
7.2.8. Hyaluronidase degradation of HA and Gelatin based co-gels 
Hydrogels containing varying concentrations of HA, HAMA and GelMA were photocrosslinked as 
described previously. Hydrogels were then swollen overnight at room temperature in PBS to 
achieve complete swelling. Samples were weighed (100% hydrogel weight) and incubated with 1 
mL 0.1 mg/mL hyaluronidase in PBS at 37 °C with mild shaking. After 2, 4, 6, 8 and 24 hours, all 
hyaluronidase solution was removed, remaining gels were blotted and the samples weighed. All 
hydrogel measurements were carried out in triplicate. The change in weight of hydrogels over 
time was then plotted as a % of the original weight.   
 
 
Figure 7.2: Structure of the tetrazolium dye MTT and its subsequent reduction by mitochondrial 
reductase to the insoluble purple product Formazan 
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7.3. Results and Discussion  
7.3.1. Imprinting of hydrogels 
7.3.1.1. Cast moulding of lithographic prints through Hot Embossing  
Hot embossing was found to be a robust technique which gave good quality, reproducible prints 
with varying sizes and shapes. Silicon wafers (Figure 7.3 a) and b)) could be spin-coated with a 
variety of patterns and used repeated times to form PDMS pre-moulds. These PDMS moulds 
(Figure 7.3 c) could either be used directly to print hydrogels, or further used to print 
polystyrene prints, depending on the print properties required. Polystyrene was chosen for all 
printing as these formed hard prints that retained their pattern and which could be washed after 




















Figure 7.3: a) Silicon wafer line patterned with photoresist b) Large silicon wafer with multiple photoresist 
patterns c) PDMS mould of patterned silicon wafer leads to a negative patterning d) Polystyrene master 
formed through hot embossing with PDMS mould 
a) b) 
d) c) 




SEM images (Figure 7.4) of polystyrene line prints with varying line width were taken to assess 
surface morphology. These sizes were thin line prints (10 and 15 µm line width) and large line 
prints (80 µm line width). In all sizes, a consistent straight line was seen with equal line spacing 









7.3.1.2. Printing of HAMA hydrogels 
2% HAMA hydrogels containing a range of PEGDA concentrations were UV-irradiated with 10, 
15, 50 and 80 µm line prints (20 µm deep). It was previously understood that with an increasing 
concentration of PEGDA, an increase in non-specific free radical polymerisation to the 
polystyrene mould occurs, making the mould hard to remove from the crosslinked hydrogel. 
Hydrogels containing 0% PEGDA were found to be too elastic to retain print on irradiation. Both 
5% and 10% PEGDA hydrogels were too brittle to be removed from the polystyrene mould. It 
was also found that prints with smaller line spacing (10 and 15 µm) were harder to remove from 
Figure 7.4: Scanning Electron Microscopy (SEM) images of 10, 15 and 80 µm polystyrene prints formed by 
Hot Embossing. Scale bar = 50 µm. Images courtesy of Ping Li 
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irradiated hydrogel than larger prints. It was decided that 1% PEGDA gave the optimum hydrogel 
















2% HAMA hydrogels containing 1% PEGDA co-crosslinker were printed with line prints of varying 
width: 10, 15, 50 and 80 µm (Figure 7.5). In all cases defined, regular prints were seen by light 
microscopy which retained structure over time. On swelling however, printed patterns became 
distorted (Figure 7.6). In 10 and 15 µm prints, no pattern was seen after 24 hours swelling in PBS 
buffer. In 50 and 80 µm prints, a patterned structure was still seen, although in a far less defined 







Figure 7.5: Light microscopy images of a) 10 µm, b) 15 µm, c) 50 µm and d) 80 µm line width prints formed 
on 2% HAMA/1%PEGDA/1%I2959 hydrogels. Scale bar = 100 µm 















7.3.2. NIH-3T3 culture on HAMA hydrogels 
7.3.2.1. Culture of NIH-3T3 fibroblasts 
NIH-3T3 fibroblasts, originally isolated from mouse embryo tissue, are the standard cell line used 
in fibroblast cell culture experiments. Initial binding to flask bottoms is seen after approximately 
two hours; with cells appearing flattened and elongated (Figure 7.7). The doubling time for NIH-
3T3 fibroblasts is approximately 20 hours, and as seen in Figure 7.7 b, once attached to the 
surface cells extend filopodia to their surroundings and to other cells. Nuclei also become bigger 
and more visible, with contracted genetic material visible as dark spots under the light 






Figure 7.6: Light microscopy images of a) 50 µm and b) 80 µm line width prints formed on 2% HAMA/ 
1%PEGDA/ 1%I2959 hydrogels after 24 hours swelling in PBS buffer. Scale bar = 100 µm 











7.3.2.2. Cell culture on flat HAMA hydrogels 
In recent years, a wide range of polymers, including HA and PEG, have been reportedly used in 
hydrogel systems for cell culture and tissue engineering. The long polymer chains provide an 
advantageous environment to promote cell attachment. In this respect, NIH-3T3 fibroblasts 
were firstly incubated on HAMA hydrogels co-crosslinked with PEGDA (the same HAMA mix 
investigated in detail in Chapter 5).  It was hypothesised that by increasing the PEGDA 
concentration in HAMA gels, cell binding would increase. As described previously, ease of 
hydrogel printing changed depending on concentration of PEGDA; flat HAMA hydrogels 
containing varying concentrations of PEGDA were firstly incubated with NIH-3T3 fibroblasts.  
 
 
Figure 7.7: Light microscopy images of NIH-3T3 fibroblasts cultured on polystyrene cell culture flasks in 
DMEM medium after a) 2 hours, b) 24 hours and c) 48 hours growth. Scale bar = 100 µm 






2% HAMA hydrogels containing 0, 1, 5 and 10% PEGDA with no print were incubated with NIH-
3T3 fibroblasts for 48 hours (Figure 7.8). In all cases, no cell attachment was seen to hydrogels, 
with cells instead forming spherical aggregates that permeated through the gel. More 
aggregates were seen on incubation with 1% and 5% PEGDA, although in all cases no cell binding 
was seen to gels. This was most probably due to the chemical properties of HA. HA is inherently 
non-cell binding due their negative charge14. Also, because of the high water content of the gel it 
is possibly hard for cells to gain a strong binding between polysaccharide fibres as they are so far 
apart.  
7.3.2.3. Cell culture on printed HAMA hydrogels 
To increase cell binding, hydrogels were printed to impart a surface ‘roughness’. Cells were 
investigated with 10, 15, 50 and 80 µm prints (Figure 7.9). NIH-3T3 fibroblasts were still found 
not to attach to hydrogel membranes after 48 hours, regardless of surface roughness. On 
attachment, NIH-3T3 fibroblasts normally exhibit a flattened shape as the cells bind to the 
Figure 7.8: Light microscopy images of NIH-3T3 fibroblasts grown on unprinted 2% HAMA /1%I2959 
hydrogels. Hydrogels contained a) 0% PEGDA, b) 1% PEGDA, c) 5% PEGDA and d) 10% PEGDA. Scale bar = 
100 µm 





Figure 7.9: Light microscopy images of NIH-3T3 fibroblasts grown on printed 2% HAMA/1% I2959/1% 
PEGDA hydrogels for 48h. Hydrogels were printed with a) 10 µm, b) 15 µm, c) 50 µm and d) 80 µm. Scale 
bar = 100 µm 
surface. As cells grow on an adherent surface, cells become increasingly branched and 
proliferate to a confluent sheet.  
 
In this case, no branching was seen, with cells clustering into multicellular aggregates both on 
the surface and inside the hydrogel. This is characteristic of the surface being non-adherent and 
not conducive to cell binding. Hydrogels printed with 10, 15 and 50 µm lines did not induce 
directed growth. With 80 µm prints, although aggregated, cells did show directed growth with 
cells predominantly in the wells of the pattern. In Figure 7.9, direction of line print is shown by 
an arrow. In all cases, on washing with PBS buffer, no cells remained confirming non-adhesion. 
7.3.2.4. Printing of HA hydrogels with varying concentration of HA 
HA hydrogels were cast containing varying concentrations of HAMA to increase the crosslinking 
density and to decrease the length between polysaccharide fibres. By doing this it was proposed 























Figure 7.10: Swelling ratio values for varying 1% PEGDA/1% I2959 HAMA hydrogels containing 1 
– 6% HAMA 
that not only would a more sturdy print be formed (by making hydrogels with a decreased 
swelling ratio), but also that cells would have more polysaccharide fibres to bind to.  
Hydrogels were investigated with concentrations of 1, 2, 3, 4, and 6% w/v HAMA and a line print 
of 80 µm; with any higher concentrations of HAMA the pre-crosslinked solution was found to be 
too viscous to reliably quantify. As expected, by increasing the concentration of HAMA in 
hydrogels, the swelling ratio decreased from 46.6 ± 2.7 for 1% HAMA gels to 20.0 ± 0.2 for 6% 












Hydrogels were then printed, and NIH-3T3 fibroblasts incubated on these hydrogels to assess 
cell attachment (Figure 7.11). Firstly, as HAMA concentration increased, a more defined print 
was seen that was retained after swelling in cell solution for 48 hours. In hydrogels of lower 
concentration, prints were ill-defined after swelling and did not induce directed cell growth. 
However, 3, 4 and 6% HAMA printed hydrogels all showed defined prints and on incubation with 
cells, cells were predominantly found in the wells of the pattern. Even so, cells were still 
clustered and spherical in shape with no binding to hydrogel surfaces. 
 
 





7.3.2.5. Cytotoxicity of Irgacure 2959  
The cytotoxicity of Irgacure 2959 to NIH-3T3 fibroblast was measured to assess if cell damage 
was seen at high photoinitiator concentrations. On UV exposure, the free radicals created from 
photoinitiators are able to react with and damage eukaryotic cells. Radical species can react with 
a range of cellular components (e.g. cell membranes, DNA and proteins) causing damage. As 
previously described in Chapter 5, the photoinitiator Irgacure 2959 was chosen over other 
photoinitiators because of its low cytotoxicity. It has also been used successfully in a range of 
crosslinked polysaccharide hydrogels15, 16.  
 
Figure 7.11: NIH-3T3 fibroblast growth on 80 µm hydrogel prints formed from varying HAMA 
concentrations – a) 2%, b) 3%, c) 4% d) 6% w/v HAMA/1% PEGDA/1% I2959. Scale bar = 100 µm 
d) c) 
b) a) 




The cytotoxicity of various photoinitiators (but not Irgacure 2959) to NIH-3T3 fibroblasts was 
assessed in 2000 by Bryant et al, showing that at high concentrations cell death can occur17. In 
2005, Williams et al similarly reported on the cytotoxicity of Irgacure 2959 to six separate cell 
lines; however NIH-3T3 fibroblasts were not investigated13. Although in this investigation cells 
were not encapsulated in the hydrogel matrix, and so were not directly exposed to UV or free 
radicals created from Irgacure 2959, it was important to determine if cytotoxicity was seen at 
concentrations required to crosslink hydrogels.  
NIH-3T3 fibroblasts were incubated for 24 hours in DMEM growth media containing 0, 0.03, 0.05 
and 0.1% Irgacure 2959. In this case, higher concentrations of photoinitiator were not 
investigated because of solubility issues. The cellular metabolic activity was then measured using 
the MTT assay, alongside a calibration curve that allowed the number of live cells to be 
calculated (Figure 7.12).   
In general, the % live NIH-3T3 fibroblast cells found to be actively metabolising after 24 hours 
incubation with Irgacure 2959 was found to decrease significantly with increasing photoinitiator 
concentration. Incubation with no photoinitiator was set at 100% live cells, which equated to 
approximately 75,000 cells/mL after 24 hours. Even low concentrations were able to lower live 
a) b) 
c) d) 















Figure 7.12: % live NIH-3T3 fibroblast cells after 24 hours incubation with 0, 0.03, 0.05 and 0.1% Irgacure 
2959 
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Figure 7.13: NIH-3T3 cell growth in (left) 0% gelatin and (right) 5% gelatin hydrogels after 48 hours. Scale 
bar = 100 µm 
cell number, with approximately 90% after incubation with 0.03%, 75% after incubation with 
0.05% and 60% after incubation with 0.1% Irgacure 2959 respectively.   
In the 12 well plates used for cell culture, 1 mL hydrogel solution is present per well containing 
1% w/v Irgacure 2959. This is far higher than the concentrations investigated in the MTT assay, 
however after the UV irradiation of the hydrogel the photoinitiator is degraded and so would be 
present in far lower amounts when cell solution is added.  
7.3.3. NIH-3T3 culture on HAMA/gelatin hydrogels 
In order to improve the cell adhesive properties of the hydrogel, gelatin was then added as it 
contains the cell attachment motif RGD. Firstly, NIH-3T3 fibroblasts were incubated on hydrogels 
containing gelatin, gelatin + 1% I2959 and gelatin + 3% HAMA + 1% I2959 and imaged after 48 
hours. Cell adhesion to hydrogels was investigated on both flat and 80 µm printed gels.  
Firstly, as expected, on incubation at 37 °C gelatin hydrogels were not stable, with the hydrogel 
able to melt and mix into the cell culture medium (even after UV irradiation). This caused a 
positive effect on cell growth; more cells attached to the well bottom and cells were seen to link 
and extend more towards each other. However, eventually cells became overgrown compared 
to control wells. Example light microscopy images can be seen of cells incubated with and 
without 5% gelatin for 48 hours in Figure 7.13. 
Cells were also incubated with hydrogels containing gelatin and the photoinitiator Irgacure 2959 
(Figure 7.14). The incorporation of photoinitiator greatly affected the morphology and cell 
binding of NIH-3T3 cells.  




Figure 7.14: NIH-3T3 cell growth in 5% gelatin + 1% Irgacure 2959 after 48 hours. Scale bar = 100 µm 
Figure 7.15: NIH-3T3 cell growth in 80 µm printed 3% HAMA/ 10% gelatin hydrogels after 48 hours. Scale 
bar = 100 µm 
Again, hydrogels did not retain shape and instead melted into the cell culture medium. In this 
case however, cells were now spherical and clumped together. Greater cell clumping was again 
seen with increasing gelatin concentration, however cells did not adhere to the surface and no 







When 3% HAMA was added to gelatin solutions hydrogels retained shape on UV irradiation and 
did not dissolve into the surrounding environment. Because of this, the 80 µm print was also 
retained. In general, greater numbers of cells were seen on hydrogels containing more gelatin. 
Cells remained in an aggregated, spherical shape with no filopodia extending. In printed gels 
cells aligned in the bottom wells of the striped print, with the most defined lines of cells being 






Overall, the incorporation of gelatin into the HAMA matrix did encourage cell growth; however 
cells did not bind and instead were spherical and aggregated. It was thought that the high 
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concentration of photoinitiator that could remain in the gels after crosslinking could contribute 
to the lack of cell binding.  
7.3.3.1. Cell culture on HAMA-gelatin co-gels with 0.1% Irgacure 2959 
The concentration of Irgacure 2959 was reduced from 1% to 0.1% w/v in order to promote cell 
adhesion onto the hydrogels. 3% HAMA was mixed with varying concentrations of gelatin and 
crosslinked with UV irradiation. Although gelatin was known to melt above room temperature, 
by co-crosslinking with HAMA, the HAMA crosslinks would entrap gelatin fibres within the 
matrix. 80 µm prints were also investigated to assess if directed growth was seen.  
In general, as gelatin concentration increased a higher number of cells were seen on the 
hydrogel surface, with cells again aligning within the wells of the print (Figure 7.16).  Hydrogels 
containing no gelatin showed very few cells on the surface; due to no gelatin being present, the 
hydrogel structure was soft and print was not retained well, meaning that cells diffused into the 
matrix.  
In all hydrogels which contained gelatin, the improved structure meant the print was retained, 
allowing cells to align in the wells. In 10% gelatin gels the alignment is most defined as cells were 
able to replicate more. Although directed growth was seen, in all cases cells remained spherical 
and non-adhered. 
 





7.3.3.2. Cell culture on HAMA-gelatin co-gels with prewashing 
In order to remove any Irgacure 2959 from the hydrogels after crosslinking but before the 
addition of cells, hydrogels were incubated in cell culture medium for 2 x 1 hour. The majority of 
unreacted photoinitiator would pass into the medium through diffusion and be removed from 
the hydrogel before cell addition. By lowering the photoinitiator concentration in cell culture 




Figure 7.16: NIH-3T3 cell growth in 80 µm printed 3% HAMA hydrogels containing a) 0%, b) 3%, c) 5% and d) 
10% gelatin and 0.1% Irgacure 2959 after 48 hours. Scale bar = 100 µm 
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In this case, a positive effect on cell growth was seen with the removal of excess Irgacure 2959 
(Figure 7.17). Instead of cells appearing to be spherical and aggregated in nature, cells had 
proliferated into multicellular growing clusters; this effect was similar to that seen by Park et al 
in 2003 where they incubated fibroblast cells on HAMA combined with RGD peptide18. With 
increasing gelatin concentration, cells were able to bind to the matrix and exhibit directed 
growth on printed hydrogels without clustering.  
 
7.3.4. NIH-3T3 culture on gelatin methacrylate (GelMA) hydrogels 
The use of gelatin as a photocrosslinkable hydrogel was then assessed for growth with NIH-3T3 
fibroblasts. As described earlier, gelatin is useful as the protein structure contains cell-binding 
RGD sequences which could promote cell adhesion. Because non-modified gelatin hydrogels are 
able to melt at 37 °C, the gelatin was modified in a similar way to HA, with methacrylation and 
subsequent photo-crosslinking. From earlier experiments methacrylated HA gave a high degree 
of control over crosslinking as this only occurred in the presence of UV. Therefore gelatin was 
methacrylated to form gelatin methacrylate (GelMA) and crosslinked into temperature stable 
hydrogels with Irgacure 2959 and UV irradiation. 
7.3.4.1. Preparation of GelMA  
The reaction scheme for gelatin methacrylation and 1H NMR spectrum can be seen in Figure 7.18 
and Figure 7.19. Free amine groups in the protein structure (notably lysine and arginine) were 
reacted with methacrylic anhydride to form methacrylated gelatin and methacrylic acid by-
Figure 7.17: NIH-3T3 cell growth in non-printed (left) and 80 µm printed (right) 3% HAMA/ 10% gelatin 
hydrogels after 48 hours with prewashing. Scale bar = 100 µm 




products. The lowering of pH by the production of the acid by-products was buffered by the use 
of PBS as a reaction buffer.    
The degree of gelatin methacrylation was determined by 1H NMR (Figure 7.19). NMR analysis on 
GelMA was carried out using the method described by Brinkman et al19. Peaks corresponding to 
methylene protons were seen at 5.2 and 5.4 ppm; the degree of functionalisation was calculated 
using the ratio of these peaks to aromatic protons found at 7.2 ppm as approximately 73%.   
 
Figure 7.18: Reaction scheme for gelatin methacrylation with methacrylic anhydride 
Figure 7.19: 1H NMR spectrum of gelatin methacrylate in D2O 
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7.3.4.2. Swelling of GelMA hydrogels  
Hydrogels containing varying concentrations of GelMA were formed (containing additional HA 
and HAMA) by exposure to UV light. Gels containing purely gelatin or HA were not investigated, 
as they could not be photo-crosslinked. In the case of gelatin the gels also melted at increased 
temperatures. Swelling ratios were calculated using previously described methods (Figure 7.20). 
In general, in HA/GelMA gels a swelling ratio of approximately 20 was seen, with swelling 
decreasing with an increase in HA concentration. This trend however became less distinct with 
increasing GelMA concentration. Indeed by 10% w/v GelMA the trend switched, with a higher 
swelling seen in 3% HA. It was hypothesised that this was because at such high polymer 
concentrations complete dissolution and mixing of polymers became difficult; the polymers 
formed domains that made swelling measurements inaccurate. 
 
Compared to HA hydrogels, a lower viscosity was seen with HAMA/GelMA mixes; the addition of 
methacrylate groups to the HA reduced intermolecular attractive interactions, lowering 
viscosity. In general, swelling ratios decreased with the addition of more HAMA, as more 
crosslinks were able to be formed. Addition of GelMA did lower swelling ratios further, however 
significant differences were not seen with increasing GelMA concentrations. 
 




















































Figure 7.20: Swelling ratio values for hydrogels containing 1 – 3% HA (a) or HAMA (b) and 0 – 10% GelMA. 
methylene 




7.3.4.3. Cell culture on GelMA 
NIH-3T3 fibroblasts were incubated on 5% GelMA hydrogels crosslinked with 0.1% and 1% 
photoinitiator (Figure 7.21). In the presence of low concentrations of Irgacure 2959, a good 
degree of cell attachment and growth is seen. The cells adopted a highly branched shape with 
many filopodia and connections between cells; in fact the cells appear ‘over-stretched’ 
compared to cells incubated with no hydrogel. In 1% Irgacure GelMA hydrogels, the cells appear 
to have attached to the hydrogel surface, however growth and extension of cells is significantly 
reduced. Some cells were in the process of stretching and extending, suggesting that the growth 







7.3.4.4. Cell culture on HAMA-GelMA co-gels 
GelMA was added to 3% HAMA hydrogel mixes to form strong hydrogels with a higher 
crosslinking density and so lower swelling ratio. A higher crosslinking density was again 
hypothesised to give more points available for cell binding.  
Firstly, the addition of GelMA did show higher crosslinking, with hydrogels binding very strongly 
to the prints used for patterning. Indeed, in most cases prints could not be removed successfully 
from hydrogels without considerable damage to the hydrogel print. Due to this, two parameters 
were altered to reduce the ‘over-crosslinking’ seen. Firstly, the overall concentration of 
photoinitiator was decreased from 1% w/v to 0.1% w/v. Not only would this reduce the number 
of crosslinks made, but also lower the cytotoxicity of the hydrogel. Secondly, the hydrogel was 
UV irradiated for a shorter time from 5 minutes to 3 minutes. After 3 minutes, the complete 
Figure 7.21: NIH-3T3 fibroblast growth on 5% GelMA hydrogels containing 0.1% (left) and 1% (right) I2959. 
Scale bar = 100 µm. Images courtesy of Ping Li 
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hydrogel was still formed. Hydrogels were also investigated with and without prewashing in cell 
culture medium as previously described. 
In general, the decrease in Irgacure 2959 concentration did not cause a significant change in cell 
appearance, with cells remaining spherical and non-adhered. The more defined hydrogel formed 
did allow more cells to assemble in the wells of the line prints used instead of in the matrix; here 
3% HAMA/10% GelMA showed high directionality compared to gels containing no gelatin  
(Figure 7.22). 
 
Prewashing of hydrogels before incubation with NIH-3T3 cells did show a slight improvement in 
cell morphology. Cells were still spherical in shape; however cells were now clumped together 







Figure 7.22: NIH-3T3 cell growth on 3% HAMA 80 µm printed hydrogels after 48 hours with (left) 0% 
GelMA and (right) 10% GelMA. Scale bar = 100 µm 
Figure 7.23: NIH-3T3 cell growth on 3% HAMA 80 µm printed hydrogels after 48 hours with (left) 0% 
GelMA and (right) 10% GelMA with prewashing. Scale bar = 100 µm 




7.3.4.5. Cell culture on 5% GelMA hydrogels with and without HA and PEGDA 
GelMA hydrogels were formed with and without HA and PEG diacrylate in order to assess if 
these additives influenced cell growth. 80 µm prints were also included to determine if cells 
were able to align with the print. In Figure 7.24, no HA was included in the hydrogels, and in 
Figure 7.25, hydrogels contained 1% HA.     
Firstly, in Figure 7.24, it can be seen that hydrogels containing no HA and no PEG diacrylate show 
significantly different cell morphology than in hydrogels containing 1% PEG diacrylate. In images 
a) and c), cells are attached to the hydrogel and exhibiting a flattened shape with clearly visible 
filopodia. There is also a high extension to neighbouring cells. When incubated on a printed 
hydrogel, directed cell growth was not apparent. In the case of hydrogels containing 1% PEG 
diacrylate, clustering of cells is seen with no attachment to the surface. Cells are also spherical in 















Figure 7.24: NIH-3T3 cell growth on crosslinked GelMA hydrogels containing no HA. No print with a) no 
PEGDA and b) 1% PEGDA. 80 µm line print with c) no PEGDA and d) 1% PEGDA. Scale bar = 100 µm 
a) b) 
c) d) 
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Cells were then incubated on hydrogels containing 1% HA as well as PEG diacrylate. Again, 80 
µm line prints were also included (Figure 7.25). Here, the opposite trend to that described 
previously was seen; good cell growth was observed in hydrogels containing 1% PEG diacrylate, 
but cell growth was hindered with no PEG diacrylate. With no PEG diacrylate the cells adopted a 
spherical, clustered appearance with cells aggregating in the wells of the 80 µm print.  In 1% PEG 
diacrylate hydrogels cells were able to adhere to the surface and extend filopodia to 

















In general, cell attachment and growth was only seen here in two cases: either in hydrogels 
containing only GelMA or GelMA with HA and PEG diacrylate. In the first case, this is plausible as 
the cell-binding RGD sequence found in gelatin would promote cell attachment, as well as the 
hydrophilic polymer properties. In the second case, the reason why we see cell attachment and 
growth is more unclear. This could be due to the shear concentration of GelMA, HA and PEG 
d) c) 
a) b) 
Figure 7.25: NIH-3T3 cell growth on crosslinked GelMA hydrogels containing 1% HA. No print with a) no 
PEGDA and b) 1% PEGDA. 80 µm line print with c) no PEGDA and d) 1% PEGDA. Scale bar = 100 µm 




diacrylate polymer fibres in the hydrogel; the high density could be enough for cells to be able to 
attach across the polymer network. 
7.3.4.6. Hyaluronidase degradation of GelMA gels containing HA  
Hydrogels containing 5% and 10% GelMA were formed containing 1%, 2% and 3% 
unmodified HA, and were subsequently degraded with 1 mg/mL hyaluronidase solution, 
as described by Camci-Unal et al20. The degradation of the hydrogel was followed using 
the loss of weight of the hydrogel due to degraded polymer units going into solution 
(Figure 7.26).  
 
 
In general, the extent and rate of weight loss seen during incubation with hyaluronidase 
increased with increasing HA concentration. In 5% GelMA hydrogels containing 1% HA, 
approximately 60% of the original hydrogel weight remained after 24 hours, whereas in 2% and 
3% HA only 30% remained. In 1% HA degradation plateaued after 2 hours, and 2% and 3% HA a 
plateau was seen after 8 hours.  
Similarly, in 10% GelMA hydrogels the extent and rate of degradation by hyaluronidase 
increased with increasing HA concentration. In 1% HA a similar response to hydrogel containing 
5% GelMA was observed; approximately 60% initial weight remained after 24 hours. In 2% HA 
degradation was slightly more with approximately 45% remaining. Compared to 3% HA 























































Figure 7.26: Weight loss of GelMA/HA hydrogels through degradation with 1 mg/mL hyaluronidase. (left) 
5% GelMA and (right) 10% GelMA  
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Figure 7.27: Weight loss of GelMA/HAMA hydrogels through degradation with 1 mg/mL hyaluronidase. a) 
1% HAMA, b) 2% HAMA and c) 3% HAMA 
hydrogels containing 5% GelMA, in 10% GelMA a significantly higher amount of degradation was 
seen; by 6 hours degradation only 15% of the initial weight remained.   
7.3.4.7. Hyaluronidase degradation of GelMA gels containing HAMA  
Hydrogels containing 1%, 2% and 3% HAMA were then also formed with 5% and 10% GelMA, 
and again degraded with 1 mg/mL HAase solution. The degradation of the hydrogel was 
determined using the loss of weight of the hydrogel due to degraded polymer units going into 
solution (Figure 7.27). This time, hydrogels were visibly more viscous in solution compared to 
HA/GelMA solutions.   
 
Generally as the concentration of HAMA increased, the extent and rate of weight loss seen 
during incubation with HAase increased. With 5% GelMA hydrogels, the effect was less 
pronounced with approximately 50% initial weight remaining in 1% HAMA hydrogels and 40% in 
2% and 3% HAMA hydrogels. In 10% GelMA hydrogels, the hydrogels were slightly more 
resistant to HAase degradations, with 65%, 60% and 40% initial weight remaining after 24 hours 
for 1%, 2% and 3% HAMA hydrogels respectively.  
7.4. Conclusions 
This chapter focussed on the use of hot embossed polystyrene lithographic prints to form 
hydrogels with a printed surface, in order to aid cell adherence or impart directed growth to 




























































fibroblast cells. Hot embossing was found to be a useful technique which gave durable, high 
quality prints for hydrogel printing. HAMA was successfully printed with 50 and 80 µm line prints 
using UV irradiation. On seeding printed HAMA hydrogels with NIH-3T3 fibroblasts, directionality 
was seen as the cells aggregated in the line wells of the print, however they were unable to bind 
to the surface properly or proliferate. Gelatin methacrylate hydrogels were then investigated 
with and without HAMA, resulting in a more successful attachment to the surface.      
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8.1. General Conclusions 
The development of resistance of bacteria to common antibiotics is, and will continue to be, 
widespread globally in the subsequent decades. It will remain an issue of critical political, 
medical and social importance. Although certain measures have been introduced to slow this, 
the seemingly universal and unregulated use of antibiotics (especially within agriculture and the 
developing world) means that the problem must be confronted on many lines of attack to be 
solved.  
Research in the West into the use of bacteriophage as alternatives to antibiotics has increased 
significantly in response to antibiotic resistance. Combined with fast, modern sequencing 
techniques and a better understanding of bacteriophage genetics, bacteriophage therapy is a 
promising new way of treating common bacterial infections in humans, food and agriculture. 
Although most likely not a complete alternative to antibiotics, bacteriophage still can be active 
as another weapon in the antibacterial arsenal.  In this work, Bacteriophage K was investigated 
as an active bacteriophage against S. aureus. The bacteriophage exhibited a broad efficacy and 
was effective against bacterial liquid culture and biofilms, as well as in both lysate solution and 
when combined into hydrogels.  
In recent years, triggered release systems have been widely explored in order to reduce the 
overuse of antibiotics, and so curb the development of bacterial resistance. By preventing the 
exposure of bacteria to sub-lethal levels of antibiotic, the selection pressure on bacteria to 
mutate is reduced. In this way, the original aim of this project was to create a hydrogel system 
which gave triggered release of bacteriophage instead of antibiotics by pathogenic bacterial 
virulence factors. This was successfully accomplished through the formation of a bilayered 
hydrogel matrix comprising a lower hydrogel layer containing Bacteriophage K and an upper 
crosslinked hyaluronic acid layer. Hyaluronidase secreted by S. aureus was able to specifically 
degrade the upper layer and release bacteriophage compared to non-active strains.  
The use of hydrogels in wound care has been proven to be beneficial in promoting wound 
healing. Hydrogels are able to protect the wound from the external environment, as well as 
provide a highly hydrated environment which allows for cell proliferation and migration. They 
combine the viscoelastic properties of a solid with the diffusive properties of a liquid. 
Additionally, they are generally biocompatible, non-toxic, non-immunogenic and in some cases 
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biodegradable. The chemical structure of the hydrogel can also be tailored for specific roles, by 
addition of other polymers, proteins or drug molecules.  
HA was focussed on in this investigation, as in the body the biopolymer makes up a large part of 
skin and soft tissue and has many reported roles in wound healing.  Additionally, the polymer 
can be selectively degraded by the S. aureus virulence factor, hyaluronidase. In this way, the 
polymer was used as a trigger mechanism for release of bacteriophage from other hydrogels. In 
general, the use of hydrogels (including hyaluronic acid) in wound dressings will only benefit 
wound treatment compared to conventional dressings, as they are able to play a more active 
role in the wound healing process.   
In Chapter 7, the lithographic printing of hydrogels for use in cell culture was investigated. The 
technique is an effective way of imparting directional prints to a hydrogel, and subsequent 
directed growth of cells. However, the use of HA based hydrogels was found to give poor 
attachment compared to later gelatin-based hydrogels. This could be beneficial in a wound 
dressing, as this would prevent cell attachment to the dressing surface, allowing for easier 
removal. 
8.1.1. Limitations of the presented work 
Although the presented work showed novel findings, there are certain limitations which must be 
addressed in order to take the research further.  
Firstly, the main limitation of the bilayer system described in Chapter 6 is that the HAMA upper 
layer does not give complete prevention of bacteriophage diffusion. Passive leakage is seen in 
some cases, and indeed when incubated with live culture (a more authentic model of how 
bacteria will affect the system) no triggered killing of S. aureus was seen.  
Secondly, further investigation needs to be carried out into the type of hydrogel used for the 
lower layer. In this research, PVA was found to be damaging to bacteriophage on exposure to 
UV, and agarose has very poor mechanical properties which would be unsuitable in a normal 
environment (the hydrogel cracks and breaks when exposed to any external stress). Thankfully 
the vast selection of natural and synthetic polymers available means that there is a high chance 
that a suitable alternative could be found which does not damage bacteriophage, has mild 
gelation conditions and a high flexibility and strength.  
The reliance of the system on hyaluronidase as a trigger mechanism is also an issue. Firstly, 
bacteria do not continually secrete the same quantity and type of virulence factors; it is 
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dependent on many external factors including the concentration of available oxygen and energy 
sources, temperature and if bacteria are planktonic or in a biofilm. In Chapter 5, the secretion of 
HAase in both planktonic and biofilm systems was investigated, however even these were in 
optimised laboratory conditions. Similarly, HAase is also prevalent in the human body, where it 
is secreted by cells during normal HA metabolism. For the system to be effective the 
concentration of HAase secreted by S. aureus on infection must be far higher than baseline 
HAase, as well as the concentrations found during inflammation. The secretion of HAase by NIH-
3T3 fibroblasts was investigated which showed no HAase activity, however this is only one, non-
human cell line. The breakdown products of the bilayered hydrogel system (low molecular 
weight HA) are also known to promote an inflammatory response during wound healing. 
The UV irradiation of bacteriophage must also be discouraged, as it not only greatly decreases 
the concentration of bacteriophage available for bacterial infection, but also exposes the virions 
to possible genetic mutations or scission of toxic elements. These toxic elements could later be 
taken up by any bacteria present, causing the formation of dangerous bacterial mutants.  
8.2. Future Project Development 
The research presented in this thesis offers a number of avenues for future investigation and 
development.  
8.2.1. Bacteriophage cocktails 
The use of bacteriophage therapy in general will only escalate in the future, as more antibiotics 
become inactive against pathogenic bacteria. Single bacteriophage may be effective in certain 
cases, but in order to become a viable alternative (or addition) to antibiotics, bacteriophage 
cocktails are more useful. These are mixtures of two or more bacteriophage which when 
combined give a broader range of infectivity than single bacteriophage. Cocktails are more 
successful in hospital environments, where it is frequently not possible to quickly identify the 
exact strain (even species) of an infection. The addition of a bacteriophage cocktail into this 
system instead of only Bacteriophage K would be beneficial and more likely to be active with 
unknown bacteria. 
Also, novel bacteriophage can be isolated from the surrounding environment (e.g. sewage, river 
water) which are able to infect different bacterial strains. In a clinical setting, a bacteriophage 
which has activity against any of the ESKAPE pathogens provides a valuable alternative 
treatment to antibiotics.  
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8.2.2. Theranostic wound dressings 
A 1st generation antimicrobial hydrogel can be thought of as systems described in Chapter 4, 
where a passive release is seen. On addition of the virulence factor-sensitive HAMA layer (2nd 
generation) an active response is now seen, where incorporation of HAMA layer gives triggered 
release of bacteriophage. This bilayered hydrogel system then has the possibility of being 
incorporated into a theranostic wound dressing; a theranostic is a device which combines 
diagnostics and therapeutics into a single system.  Here, the diagnostic component will be dye-
containing phospholipid vesicles currently investigated by the group, which in the presence of 
pathogenic bacteria release the dye and cause a fluorescent warning that infection is present. 
The therapeutic component will be the bilayered hydrogel system described in this thesis, where 
on infection bacteriophage will be selectively released causing a therapeutic response through 
killing of bacteria.  
8.2.3. Triggered release hydrogels 
The formation of hydrogels which give a triggered release of bacteriophage by bacterial 
virulence factors still has leverage, and can be investigated in different ways.   
Firstly, as mentioned earlier the structure and properties of the existing bilayered hydrogel 
system could be altered to prevent the passive diffusion of bacteriophage. This could be 
overcome in a number of ways. The bacteriophage particles could be physically immobilised in 
the lower hydrogel layer, either by chemical coupling to the main hydrogel polymer or to a 
separate polymer which can later be broken down. For example, the bacteriophage could be 
coupled to hyaluronic acid through reaction of the HA carboxylic acid and amine residues on the 
bacteriophage head, and then incorporated into the agarose lower layer before gelation. The 
bacteriophage are then prevented from passively diffusing by polymer entanglement, but in the 
presence of HAase the HA could be broken down into smaller units which could allow 
bacteriophage diffusion. Also, the bacteriophage could be immobilised into micro- or 
nanoparticles which are subsequently embedded in the lower layer. The upper layer could also 
be altered to take advantage of other bacterial virulence factors which can breakdown hydrogel 
forming polymers, e.g. ester based hydrogels which respond to lipase, or protein/amine linked 
hydrogels which respond to protease.   
In the future, the bilayered hydrogel system for triggered release of bacteriophage originally 
described in this thesis can be adapted for different external triggers or bacterial systems. For 
example, these can include PNIPAAm based hydrogels which are temperature responsive, or pH 
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sensitive hydrogels. Recently within the group (Scarlet Milo) a bilayered hydrogel has been 
developed which gives triggered release of bacteriophage for the treatment of Proteus mirabilis, 
a common bacterium found in the majority of urinary tract infections. Here, the HAMA layer is 
replaced by the pH-sensitive polymer Eudragit®. When P. mirabilis grows, it secretes the enzyme 
urease which breaks down urea into ammonia and carbamate molecules. The excess ammonia 
causes a general increase in the urine pH from pH 5.5 - 6.5 to pH 8. The Eudragit coating exploits 
the change in pH, as it is selectively degraded at high pH, giving triggered release of P. mirabilis 
bacteriophage.  
8.2.4. Testing with established biofilms 
In the majority of cases, bacteria in a wound infection exist in a biofilm of either one or more 
species or strains, instead of isolated floating planktonic bacteria. An established biofilm is a 
complex community able to sense and respond to its external environment. As mentioned 
earlier, bacteria do not continually secrete the same quantity and type of virulence factors, and 
so any dressing which will be used on a wound must be tested with established biofilms (both in 
vitro and in vivo). Further work would include further assessment of HAase secretion from 
biofilms, and to see if triggered killing can be seen on incubation of the bilayered hydrogel 
system on biofilms.   
8.2.5. In vivo testing 
Any therapeutic that aims to be used in a clinical setting must be rigorously tested before being 
used on patients. Firstly, pre-clinical phase studies must be carried out in vivo, which evaluate 
the biocompatibility of the therapeutic, as well as its response in the presence of inflammation. 
This is initially carried out on small animals (mice and rats) before going on to higher species. In 
wound dressings used for the skin and soft tissues, testing is frequently done on pigs as they 
have a very similar dermal structure to humans.  
If initial in vivo results prove promising, clinical trials on humans (Phase I – III) are then 
undertaken. Randomised double-blind clinical trials are seen as the best and most accurate, as 
the possibility of bias is prevented. 
8.2.6. Hydrogels for eukaryotic cell culture 
Although not particularly successful with HA based polymers, the use of gelatin hydrogels for cell 
culture still provides scope for future work. In general, hydrogels provide a good environment to 
promote cell proliferation and migration - both highly important in wound healing. By altering 
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the structure, porosity and chemical composition of hydrogels, growth of cells can be promoted, 
or suppressed (e.g. to prevent biofouling).  
8.2.7. Lithographic printing of hydrogels  
By printing a hydrogel, this gives a better opportunity for cell attachment or directed growth, 
depending on the size and shape of the print. The ordered and directed growth of cells has many 
applications in biomedicine and tissue engineering, such as in neurology. Lithographic printing 
allows the easy investigation of how the size and shape of a print affects cell growth.  
In the Schönherr group, hydrogel printing technology has been adapted to form hydrogel cubes 
(instead of lines). These can then be used as hydrogel “building blocks” which can be stacked 
and arranged in different ways. Also, patterned hydrogels can be formed which contain either 
cell-adhesive or cell-repulsive regions. Again this enables the directed or patterned growth of 
cells on a surface. They have also investigated the printing of hydrogels with square wells which 
hold single cells; here to see how different factors affect single cells can be investigated. 
 
 
